

CITATION REPORT

List of articles citing

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

DOI: 10.1073/pnas.0405220101

Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 13306-11.

Source: <https://exaly.com/paper-pdf/36673686/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2312	Soluble epidermal growth factor receptor (sEGFR) and carcinoembryonic antigen (CEA) concentration in patients with non-small cell lung cancer: correlation with survival after erlotinib and gefitinib treatment. 2010 , 4, 178		12
2311	Molecular markers help characterize neuroendocrine lung tumors. 1996 , 62, 798-809; discussion 809-10		109
2310	The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy. 2004 , 1, 2-3		15
2309	Biomarkers of response to gefitinib in non-small-cell lung cancer. 2004 , 1, 66-7		5
2308	The impact of EGFR mutations on gefitinib sensitivity in non-small cell lung cancer. 2004 , 1, 27-34		4
2307	A molecular chink in the lung cancer armour. 2004 , 9, 426-7		
2306	Smoking out differences. 2004 , 4, 752-752		
2305	Gefitinib--a novel targeted approach to treating cancer. 2004 , 4, 956-65		283
2304	Strategies to overcome resistance to targeted protein kinase inhibitors. 2004 , 3, 1001-10		276
2303	G1 cell-cycle control and cancer. 2004 , 432, 298-306		929
2302	Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes. 2004 , 6 Suppl 1, S24-9		38
2301	Predictors of sensitivity and resistance to epidermal growth factor receptor inhibitors. 2004 , 6 Suppl 1, S30-4		15
2300	Effect of epidermal growth factor receptor mutations on the response to epidermal growth factor receptor tyrosine kinase inhibitors: target-based populations for target-based drugs. 2004 , 6 Suppl 1, S35-42		8
2299	Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of bronchoalveolar carcinoma. 2004 , 6 Suppl 1, S43-7		3
2298	Somatic alterations in the human cancer genome. 2004 , 6, 433-8		128
2297	Somatic mutations in human cancer: insights from resequencing the protein kinase gene family. 2005 , 70, 43-9		21
2296	Targeted therapies and non-small cell lung cancer: methodological and conceptual challenge for clinical trials. 2005 , 17, 123-9		7

2295	Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists. 2005 , 128, 3975-84	88
2294	Emerging trends in combinations of gefitinib and cytotoxic agents: new opportunities. 2005 , 28, 467-70	
2293	Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. 2005 , 70, 419-26	91
2292	Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors. 2005 , 70, 73-81	34
2291	Bibliography Current World Literature. 2005 , 11, 345-362	
2290	Somatic mutations in epidermal growth factor receptor underlying complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung. 2005 , 16, 739-42	2
2289	Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer. 2005 , 17, 118-22	54
2288	Drugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeutics. 2005 , 70, 499-515	24
2287	Targeted lung cancer therapy: what have we learned from gefitinib?. 2005 , 2, 1-2	3
2286	Update in oncology. 2005 , 143, 587-92	
2285	EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. 2005 , 65, 7568-72	227
2284	New approaches to drug development in pediatric oncology. 2005 , 11, 324-30	16
2283	Therapeutic challenges of kinase and phosphatase inhibition and use in anti-diabetic strategy. 2005 , 33, 343-5	7
2282	Targeting ligand cleavage to inhibit the ErbB pathway in cancer. 2005 , 1059, 56-60	3
2281	Evolving molecular-based targeted therapy for cancer: an exciting field. 2005 , 31, 299-305	
2280	New agents for the treatment of ovarian cancer: the next generation. 2005 , 15 Suppl 3, 252-7	7
2279	Demonstration of EGFR gene copy loss in colorectal carcinomas by fluorescence in situ hybridization (FISH): a surrogate marker for sensitivity to specific anti-EGFR therapy?. 2005 , 47, 560-4	45
2278	Throwing new light on lung cancer pathogenesis: updates on three recent topics. 2005 , 96, 63-8	19

2277	HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. 2005 , 93, 1334-40	70
2276	A small molecule-kinase interaction map for clinical kinase inhibitors. 2005 , 23, 329-36	1569
2275	Response to MoleculeKinase interaction map. 2005 , 23, 1346-1348	0
2274	Plant transgenic science knowledge. 2005 , 23, 1348-9	9
2273	Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. 2005 , 37, 1315-6	405
2272	ERBB receptors and cancer: the complexity of targeted inhibitors. 2005 , 5, 341-54	2593
2271	The concept of synthetic lethality in the context of anticancer therapy. 2005 , 5, 689-98	1061
2270	Oncogenic PI3K deregulates transcription and translation. 2005 , 5, 921-9	622
2269	Erlotinib hydrochloride. 2005 , 4, 13-4	142
2268	EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. 2005 , 18, 1027-33	252
2267	Targeted therapies for non-small cell lung cancer. 2005 , 59, 1055-62	13
2266	ERBB2 kinase domain mutation in a gastric cancer metastasis. 2005 , 113, 683-7	17
2265	Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. 2005 , 7, 301-11	794
2264	The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. 2005 , 8, 287-97	348
2263	Clinical development of gefitinib in non-small-cell lung cancer and the Iressa Survival Evaluation in Lung Cancer trial. 2005 , 6, 214-6	1
2262	2004 Highlights From: 29th European Society of Medical Oncology Congress Vienna, Austria October 29 through November 2, 2004. 2005 , 6, 209-213	
2261	Adjuvant chemotherapy in early-stage non-small cell lung cancer. 2005 , 32, 279-83	10
2260	Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations. 2005 , 32, S9-15	69

2259	The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro. 2005 , 129, 1010-7	15
2258	Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. 2005 , 205, 355-63	26
2257	Establishment of a human non-small cell lung cancer cell line resistant to gefitinib. 2005 , 116, 36-44	119
2256	Epidermal growth factor receptor and angiogenesis: Opportunities for combined anticancer strategies. 2005 , 117, 883-8	133
2255	High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. 2005 , 103, 2344-8	188
2254	Distribution according to histologic type and outcome by gender and age group in Taiwanese patients with lung carcinoma. 2005 , 103, 2566-74	67
2253	EGFR gene copy number heterogeneity in fine-needle aspiration cytology from breast carcinomas determined by chromogenic in situ hybridization. 2005 , 33, 228-32	11
2252	Epidermal growth factor receptor domain II, IV, and kinase domain mutations in human solid tumors. 2005 , 83, 976-83	25
2251	Genetic analysis of the kinome and phosphatome in cancer. 2005 , 62, 2092-9	47
2250	Blockade of epidermal growth factor receptor (EGFR) activity. 2005 , 53, 179-92	17
2249	Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. 2005 , 446, 483-8	89
2248	Facteurs pronostiques et prđictifs des cancers bronchiques non ^petites cellules. 2005 , 7, 443-446	1
2247	Sensibilit^et rđistance aux inhibiteurs des rđcepteurs Erb B. 2005 , 7, 656-659	1
2246	Clinical review of Iressa for the treatment of NSCLC. 2005 , 2, 829-833	
2245	Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer. 2005 , 7, 241-7	21
2244	HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme. 2005 , 74, 77-86	60
2243	Small tumor size and limited smoking history predicts activated epidermal growth factor receptor in early-stage non-small cell lung cancer. 2005 , 128, 308-16	18
2242	ErbB family of receptors include 4 different receptors, each of which, with the exception of ErbB 2, has a number of ligands. 2005 , 6, 241-2	

2241	Targeted therapies for esophageal cancer. 2005 , 10, 590-601	114
2240	Practical management of patients with non-small-cell lung cancer treated with gefitinib. 2005 , 23, 165-74	150
2239	KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. 2005 , 2, e17	1160
2238	Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. 2005 , 16, 1081-6	189
2237	Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities. 2005 , 23, 3288-93	60
2236	Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. 2005 , 65, 7525-9	130
2235	Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors. 2005 , 11, 5668-70	24
2234	Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. 2005 , 2, e73	2628
2233	When clinical trials are compromised: a perspective from a patient advocate. 2005 , 2, e358	3
2232	Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. 2005 , 11, 3032-7	113
2231	Gene mutations in lung cancer: promising predictive factors for the success of molecular therapy. 2005 , 2, e13	17
2230	EGFR inhibition in non-small cell lung cancer: resistance, once again, rears its ugly head. 2005 , 2, e75	18
2229	Acquired gefitinib-resistant mutation of EGFR in a chemo-naive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R. 2005 , 2, e269	22
2228	EGFR tyrosine kinase domain mutations in human gliomas. 2005 , 64, 1444-5	62
2227	Molecule-kinase interaction map. 2005 , 23, 1346; author reply 1346-8	4
2226	Pharmacogenomics steps toward personalized medicine. 2005 , 2, 325-337	60
2225	Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. 2005 , 65, 9176-84	157
2224	Application of Pharmacogenomic Approaches in the Study of Drug Response in Complex Diseases. 2005 , 3, 177-190	

2223	Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. 2005 , 2, e313	527
2222	A curious link between epidermal growth factor receptor amplification and survival: effect of "allele dilution" on gefitinib sensitivity?. 2005 , 97, 621-3	22
2221	High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. 2005 , 65, 11478-85	124
2220	EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler. 2005 , 11, 2924-9	112
2219	Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. 2005 , 11, 5539-48	234
2218	Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. 2005 , 11, 3750-7	269
2217	Translating research into cancer molecular diagnostics and patents. 2005 , 58, 793-4	1
2216	Epidemiology of bronchioloalveolar carcinoma: improvement in survival after release of the 1999 WHO classification of lung tumors. 2005 , 23, 8396-405	110
2215	Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. 2005 , 65, 7276-82	445
2214	Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. 2005 , 11, 1983-9	114
2213	Gefitinib versus cetuximab in lung cancer: round one. 2005 , 97, 1168-9	14
2212	Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. 2005 , 23, 3227-34	343
2211	HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. 2005 , 16, 538-48	39
2210	Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. 2005 , 65, 6401-8	221
2209	Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. 2005 , 11, 8105-8	120
2208	Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. 2005 , 23, 3235-42	183
2207	Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. 2005 , 65, 5561-70	285
2206	Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). 2005 , 10, 579-89	100

2205	An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. 2005 , 65, 7096-101	231
2204	Differential expression of biomarkers in lung adenocarcinoma: a comparative study between smokers and never-smokers. 2005 , 16, 1906-14	52
2203	Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out?. 2005 , 23, 5856-8	67
2202	Targeting HER1/EGFR in cancer therapy: experience with erlotinib. 2005 , 1, 449-60	17
2201	Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors?. 2005 , 58, 700-4	79
2200	Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. 2005 , 16, 189-94	130
2199	Factors predicting response to EGFR tyrosine kinase inhibitors. 2005 , 26, 314-22	18
2198	The role of adjuvant chemotherapy for non-small cell lung cancer. 2005 , 26, 298-303	7
2197	Epidermal growth factor receptor inhibitors in cancer treatment. 2005 , 1, 221-34	49
2196	Promises and pitfalls in the prediction of antiepidermal growth factor receptor activity. 2005 , 5, 727-35	2
2195	Erlotinib hydrochloride. 2005 , 4, S14-S15	18
2194	Pulmonary adenocarcinomas with mutant epidermal growth factor receptors. 2005 , 352, 1724-5	8
2193	Responsiveness to cetuximab without mutations in EGFR. 2005 , 353, 208-9	111
2192	Erlotinib in lung cancer. 2005 , 353, 1739-41; author reply 1739-41	29
2191	Crossing the rubicon in lung adenocarcinoma: the conundrum of EGFR tyrosine kinase mutations. 2005 , 1, 319-22	
2190	How Cancer Could be Cured by 2015. 2005 , 4, 268-277	35
2189	Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling. 2005 , 5, 487-99	26
2188	Chemoprevention of lung cancer: concepts and strategies. 2005 , 5, 549-65	4

2187	Assessment of Epidermal Growth Factor Receptor (EGFR) signaling in paired colorectal cancer and normal colon tissue samples using computer-aided immunohistochemical analysis. 2005 , 4, 1381-6		33
2186	Gefitinib in non-small cell lung cancer. 2005 , 6, 985-93		41
2185	Recent advances in targeted therapy of human myelogenous leukaemia. 2005 , 9, 1147-63		2
2184	Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients. 2005 , 92, 1877-80		16
2183	Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. 2005 , 93, 355-63		141
2182	EGFR inhibitors: what have we learned from the treatment of lung cancer?. 2005 , 2, 554-61		69
2181	Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. 2005 , 97, 339-46		1919
2180	Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 7665-70	11.5	827
2179	Epidermal growth factor receptor inhibitors: a moving target?. 2005 , 11, 7203-5		16
2178	Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer. 2005 , 11, 4289-94		107
2177	Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. 2005 , 23, 6976-81		98
2176	Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 11011-6	11.5	487
2175	Modern treatment of lung cancer: case 1. Amplification and mutation of the epidermal growth factor receptor in metastatic lung cancer with remission from gefitinib. 2005 , 23, 7736-8		7
2174	Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 802-7	11.5	688
2173	Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study. 2005 , 23, 6172-80		92
2172	FDA drug approval summary: erlotinib (Tarceva) tablets. 2005 , 10, 461-6		305
2171	ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 3788-93	11.5	437
2170	Reply to the Letter to the Editor on Relevance of EGFR expression in colorectal cancer by C. Alliot (Ann Oncol 2005; 16: 1557). 2005 , 16, 1558-1559		

2169	Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. 2005 , 11, 7841-50	224
2168	Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. 2005 , 97, 1185-94	268
2167	Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. 2005 , 23, 6838-45	513
2166	Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer. 2005 , 10, 855-74	8
2165	Molecularly-targeted therapies for non-small cell lung cancer. 2005 , 6, 2667-79	5
2164	Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. 2005 , 65, 1642-6	569
2163	Genomic profiling of cancer: what next?. 2005 , 23, 7253-6	10
2162	Predicting the future from trials of the past: epidermal growth factor receptor expression and outcome of fractionated radiation therapy trials. 2005 , 23, 5437-9	1
2161	Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. 2005 , 65, 6275-81	190
2160	Genetic classification of lung adenocarcinoma based on array-based comparative genomic hybridization analysis: its association with clinicopathologic features. 2005 , 11, 6177-85	93
2159	Impact of molecular pathology on the clinical management of lung cancer. 2005 , 72, 229-32	4
2158	Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. 2005 , 11, 8288-94	193
2157	The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer. 2005 , 10, 467-70	60
2156	Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. 2005 , 65, 8968-74	145
2155	Raf kinase as a target for anticancer therapeutics. 2005 , 4, 677-85	221
2154	Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. 2005 , 11, 2785-808	512
2153	Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. 2005 , 23, 9089-96	141
2152	Therapeutic targeting of receptor tyrosine kinases in lung cancer. 2005 , 9, 533-59	20

2151	Maternal embryonic leucine zipper kinase/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers. 2005 , 65, 9751-61	133
2150	Somatic mutations of epidermal growth factor receptor in colorectal carcinoma. 2005 , 11, 1368-71	124
2149	Relevance of EGFR expression in colorectal cancer. 2005 , 16, 1557-8; author reply 1558-9	2
2148	Epithelial membrane protein-1 is a biomarker of gefitinib resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 11858-63	11.5 74
2147	Novel targeted therapies in the treatment of gastric and esophageal cancer. 2005 , 16, 1740-8	59
2146	EGFR gene mutations: a call for global x global views of cancer. 2005 , 97, 326-8	23
2145	Mutated PI 3-Kinases: Cancer Targets on a Silver Platter. 2005 , 4, 571-574	46
2144	The ErbB receptors and their ligands in cancer: an overview. 2005 , 6, 243-57	234
2143	[Basic principles of signal transduction]. 2005 , 28 Suppl 4, 14-7	2
2142	EGFR tyrosine kinase inhibitors in non-small cell lung cancer: report of a 3-year compassionate use experience with gefitinib in stage IIIB/IV outpatients. 2005 , 28, 623-7	3
2141	[EGF receptor blockade with monoclonal antibodies and so-called "small molecules"]. 2005 , 28 Suppl 4, 18-24	5
2140	Combining EGFR targeted therapy with chemotherapy in pancreatic cancer: is timing important?. 2005 , 4, 1096-7	4
2139	Biomarkers to predict response to epidermal growth factor receptor inhibitors. 2005 , 4, 1369-72	63
2138	Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). 2005 , 366, 1527-37	1802
2137	Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. 2005 , 11, 2879-82	227
2136	Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. 2005 , 6, 279-86	833
2135	Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. 2005 , 50, 375-84	136
2134	Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. 2005 , 23, 8081-92	551

2133	Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. 2005 , 23, 6829-37	641
2132	Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. 2005 , 23, 5007-18	333
2131	Erlotinib in lung cancer - molecular and clinical predictors of outcome. 2005 , 353, 133-44	1594
2130	Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. 2005 , 97, 643-55	1367
2129	Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. 2005 , 23, 2513-20	839
2128	Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. 2005 , 23, 2493-501	681
2127	Race, gender and mutations in the prediction of anti-EGFR activity. 2005 , 1, 201-4	
2126	Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. 2005 , 11, 2106-10	133
2125	Des mutations activatrices du domaine kinase du r�cepteur ^EGF rendent compte des r�ponses au Gfitinib (IRESSA) dans les CBNPC EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, J. Paez, P. Janne, J. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, E. J. Kave, N. Lindeman, T. J. Bodron, K. Naoki, H. Sasaki, Y. Fujii, M. J. Eck, W. R. Sellers, B. E. Johnson, M. Meyerson, in: Science, 304 (2004) 59-63. 1497-1509	
2124	EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. 2005 , 23, 857-65	692
2123	Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. 2005 , 7, 396-403	200
2122	Targeted therapies for prostate cancer. 2005 , 9, 283-98	10
2121	Overcoming Acquired Resistance to Iressa/Tarceva with Inhibitors of a Different Class. 2005 , 4, 4057-4059	11
2120	Erlotinib in non-small cell lung cancer: a review. 2005 , 6, 995-1002	8
2119	Second-generation kinase inhibitors. 2005 , 9, 975-93	48
2118	Novel therapeutics in adult malignant brain gliomas. 2005 , 14, 643-58	4
2117	Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. 2005 , 23, 5900-9	1250
2116	Genomics and the second golden era of cancer drug development. 2005 , 1, 17-26	43

2115	Current chemotherapy options for thymic epithelial neoplasms. 2005 , 6, 1169-77	5
2114	The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it?. 2005 , 9, 1009-30	45
2113	Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. 2005 , 23, 2445-59	613
2112	EGFR pharmacogenomics: the story continues to mutate and evolve. 2005 , 5, 137-9	1
2111	Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. 2005 , 11, 5878-85	295
2110	Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. 2005 , 11, 6414-21	182
2109	TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. 2005 , 23, 5892-9	1267
2108	Pharmacogenetics and Drug Development. 2005 , 417-427	
2107	Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy. 2005 , 23, 3219-26	78
2106	Tyrosine kinases as targets for cancer therapy. 2005 , 353, 172-87	1084
2105	The progress and promise of molecular imaging probes in oncologic drug development. 2005 , 11, 7967-85	194
2104	Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. 2005 , 36, 486-93	198
2103	Epidermal growth factor receptor expression status in lung cancer correlates with its mutation. 2005 , 36, 1127-34	48
2102	Mutational analysis of gene families in human cancer. 2005 , 15, 5-12	40
2101	Recent developments related to the EGFR as a target for cancer chemotherapy. 2005 , 5, 343-9	27
2100	Tumour invasion and metastasis: challenges facing drug discovery. 2005 , 5, 374-81	24
2099	Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters. 2005 , 8, 15-26	111
2098	How to develop a successful cancer drug--molecules to medicines or targets to treatments?. 2005 , 41, 676-82	34

2097	Assessing epidermal growth factor receptor expression in tumours: what is the value of current test methods?. 2005 , 41, 1383-92	91
2096	Antitumor activity of HER-2 inhibitors. 2005 , 227, 9-23	77
2095	Overcoming limitations of natural anticancer drugs by combining with artificial agents. 2005 , 26, 77-81	56
2094	Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. 2005 , 23, 3279-87	223
2093	ADAM proteases, ErbB pathways and cancer. 2005 , 14, 591-606	20
2092	Mutated kinases as targets for cancer drugs. 2005 , 2, 139-144	7
2091	Mechanisms of lung cancer. 2005 , 2, 213-223	14
2090	EGFR mutations in malignant pleural effusion of non-small cell lung cancer: a case report. 2005 , 49, 413-5	22
2089	Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung. 2005 , 50, 1-8	105
2088	Benefit in lung function improvement and side-effect profile of long-term responders: an analysis of 14 NSCLC patients treated for at least 9 months with gefitinib. 2005 , 50, 107-14	7
2087	Consensus on medical treatment of non-small-cell lung cancer—update 2004. 2005 , 50, 129-137	2
2086	Response to gefitinib in bronchioloalveolar carcinoma in the absence of EGFR mutation. 2005 , 50, 259-63	8
2085	Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer. 2005 , 50, 25-33	70
2084	Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery. 2005 , 50, 385-91	33
2083	Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer. 2005 , 50, 417-8	29
2082	EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. 2005 , 352, 786-92	3250
2081	Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. 2005 , 353, 2012-24	1211
2080	Novel therapies in lung cancer. 2005 , 19, 343-67, vii	4

2079	Erlotinib. 2005 , 4, 247-252	3
2078	Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. 2005 , 11, 6816-22	125
2077	Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. 2005 , 23, 2556-68	525
2076	Erlotinib in previously treated non-small-cell lung cancer. 2005 , 353, 123-32	4590
2075	Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. 2005 , 7, R1028-35	116
2074	Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy. 2006 , 3, 448-57	552
2073	A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. 2006 , 95, 998-1004	244
2072	Forthcoming receptor tyrosine kinase inhibitors. 2006 , 10, 793-7	4
2071	Role of Non-Taxane-Containing Chemotherapy in Advanced Non-Small Cell Lung Cancer. 2006 , 5, 223-244	2
2070	New and emerging radiosensitizers and radioprotectors. 2006 , 24, 444-56	30
2069	Lung cancer preneoplasia. 2006 , 1, 331-48	150
2068	The place of targeted therapies in the management of non-small cell bronchial carcinoma. 2006 , 23, 137-147	2
2067	Epidermal growth factor receptor status in anaplastic thyroid carcinoma. 2007 , 60, 881-4	31
2066	Pharmacodynamic biomarkers for molecular cancer therapeutics. 2007 , 96, 213-68	124
2065	Should every lung cancer patient be tested for EGFR mutation?. 2006 , 10, 789-91	1
2064	Is EGFR expression important in non-small cell lung cancer?. 2006 , 61, 98-9	33
2063	Cancer therapies targeted to the epidermal growth factor receptor and its family members. 2006 , 16, 147-164	3
2062	Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients. 2006 , 24, 310-7	39

2061	Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. 2006 , 24, 5034-42	623
2060	Prospective phase II study of gefitinib for chemotherapy-naïve patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. 2006 , 24, 3340-6	449
2059	Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer. 2006 , 36, 344-50	25
2058	Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients. 2006 , 52, 225-33	26
2057	Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. 2006 , 24, 1700-4	184
2056	Epidermal growth factor receptor gene mutation defines distinct subsets among small adenocarcinomas of the lung. 2006 , 52, 47-52	44
2055	First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study. 2006 , 24, 64-9	147
2054	Uncommon V599E BRAF mutations in Japanese patients with lung cancer. 2006 , 133, 203-6	55
2053	Where next for gefitinib in patients with lung cancer?. 2006 , 7, 499-507	101
2052	The epidermal growth factor receptor pathway: a model for targeted therapy. 2006 , 12, 5268-72	649
2051	Posttranslational protein modifications: current implications for cancer detection, prevention, and therapeutics. 2006 , 5, 1799-810	168
2050	Lung adenocarcinoma harboring mutations in the ERBB2 kinase domain. 2006 , 8, 351-6	32
2049	De l'ASCO et du WCLC 2005 à la pratique clinique : thérapies ciblées. 2006 , 62, 30-34	
2048	Formes cliniques des cancers thoraciques. 2006 , 23, 158-163	1
2047	Recent advances in the treatment of malignant astrocytoma. 2006 , 24, 1253-65	258
2046	Novel therapies targeting signaling pathways in lung cancer. 2006 , 16, 379-96, vi	10
2045	Rapid and simple detection of hot spot point mutations of epidermal growth factor receptor, BRAF, and NRAS in cancers using the loop-hybrid mobility shift assay. 2006 , 8, 504-12	37
2044	A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. 2006 , 8, 335-41	162

2043	Bronchioloalveolar carcinoma: a review. 2006 , 7, 313-22	58
2042	Second-line treatment for advanced-stage non-small-cell lung cancer: current and future options. 2006 , 7 Suppl 4, S118-25	14
2041	Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations. 2006 , 7 Suppl 4, S138-44	61
2040	Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors. 2006 , 49, 1475-85	72
2039	Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay. 2006 , 1, 19	97
2038	Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. 2006 , 24, 2158-63	127
2037	A review of erlotinib and its clinical use. 2006 , 7, 177-93	53
2036	Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese. 2006 , 51, 71-7	49
2035	EGFR mutation status and prognosis for gefitinib treatment in Japanese lung cancer. 2006 , 51, 135-6	15
2034	EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib. 2006 , 51, 363-8	65
2033	EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. 2006 , 51, 207-15	123
2032	Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial. 2006 , 52, 93-7	84
2031	Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer. 2006 , 53, 117-21	53
2030	Gefitinib is of more benefit in chemotherapy-naive patients with good performance status and adenocarcinoma histology: retrospective analysis of 575 Korean patients. 2006 , 53, 339-45	15
2029	L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer. 2006 , 54, 103-8	29
2028	Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer. 2006 , 53, 311-22	64
2027	Activation of the AKT and STAT3 pathways and prolonged survival by a mutant EGFR in human lung cancer cells. 2006 , 54, 25-33	46
2026	EGFR genotyping in pleural fluid specimens in NSCLC patients. 2006 , 54, 265-6	3

2025	PIK3CA mutation status in Japanese lung cancer patients. 2006 , 54, 209-15	219
2024	Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients. 2006 , 54, 201-7	31
2023	Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer. 2006 , 54, 193-9	32
2022	Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer. 2006 , 54, 387-98	88
2021	Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L. 2006 , 54, 419-22	50
2020	Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. 2006 , 66, 944-50	446
2019	A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer. 2006 , 22, 561-73	77
2018	ErbB receptors and epithelial-cadherin-catenin complex in human carcinomas. 2006 , 2, 765-81	32
2017	Gefitinib prevents bleomycin-induced lung fibrosis in mice. 2006 , 174, 550-6	86
2016	Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. 2006 , 12, 4283-7	142
2015	A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer. 2006 , 94, 1599-603	33
2014	Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications. 2006 , 10, 306-15	34
2013	Molecular and genetic markers in thoracic surgery. 2006 , 82, 2335-6	
2012	Genetic testing for pharmacogenetics and its clinical application in drug therapy. 2006 , 363, 177-86	33
2011	Prognostic biomarkers in non-small-cell lung carcinoma. 2006 , 12, 418-428	7
2010	An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. 2006 , 125, 1137-49	1137
2009	Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines. 2006 , 340, 469-75	52
2008	Epidermal growth factor receptor (EGFR) signaling in cancer. 2006 , 366, 2-16	1421

2007	ERBB2 kinase domain mutation in the lung squamous cell carcinoma. 2006 , 237, 89-94	39
2006	High frequency of mutation of epidermal growth factor receptor in lung adenocarcinoma in Thailand. 2006 , 239, 292-7	22
2005	Predicting the outcome of chemotherapy for lung cancer. 2006 , 6, 323-31	62
2004	Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. 2006 , 32, 74-89	137
2003	Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy. 2006 , 42, 17-23	133
2002	BRAF and c-kit gene copy number in mutation-positive malignant melanoma. 2006 , 37, 520-7	84
2001	Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression. 2006 , 37, 755-63	56
2000	Epidermal growth factor receptor pathway inhibitors. 2006 , 1, 299-310	5
1999	Drugs for Lung Cancer Treatment. 2006 , 60, 123	
1998	Bronchioloalveolar Carcinoma of the Lung. 2006 , 313-320	
1997	The Trend Toward Personalized Medicine. 2006 ,	
1996	Kinase mutations in cancer: chinks in the enemy's armour?. 2006 , 18, 69-76	6
1995	EGF receptor testing for non-small cell lung carcinomas. 2006 , Chapter 10, Unit 10.9	1
1994	A useful protocol for analyses of mutations of the epidermal growth factor receptor gene. 2006 , 15, 1503	
1993	Epidermal growth factor receptor mutations in non-small cell lung cancer: a basic science discovery with immediate clinical impact. 2006 , 331, 139-49	10
1992	BAC Consensus Conference, November 4-6, 2004: Epidemiology, Pathogenesis, and Preclinical Models. 2006 , 1, S2-S7	2
1991	The Bronchioloalveolar Carcinoma and Peripheral Adenocarcinoma Spectrum of Diseases. 2006 , 1, 344-359	29
1990	Molecular Biology, Genomics, and Proteomics in Bronchioloalveolar Carcinoma. 2006 , 1, S8-S12	4

1989	Mutations of the epidermal growth factor receptor gene in gastrointestinal tract tumor cell lines. 2006 , 15, 1205	2
1988	Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib and Erlotinib in the Treatment of Non-small Cell Lung Cancer: A Systematic Review. 2006 , 1, 367-376	24
1987	Systemic Therapy of Bronchioloalveolar Carcinoma: Results of the First IASLC/ASCO Consensus Conference on Bronchioloalveolar Carcinoma. 2006 , 1, S32-S36	13
1986	Update on Epidermal Growth Factor Receptor Inhibitor Development in Lung Cancer. 2006 , 1, 740-743	2
1985	PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients. 2006 , 1, 629-634	25
1984	Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy. 2006 , 16, 533	1
1983	Targeting the Phosphoinositide-3-kinase/Akt/Mammalian Target of Rapamycin Pathway. 966-996	
1982	Acetylsalicylic acid enhances antiproliferative effects of the EGFR inhibitor gefitinib in the absence of activating mutations in gastric cancer. 2006 , 29, 615-23	6
1981	EGF Receptor Gene Mutations Are Common in Lung Cancers From Never Smokers and Are Associated With Sensitivity of Tumors to Gefitinib and Erlotinib. 2006 , 2006, 132-134	
1980	EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naïve non-small cell lung cancer. 2006 , 1, 260-7	60
1979	Systemic Therapy of Bronchioloalveolar Carcinoma: Results of the First IASLC/ASCO Consensus Conference on Bronchioloalveolar Carcinoma. 2006 , 1, S32-S36	16
1978	Clinico-Pathological and Biological Significance of Tyrosine Kinase Domain Gene Mutations and Overexpression of Epidermal Growth Factor Receptor for Lung Adenocarcinoma. 2006 , 1, 787-795	6
1977	Combined Analysis of Molecular and Clinical Predictors of Gefitinib Activity in Advanced Non-Small Cell Lung Cancer: Epidermal Growth Factor Receptor Mutations Do Not Tell the Whole Story. 2006 , 1, 52-60	
1976	Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib and Erlotinib in the Treatment of Non-small Cell Lung Cancer: A Systematic Review. 2006 , 1, 367-376	28
1975	PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients. 2006 , 1, 629-634	62
1974	The Bronchioloalveolar Carcinoma and Peripheral Adenocarcinoma Spectrum of Diseases. 2006 , 1, 344-359	62
1973	Rational Development of Targeted Cancer Therapies Using Biomarkers. 2006 , 37, 482-489	
1972	Investigating the molecular basis of drug action and response: chemocentric genomics and proteomics. 2006 , 7, 387-95	5

1971	Molecular Targeting of Cell Death Signal Transduction Pathways in Cancer. 2006 , 1, 113-131	9
1970	BAC Consensus Conference, November 4 th , 2004: Epidemiology, Pathogenesis, and Preclinical Models. 2006 , 1, S2-S7	1
1969	Monitoring EGFR-mutant lung cancers by means of the blood. 2006 , 1, 199-200	1
1968	Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. 2006 , 1, 231-9	102
1967	Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvIII. 2006 , 5, 1361-8	63
1966	Mutation and Polymorphism in the EGFR-TK Domain Associated with Lung Cancer. 2006 , 1, 635-647	3
1965	Update on Epidermal Growth Factor Receptor Inhibitor Development in Lung Cancer. 2006 , 1, 740-743	4
1964	The Role of Gefitinib Treatment for Korean Never-Smokers with Advanced or Metastatic Adenocarcinoma of the Lung: A Prospective Study. 2006 , 1, 965-971	11
1963	A simple and sensitive method for detecting major mutations within the tyrosine kinase domain of the epidermal growth factor receptor gene in non-small-cell lung carcinoma. 2006 , 15, 101-8	28
1962	Bronchioloalveolar Carcinoma and Lung Adenocarcinoma: The Clinical Importance and Research Relevance of the 2004 World Health Organization Pathologic Criteria. 2006 , 1, S13-S19	36
1961	Molecular Biology, Genomics, and Proteomics in Bronchioloalveolar Carcinoma. 2006 , 1, S8-S12	10
1960	Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC). 2006 , 1, 1-13	38
1959	Side effects of anti-cancer molecular-targeted therapies (not monoclonal antibodies). 2006 , 18, 307-15	9
1958	Epidermal growth factor receptor pathway targeted therapy in patients with aerodigestive malignancies. 2006 , 18, 609-14	3
1957	Clinical experience with erlotinib in non-small-cell lung cancer. 2006 , 42, 147-56	15
1956	Advances in chemotherapy of non-small cell lung cancer. 2006 , 130, 1211-9	139
1955	Inhibition of Growth Factor Signaling by Small-Molecule Inhibitors of ErbB, Raf, and MEK. 2006 , 83-132	1
1954	Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. 2006 , 11, 687-92	27

1953	Worldwide trends in lung cancer pathology. 2006 , 11, 533-8	98
1952	Clinical aspects of epidermal growth factor receptor inhibitors: benefit and risk. 2006 , 11, 693-8	18
1951	Molecular diagnostics of non-small cell lung cancer using mediastinal lymph nodes sampled by endoscopic ultrasound-guided needle aspiration. 2006 , 17, 3-9	10
1950	The role of pharmacogenetics in cancer therapeutics. 2006 , 62, 35-46	54
1949	High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. 2006 , 97, 642-8	120
1948	EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification. 2006 , 97, 753-9	64
1947	A critical appraisal of prognostic and predictive factors for common lung cancers. 2006 , 48, 779-86	18
1946	The role of companion diagnostics in the development and use of mutation-targeted cancer therapies. 2006 , 24, 985-95	108
1945	Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. 2006 , 12, 852-5	283
1944	Comparing antibody and small-molecule therapies for cancer. 2006 , 6, 714-27	531
1943	Protein therapeutics: new applications for pharmacogenetics. 2006 , 5, 507-21	59
1942	EGF-ERBB signalling: towards the systems level. 2006 , 7, 505-16	1572
1941	Targeted therapy for metastatic renal cell carcinoma. 2006 , 94, 614-9	134
1940	Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. 2006 , 94, 896-903	117
1939	Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. 2006 , 94, 1136-43	114
1938	EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib. 2006 , 95, 1390-5	110
1937	Mutations in the tyrosine kinase domain of the EGFR gene are rare in synovial sarcoma. 2006 , 19, 541-7	38
1936	Epithelial growth factor receptor status in primary and recurrent ovarian cancer. 2006 , 19, 607-10	61

1935	Diversity of epidermal growth factor receptor-mediated activation of downstream molecules in human lung carcinomas. 2006 , 19, 986-98	16
1934	Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma. 2006 , 19, 1213-20	59
1933	Validating cancer drug targets. 2006 , 441, 451-6	131
1932	Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants. 2006 , 25, 1205-15	111
1931	Epidermal growth factor receptor directed therapy in head and neck cancer. 2006 , 57, 25-43	44
1930	Clinical experience with gefitinib: an update. 2006 , 58, 31-45	46
1929	Multitargeted therapy: can promiscuity be praised in an era of political correctness?. 2006 , 59, 150-8	24
1928	Novel targets in gastric and esophageal cancer. 2006 , 59, 128-38	23
1927	Cetuximab in advanced non-small cell lung cancer. 2006 , 59, 139-49	16
1926	Kinase inhibitors in the treatment of renal cell carcinoma. 2006 , 60, 216-26	26
1925	In silico identification of novel EGFR inhibitors with antiproliferative activity against cancer cells. 2006 , 16, 1969-74	64
1924	Maspin expression and its clinical significance in non-small cell lung cancer. 2006 , 13, 1517-23	27
1923	Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. 2006 , 24, 291-7	60
1922	Molecular imaging of EGFR kinase activity in tumors with ¹²⁴ I-labeled small molecular tracer and positron emission tomography. 2006 , 8, 262-77	89
1921	EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocation. 2006 , 95, 211-8	177
1920	Mutation profile of EGFR gene detected by denaturing high-performance liquid chromatography in Japanese lung cancer patients. 2007 , 133, 93-102	17
1919	Biological and clinical implications of EGFR mutations in lung cancer. 2006 , 11, 190-8	169
1918	Resistance to gefitinib. 2006 , 11, 487-91	26

1917	Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma. 2007 , 59, 183-95	70
1916	Defining clinically relevant molecular subsets of lung cancer. 2006 , 58 Suppl 1, s11-5	16
1915	The impact and role of EGFR gene mutation on non-small cell lung cancer. 2006 , 58, 25-31	7
1914	[EGFR-expression in pulmonary neuroendocrine cell hyperplasia]. 2006 , 27, 147-51	5
1913	[Targeted therapy in the treatment of solid tumors and in hematology-oncology. Advances and disappointments]. 2006 , 47, 633-41	1
1912	Emerging strategies in the treatment of advanced esophageal, gastroesophageal junction, and gastric cancer: the introduction of targeted therapies. 2006 , 1, 23-33	1
1911	Unraveling molecular markers of biologic therapies in glioma. 2006 , 6, 185-6	
1910	Phosphoinositide 3-kinase: from viral oncoprotein to drug target. 2006 , 344, 131-8	37
1909	Ovarian granulosa cell tumors frequently express EGFR (Her-1), Her-3, and Her-4: An immunohistochemical study. 2006 , 101, 18-23	27
1908	The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. 2006 , 9, 485-95	389
1907	EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans. 2006 , 9, 421-3	41
1906	Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. 2006 , 10, 39-50	311
1905	Targeting ADAMS and ERBBs in lung cancer. 2006 , 10, 7-11	33
1904	A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. 2006 , 10, 425-35	198
1903	Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. 2006 , 1766, 217-29	27
1902	Optimizing therapy in previously treated non-small cell lung cancer. 2006 , 33, S25-31	7
1901	Use of novel second-line targeted therapies in non-small cell lung cancer. 2006 , 33, S9-16	21
1900	Epidermal growth factor receptor targeting in cancer. 2006 , 33, 369-85	560

1899	Variation in the human genome and the inherited basis of common disease. 2006 , 33, S46-9	7
1898	A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma. 2006 , 6, 278	42
1897	High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. 2006 , 6, 295	223
1896	Autocrine interleukin-6/interleukin-6 receptor stimulation in non-small-cell lung cancer. 2006 , 7, 273-5	44
1895	Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors. 2006 , 7, 289	52
1894	Pathology of gastrointestinal stromal tumors. 2006 , 56, 1-9	107
1893	A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer. 2006 , 107, 1034-41	69
1892	Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer. 2006 , 107, 2858-65	45
1891	Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma. 2006 , 118, 521-2	48
1890	EGFR and erbB2 mutation status in Japanese lung cancer patients. 2006 , 118, 180-4	146
1889	ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model. 2006 , 118, 483-9	33
1888	Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. 2006 , 118, 963-9	130
1887	Response of ovarian carcinomas to gefitinib-carboplatin-paclitaxel combination is not associated with EGFR kinase domain somatic mutations. 2006 , 118, 1068-9	18
1886	Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. 2006 , 118, 257-62	507
1885	Somatic mutations of the ERBB4 kinase domain in human cancers. 2006 , 118, 1426-9	87
1884	Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer. 2006 , 118, 1814-22	52
1883	Homozygous deletion of p16INK4a and tobacco carcinogen exposure in nonsmall cell lung cancer. 2006 , 118, 1364-9	31
1882	Preclinical study of a "tailor-made" combination of NK4-expressing gene therapy and gefitinib (ZD1839, Iressa) for disseminated peritoneal scirrhous gastric cancer. 2006 , 118, 1545-55	15

1881	Frequent EGFR mutations in noninvasive bronchioloalveolar carcinoma. 2006 , 118, 2498-504	40
1880	Molecular determinants of response to RTK-targeting agents in nonsmall cell lung cancer. 2006 , 119, 727-34	16
1879	Epigenetic inactivation of the SFRP genes is associated with drinking, smoking and HPV in head and neck squamous cell carcinoma. 2006 , 119, 1761-6	101
1878	Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. 2006 , 119, 2586-91	148
1877	Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer. 2006 , 119, 2353-8	89
1876	Imatinib mesylate potentiates topotecan antitumor activity in rhabdomyosarcoma preclinical models. 2007 , 120, 1141-9	15
1875	Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development. 2006 , 26, 569-94	101
1874	The epidermal growth factor receptor gene sequence is highly conserved in primary gastric cancers. 2006 , 93, 44-6	12
1873	EGFR targeted therapy: view from biological standpoint. 2006 , 5, 2072-6	27
1872	Oncogenic shock: turning an activated kinase against the tumor cell. 2006 , 5, 2878-80	32
1871	EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. 2006 , 66, 3197-204	229
1870	Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. 2006 , 66, 11389-98	98
1869	Is there a role for the irreversible epidermal growth factor receptor inhibitor EKB-569 in the treatment of cancer? A mutation-driven question. 2006 , 24, 2225-6	16
1868	Point mutations of protein kinases and individualised cancer therapy. 2006 , 7, 2243-61	23
1867	Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. 2006 , 91, 3662-6	53
1866	Tailor-made chemotherapy for non-small cell lung cancer patients. 2006 , 2, 289-99	15
1865	Pharmacogenomics: from bedside to clinical practice. 2006 , 15 Spec No 1, R89-93	59
1864	Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. 2006 , 12, 6049-55	173

1863	Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer. 2006 , 12, 4436s-4440s	29
1862	High-throughput mutational analysis of the human cancer genome. 2006 , 7, 597-612	13
1861	Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling. 2006 , 12, 710-7	104
1860	Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. 2006 , 3, e485	242
1859	A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. 2006 , 12, 3381-8	101
1858	Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. 2006 , 24, 1807-13	134
1857	Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. 2006 , 24, 2659-65	131
1856	Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. 2006 , 4, 521-8	119
1855	Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors. 2006 , 36, 351-6	51
1854	Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. 2006 , 66, 2116-28	223
1853	Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway. 2006 , 12, 7222-31	75
1852	Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection. 2006 , 11, 655-65	42
1851	Update on epidermal growth factor receptor mutations in non-small cell lung cancer. 2006 , 12, 7232-41	315
1850	Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells. 2006 , 5, 1154-65	79
1849	Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors. 2006 , 12, 7406-13	17
1848	A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. 2006 , 12, 751-8	199
1847	Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. 2006 , 12, 43-8	173
1846	Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. 2006 , 12, 7117-25	104

1845	Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. 2006 , 126, 608-15	130
1844	Exercise induced bronchoconstriction in elite athletes: measuring the fall. 2006 , 61, 94-6	14
1843	Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer. 2007 , 44, 166-72	37
1842	EGFR mutation in gefitinib-responsive small-cell lung cancer. 2006 , 17, 1028-9	82
1841	Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. 2006 , 12, 839-44	597
1840	Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo. 2006 , 12, 617-25	77
1839	Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 9244-9	11.5 92
1838	Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. 2006 , 66, 6487-91	121
1837	Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. 2006 , 12, 4671-7	56
1836	Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment. 2006 , 5, 209-18	87
1835	Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels. 2006 , 5, 104-13	55
1834	Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. 2006 , 12, 1680-5	136
1833	Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. 2006 , 20, 1496-510	363
1832	Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. 2006 , 12, 4416s-4420s	113
1831	Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis. 2006 , 61, 140-5	102
1830	A blood-based test for epidermal growth factor receptor mutations in lung cancer. 2006 , 12, 3875-7	8
1829	Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. 2006 , 66, 7854-8	378
1828	Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. 2006 , 12, 1647-53	356

1827	Mouse modeling in oncologic preclinical and translational research. 2006 , 12, 5305-11	53
1826	Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. 2006 , 24, 1679-88	257
1825	Targeted therapies in combination with chemotherapy in non-small cell lung cancer. 2006 , 12, 4451s-4457s	16
1824	Epidermal growth factor receptor mutation testing in the care of lung cancer patients. 2006 , 12, 4403s-4408s	68
1823	Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. 2006 , 12, 5764-9	526
1822	Lung cancer in never-smokers. 2007 , 60, 337-40	32
1821	Beyond the TRIBUTE trial: integrating HER1/EGFR tyrosine kinase inhibitors with chemotherapy in advanced NSCLC. 2006 , 2, 47-51	6
1820	Dynamic profiling of the post-translational modifications and interaction partners of epidermal growth factor receptor signaling after stimulation by epidermal growth factor using Extended Range Proteomic Analysis (ERPA). 2006 , 5, 1610-27	72
1819	Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation. 2006 , 3, 50-7; quiz 1 p following 57	102
1818	Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. 2006 , 66, 8163-71	315
1817	Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib. 2006 , 66, 7708-15	34
1816	Somatic mutations lead to an oncogenic deletion of met in lung cancer. 2006 , 66, 283-9	364
1815	Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy. 2006 , 12, 3652-6	54
1814	Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. 2006 , 12, 3908-14	479
1813	Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. 2006 , 12, 2538-44	215
1812	Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. 2006 , 66, 5542-8	185
1811	Mechanisms of egfr gene transcription modulation: relationship to cancer risk and therapy response. 2006 , 12, 7252-60	89
1810	Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. 2006 , 24, 4914-21	450

1809	Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. 2006 , 12, 57-61	179
1808	Genomic approaches to lung cancer. 2006 , 12, 4384s-4391s	40
1807	Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. 2006 , 12, 5659-67	180
1806	Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. 2006 , 12, 6494-501	677
1805	Lung cancer genetics and pharmacogenomics. 2006 , 115, 298-302	2
1804	Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance. 2006 , 17 Suppl 2, ii42-45	23
1803	Decreased internalisation of erbB1 mutants in lung cancer is linked with a mechanism conferring sensitivity to gefitinib. 2006 , 153, 457-66	30
1802	The role of the ErbB family members in non-small cell lung cancers sensitive to epidermal growth factor receptor kinase inhibitors. 2006 , 12, 4372s-4376s	68
1801	Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. 2006 , 12, 7242-51	276
1800	The gefitinib-sensitizing mutant epidermal growth factor receptor enables transformation of a mouse fibroblast cell line. 2006 , 25, 246-51	11
1799	Epidermal growth factor receptor inhibition and non-small cell lung cancer. 2006 , 43, 291-323	14
1798	Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations. 2006 , 281, 40183-92	78
1797	Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 7817-22	11.5 229
1796	Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. 2006 , 66, 4802-7	136
1795	Current concepts in bronchioloalveolar carcinoma biology. 2006 , 12, 3698-704	39
1794	Phosphoproteomic analysis of Her2/neu signaling and inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 9773-8	11.5 175
1793	Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. 2006 , 66, 9601-8	174
1792	Les cancers ovariens. 2006 ,	

1791	Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer. 2006 , 6, 1179-93		30
1790	Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors. 2006 , 66, 6990-7		74
1789	Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 2316-21	11.5	436
1788	Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. 2006 , 66, 3162-8		196
1787	EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib. 2006 , 8, 137-44		68
1786	Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. 2006 , 12, 3915-21		265
1785	Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. 2007 , 12, 325-30		54
1784	Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. 2007 , 25, 5777-84		177
1783	Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. 2007 , 25, 2164-70		314
1782	Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives. 2007 , 7, 821-36		9
1781	Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. 2007 , 67, 2226-38		272
1780	Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer. 2007 , 25, 3936-44		105
1779	Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non small cell lung cancers. 2007 , 6, 2642-51		47
1778	Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor. 2007 , 13, 1540-51		94
1777	Targeting HER2 in prostate cancer: where to next?. 2007 , 25, 241-3		39
1776	Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. 2007 , 6, 1167-74		166
1775	The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer. 2007 , 13, 5763-8		71
1774	Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. 2007 , 67, 2325-30		159

1773	Telomere length and telomerase expression in atypical adenomatous hyperplasia and small bronchioloalveolar carcinoma of the lung. 2007 , 127, 254-62	24
1772	MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 20932-7	11.5 1395
1771	Pharmacology and signaling properties of epidermal growth factor receptor isoforms studied by bioluminescence resonance energy transfer. 2007 , 71, 508-18	23
1770	CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation. 2007 , 4, 603-7	16
1769	HER family inhibitors in pancreatic cancer: current status and future directions. 2007 , 11, 337-47	5
1768	Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). 2007 , 96, 1047-51	156
1767	'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. 2007 , 97, 1560-6	66
1766	PolyScan: an automatic indel and SNP detection approach to the analysis of human resequencing data. 2007 , 17, 659-66	66
1765	BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. 2007 , 4, 1669-79; discussion 1680	376
1764	Histotype in Non-Small Cell Lung Cancer Therapy and Staging: The Emerging Role of an Old and Underrated Factor. 2007 , 3, 69-77	6
1763	Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. 2007 , 67, 5779-88	102
1762	Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma. 2007 , 67, 5267-74	130
1761	Cancer Pharmacogenomics: Germline DNA, Tumor DNA, or Both?. 2007 , 5, 87-101	2
1760	Optimizing Anti-EGFR Strategies in Cancer Treatment. 2007 , 3, 267-275	
1759	Why do cancer cells become "addicted" to oncogenic epidermal growth factor receptor?. 2007 , 4, 1620-2	5
1758	Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancer. 2007 , 13, 6518-26	20
1757	PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. 2007 , 13, 378-81	108
1756	Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. 2007 , 4, 1681-89; discussion 1690	261

1755	Targeted therapies for non-small cell lung cancer. 2007 , 13, 2810-31	13
1754	Genetics of preneoplasia: lessons from lung cancer. 2007 , 7, 3-14	99
1753	Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors. 2007 , 12, 211-20	43
1752	Targeted therapy of breast cancer. 2007 , 13, 497-517	24
1751	Erlotinib in non-small cell lung cancer treatment: current status and future development. 2007 , 12, 840-9	90
1750	Detection of epidermal growth factor receptor variations by partially denaturing HPLC. 2007 , 53, 62-70	32
1749	Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. 2007 , 99, 838-46	258
1748	Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer. 2007 , 131, 1628-34	95
1747	Assessment of epidermal growth factor receptor mutation by endobronchial ultrasound-guided transbronchial needle aspiration. 2007 , 132, 597-602	179
1746	s-RT-MELT for rapid mutation scanning using enzymatic selection and real time DNA-melting: new potential for multiplex genetic analysis. 2007 , 35, e84	20
1745	A translational view of the molecular pathogenesis of lung cancer. 2007 , 2, 327-43	237
1744	Epidermal growth factor receptor-directed therapy in esophageal cancer. 2007 , 73, 281-9	30
1743	Molecular pathogenesis of early-stage non-small cell lung cancer and a proposal for tissue banking to facilitate identification of new biomarkers. 2007 , 2, S128-35	17
1742	EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). 2007 , 2, 423-9	68
1741	Epidermal growth factor receptor inhibitors in non-small-cell lung cancer. 2007 , 2, 335-48	3
1740	Pharmacogenomics of lung cancer: with a view to address EGFR-targeted therapies. 2007 , 8, 1211-20	2
1739	Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition. 2007 , 92, 4845-52	25
1738	Drug insight: advances in renal cell carcinoma and the role of targeted therapies. 2007 , 4, 470-9	26

1737	Treatment of squamous cell carcinoma of the head and neck in the metastatic and refractory settings: advances in chemotherapy and the emergence of small molecule epidermal growth factor receptor kinase inhibitors. 2007 , 7, 666-73	18
1736	Genomic landscapes of cancers: prospects for targeted therapies. 2007 , 8, 1629-33	10
1735	ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib. 2007 , 6, 548-54	78
1734	Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors. 2007 , 6, 661-7	72
1733	Assessing the roles of EGFR gene copy number, protein expression and mutation in predicting outcomes in non-small-cell lung cancer after treatment with EGFR inhibitors. 2007 , 1, 203-7	2
1732	Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors. 2007 , 3, 277-83	28
1731	Absence of activating mutations in the EGFR kinase domain in Spanish head and neck cancer patients. 2007 , 28, 273-9	33
1730	Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. 2007 , 7, 257-68	84
1729	Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents. 2007 , 3, 805-17	42
1728	Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma. 2007 , 13, 7086-92	58
1727	Distinguishing cancer-associated missense mutations from common polymorphisms. 2007 , 67, 465-73	103
1726	Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line. 2007 , 67, 7807-14	153
1725	Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. 2007 , 13, 6788-95	54
1724	Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. 2007 , 6, 532-41	160
1723	Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. 2007 , 67, 2046-53	133
1722	Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells. 2007 , 6, 773-81	20
1721	CETUXIMAB (ERBITUXfi), AN ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER. 2007 , 43-67	
1720	Oncogene addiction: setting the stage for molecularly targeted cancer therapy. 2007 , 21, 3214-31	318

1719	Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines. 2007 , 67, 11368-76	71
1718	Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. 2007 , 67, 11867-75	128
1717	PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. 2007 , 67, 11924-32	589
1716	Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations. 2007 , 128, 100-8	114
1715	Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. 2007 , 25, 2528-33	129
1714	Molecular correlates of gefitinib responsiveness in human bladder cancer cells. 2007 , 6, 277-85	56
1713	Targeting of epidermal growth factor receptor in patients affected by biliary tract carcinoma. 2007 , 25, 1145; author reply 1145-6	5
1712	ZD1839 induces p15INK4b and causes G1 arrest by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway. 2007 , 6, 1579-87	23
1711	Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. 2007 , 13, 3731-7	237
1710	HKI-272 in non small cell lung cancer. 2007 , 13, s4593-6	41
1709	The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage. 2007 , 13, 6555-60	149
1708	Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. 2007 , 67, 7319-26	127
1707	A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. 2007 , 18 Suppl 10, x3-10	105
1706	Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies. 2007 , 67, 10417-27	51
1705	Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors. 2007 , 13, s4606-12	42
1704	Pharmacogenomics. 2007 , 18 Suppl 9, ix24-8	12
1703	Clairvoyance or reliable prediction of the future?. 2007 , 18, 407-8	2
1702	ESMO Handbook on Principles of Translational Research. 2007 ,	

1701	Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. 2007 , 6, 2515-24	106
1700	Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. 2007 , 2, e810	93
1699	Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer. 2007 , 13, s4628-31	38
1698	Pharmacogenomics of Non-Small Cell Lung Cancer. 2007 , 5, 228-234	
1697	Small Molecule Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Non Small Cell Lung Cancer Treatment. 2007 , 3, 226-235	
1696	Methodological Issues of Clinical Research with EGFR Inhibitors. 2007 , 3, 292-302	3
1695	Editorial [The Role of Epidermal Growth Factor Receptor (EGFR) Targeting Drugs in the Treatment of Cancer Guest Editor: Fortunato Ciardiello]. 2007 , 3, 223-225	
1694	Lung cancer incidence in never smokers. 2007 , 25, 472-8	388
1693	Non-small cell lung cancer: new hope for a chronic illness. 2007 , 34, 963-70	7
1692	EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity. 2007 , 67, 4665-70	82
1691	A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer. 2007 , 67, 5889-95	134
1690	Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu. 2007 , 67, 6825-43	38
1689	Integrative genomic analysis of small-cell lung carcinoma reveals correlates of sensitivity to bcl-2 antagonists and uncovers novel chromosomal gains. 2007 , 5, 331-9	58
1688	EGFR activating aberration occurs independently of other genetic aberrations or telomerase activation in adenocarcinoma of the lung. 2007 , 17, 1405	
1687	The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinib. 2007 , 2, 414-22	35
1686	Mutational analysis in cytological specimens of advanced lung adenocarcinoma: a sensitive method for molecular diagnosis. 2007 , 2, 1086-90	98
1685	Genetic Heterogeneity in Patients with Multiple Neoplastic Lung Lesions: A Report of Three Cases. 2007 , 2, 12-21	14
1684	PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer. 2007 , 17, 853	5

1683	Collagen gel droplet-embedded culture drug-sensitivity test and potential for personalizing cancer treatment. 2007 , 4, 351-356	1
1682	EGFRvIII mutation in lung cancer correlates with increased EGFR copy number. 2007 ,	2
1681	M02-03: Tumor hypoxia and metastasis in non-small cell lung cancers. 2007 , 2, S154-S155	2
1680	Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. 2007 , 2, 430-9	159
1679	Combination of standard chemotherapy and targeted agents. 2007 , 2, S19-23	2
1678	M02-02: Update of EGFR inhibitors and radiation in the management of non-small cell lung cancer where do we go next?. 2007 , 2, S153-S154	2
1677	Surrogate Predictive Biomarkers for Response to Anti-EGFR Agents: State of the Art and Challenges. 2007 , 22, 10-23	3
1676	Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer. 2007 , 17, 313-9	49
1675	Microsatellite and EGFR, HER2 and K-RAS analyses in sclerosing hemangioma of the lung. 2007 , 31, 1512-20	29
1674	Incorporating molecular tools into clinical trials and treatment for gliomas?. 2007 , 20, 708-11	8
1673	Diagnosis and treatment of bronchioloalveolar carcinoma. 2007 , 13, 290-6	16
1672	Signal Transduction Therapy: Challenges to Clinical Trial Design. 2007 , 2, 21-30	1
1671	Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer. 2007 , 2, 22-28	33
1670	Systemic therapeutic options in thymic malignancies: a glimmer of hope. 2007 , 2, 191-205	1
1669	Nras and Kras mutation in Japanese lung cancer patients: Genotyping analysis using LightCycler. 2007 ,	1
1668	Nicotine activates cell-signaling pathways through muscle-type and neuronal nicotinic acetylcholine receptors in non-small cell lung cancer cells. 2007 , 20, 629-41	77
1667	Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. 2007 , 10, 81-100	62
1666	Identification of EGFR mutations in esophageal cancer. 2007 , 33, 44-8	34

1665	Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. 2007 , 131, 1190-203	1810
1664	Rational bases for the development of EGFR inhibitors for cancer treatment. 2007 , 39, 1416-31	95
1663	Deep proteome profiling of sera from never-smoked lung cancer patients. 2007 , 61, 570-7	30
1662	Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas. 2007 , 248, 186-91	44
1661	Targeting novel and established therapies for non-small cell lung cancer. 2007 , 250, 9-16	10
1660	Cellular responses to EGFR inhibitors and their relevance to cancer therapy. 2007 , 254, 165-77	121
1659	Cellular pharmacodynamics of immunosuppressive drugs for individualized medicine. 2007 , 7, 3-22	30
1658	Transcriptional profiling of non-small cell lung cancer cells with activating EGFR somatic mutations. 2007 , 2, e1226	26
1657	EGFR exon 20 insertion mutation in Japanese lung cancer. 2007 , 58, 324-8	73
1656	The survival outcomes of patients with resected non-small cell lung cancer differ according to EGFR mutations and the P21 expression. 2007 , 57, 96-102	15
1655	Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. 2007 , 25, 2248-55	198
1654	Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. 2007 , 12, 90-8	138
1653	Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens. 2007 , 6, 1223-9	48
1652	Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. 2007 , 25, 760-6	279
1651	EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. 2007 , 18, 99-103	116
1650	Ruthenium complexes can target determinants of tumour malignancy. 2007 , 1267-72	238
1649	Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. 2007 , 13, 4954-5	172
1648	Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway--therapeutic perspectives in cancer. 2007 , 4, 591-602	192

1647	Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. 2007 , 9, 320-6	169
1646	EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients?. 2007 , 1, 183-91	2
1645	Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer--a review of the literature. 2007 , 12, 201-10	69
1644	Perspectives in adjuvant chemotherapy in NSCLC. 2007 , 1, 99-110	1
1643	Lung cancer in never smokers: a review. 2007 , 25, 561-70	494
1642	Tyrosine kinase inhibitors in pediatric malignancies. 2007 , 25, 606-12	7
1641	LUNG CANCERS. 2007 , 25, 48-52	1
1640	Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice. 2007 , 6, 2652-63	32
1639	Small molecule signal transduction inhibitors for the treatment of solid tumors. 2007 , 25, 347-65	12
1638	Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. 2007 , 25, 587-95	515
1637	Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. 2007 , 25, 1545-52	777
1636	[Clinical and molecular predictors of response to EGFR tyrosine kinase inhibitors in non-small cell lung cancer]. 2007 , 27, 353-63	6
1635	Carcinome bronchio-alvéolaire (CBA) et adhocarcinome pulmonaire avec composante bronchio-alvéolaire (ADC-CBA) : un continuum anatomoclinique. 2007 , 24, 165-170	0
1634	[New biological treatments for lung cancer]. 2007 , 63, 20-8	1
1633	[Therapeutic management of extensive bronchiolo-alveolar adenocarcinoma: chemotherapy or inhibitors of epidermal growth factor receptor tyrosine kinase?]. 2007 , 63, 147-54	0
1632	Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. 2007 , 67, 5667-72	99
1631	Les inhibiteurs de tyrosine kinase de l'EGFR dans le traitement du CBNPC. 2007 , 24, 188-197	1
1630	EGFR mutation status in pleural fluid predicts tumor responsiveness and resistance to gefitinib. 2007 , 56, 445-8	28

1629	Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. 2007 , 56, 383-9	121
1628	Up-regulation of PTEN at the transcriptional level is an adverse prognostic factor in female lung adenocarcinomas. 2007 , 57, 201-6	17
1627	Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation. 2007 , 58, 411-3	95
1626	Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. 2007 , 58, 95-103	140
1625	Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis. 2007 , 1, 26-41	134
1624	The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. 2007 , 5, 203-20	323
1623	Prognostic factors for gefitinib-treated postoperative recurrence in non-small cell lung cancer. 2007 , 72, 234-42	21
1622	[Biologic therapy: current and future applications in oncology]. 2007 , 129, 184-93	3
1621	Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain. 2007 , 6, 56	20
1620	Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha. 2007 , 6, 63	48
1619	Erlotinib as a single agent in select subsets of patients with advanced non-small-cell lung cancer. 2007 , 8, 425-8	4
1618	Different epidermal growth factor receptor gene mutations in a patient with 2 synchronous lung cancers. 2007 , 8, 562-4	7
1617	Models of signal transduction in cancer. 2007 , 4, 61-66	
1616	Erlotinib in non-small-cell lung cancer. 2007 , 8, 2579-92	10
1615	Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. 2007 , 4, e294	252
1614	Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. 2007 , 2, e426	73
1613	Targeted Therapeutics in Cancer Treatment. 2007 , 117-148	
1612	The Biology of Epidermal Growth Factor Receptor and its Value as a Prognostic/predictive Factor. 2007 , 22, 3-9	

1611	ErbB receptors: from oncogenes to targeted cancer therapies. 2007 , 117, 2051-8	396
1610	Simultaneous EGFR and VEGF Alterations in Non-Small Cell Lung Carcinoma Based on Tissue Microarrays. 2007 , 3, 117693510700300	3
1609	Pharmacogenomics: clinical applications. 516-528	
1608	Somatic microindels: analysis in mouse soma and comparison with the human germline. 2007 , 28, 69-80	13
1607	Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature. 2007 , 28, 760-70	46
1606	Amplification, mutation and loss of heterozygosity of the EGFR gene in metastatic lung cancer. 2007 , 120, 1828-31; author reply 1832-3	7
1605	The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. 2007 , 120, 1239-47	110
1604	Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk. 2008 , 122, 1530-8	49
1603	Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung. 2007 , 109, 581-7	103
1602	Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component. 2007 , 109, 741-50	62
1601	Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. 2007 , 109, 1561-9	113
1600	Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer. 2007 , 109, 1836-44	61
1599	Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. 2007 , 110, 599-605	91
1598	Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer. 2007 , 110, 1321-8	18
1597	Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas. 2007 , 110, 2793-8	29
1596	Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer. 2007 , 95, 63-9	29
1595	Detection of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) using a fully automated system with a nano-scale engineered biomagnetite. 2007 , 22, 2282-8	16
1594	EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences. 2007 , 62, 53-61	101

1593	Targeting mTOR signaling in lung cancer. 2007 , 63, 172-82	61
1592	Epidermal growth factor receptor double activating mutations involving both exons 19 and 21 exist in Chinese non-small cell lung cancer patients. 2007 , 19, 499-506	43
1591	The effect of the [18F]-PEG group on tracer qualification of [4-(phenylamino)-quinazoline-6-YL]-amide moiety--an EGFR putative irreversible inhibitor. 2007 , 65, 1140-51	24
1590	Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors. 2007 , 49, 352-7	12
1589	EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer. 2007 , 26, 1567-76	71
1588	The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. 2007 , 26, 5023-7	94
1587	Bevacizumab in the treatment of non-small-cell lung cancer. 2007 , 26, 3691-8	22
1586	EGFR kinase domain mutations - functional impact and relevance for lung cancer therapy. 2007 , 26, 5693-701	58
1585	Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling. 2007 , 26, 6968-78	114
1584	Cancer: broken genes in solid tumours. 2007 , 448, 545-6	15
1583	50 & 100 Years Ago. 2007 , 448, 546-546	
1582	Magnetism: managed mess. 2007 , 448, 546-7	1
1581	High-throughput oncogene mutation profiling in human cancer. 2007 , 39, 347-51	847
1580	Epidermal growth factor receptor mutations in lung cancer. 2007 , 7, 169-81	2272
1579	Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?. 2007 , 96, 857-63	80
1578	Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib. 2007 , 96, 1191-6	39
1577	Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). 2007 , 97, 778-84	166
1576	Epidermal growth factor receptor gene mutations in atypical adenomatous hyperplasias of the lung. 2007 , 20, 967-73	33

1575	Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. 2007 , 448, 561-6	4059
1574	The epidermal growth factor receptor: from development to tumorigenesis. 2007 , 75, 770-87	246
1573	Epidermal growth factor receptor (EGFR) gene copy number detection in non-small-cell lung cancer; a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization. 2007 , 51, 631-7	24
1572	Predictive markers in breast cancer--the future. 2008 , 52, 91-8	21
1571	Association of epidermal growth factor receptor mutations in lung cancer with chemosensitivity to gefitinib in isolated cancer cells from Japanese patients. 2007 , 16, 263-7	3
1570	Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese. 2007 , 98, 96-101	81
1569	Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation. 2007 , 98, 357-63	44
1568	Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma. 2007 , 98, 985-91	29
1567	Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. 2007 , 98, 1275-80	198
1566	HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer. 2007 , 98, 1424-30	88
1565	Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. 2007 , 98, 1817-24	469
1564	Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives. 2007 , 28, 1476-93	38
1563	Epidermal growth factor receptor mutations in lung cancers. 2007 , 57, 233-44	60
1562	Key signaling pathways and targets in lung cancer therapy. 2007 , 8 Suppl 2, S52-60	8
1561	Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients. 2007 , 7, 128	32
1560	Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers. 2007 , 7, 74	30
1559	Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. 2007 , 11, 217-27	779
1558	Receptor tyrosine kinases: mechanisms of activation and signaling. 2007 , 19, 117-23	328

1557	The epidermal growth factor receptor intron1 (CA) n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with Gefitinib. 2007 , 570, 175-81	33
1556	Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer. 2007 , 141, 464-9	56
1555	Population genetic tools: application to cancer. 2007 , 34, S21-4	1
1554	Cytomorphological correlates of epidermal growth factor receptor mutations in lung carcinoma. 2007 , 35, 257-62	13
1553	["Targeted Therapies" in NSCLC - present and future]. 2007 , 157, 545-53	
1552	"Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when?". 2007 , 8, 28-37	16
1551	Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how?. 2007 , 9, 255-64	17
1550	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues. 2007 , 2, 3-12	9
1549	Mechanisms of resistance to EGFR inhibitors. 2007 , 2, 31-37	5
1548	Simple method to detect important epidermal growth factor receptor gene mutations with bronchoscopic specimens of lung cancer patients for gefitinib treatment. 2007 , 2, 145-151	3
1547	Epidermal growth factor receptor gene and immunohistochemical expression in colorectal carcinomas. 2008 , 14, 94-98	2
1546	Clinical biomarkers of kinase activity: examples from EGFR inhibition trials. 2008 , 27, 387-402	26
1545	Molecular imaging of epidermal growth factor receptor expression-activity at the kinase level in tumors with positron emission tomography. 2008 , 27, 645-53	42
1544	Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. 2008 , 61, 489-96	69
1543	Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice. 2008 , 62, 605-20	29
1542	Pharmacogenetics in lung cancer for the lay doctor. 2008 , 3, 161-171	4
1541	EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients: how do we interpret the clinical and biomarker data?. 2008 , 3, 173-186	3
1540	Targeted therapies in bronchioloalveolar carcinoma. 2008 , 3, 197-204	1

1539	Molekulardiagnostik von Mutationen des epidermalen Wachstumsfaktor-Rezeptors und Aktivierung nachgeschalteter Signalwege in nichtkleinzelligen Lungenkarzinomen. 2008 , 1, 101-108	
1538	Ground-glass opacities showing an adenoma-to-carcinoma sequence in the lung. 2008 , 56, 421-3	3
1537	Cardiac toxicity: old and new issues in anti-cancer drugs. 2008 , 10, 35-46	56
1536	Overview of chemoradiation clinical trials for locally advanced non-small cell lung cancer in Japan. 2008 , 13, 112-6	19
1535	Elevated expression level of laminin 5 may be a negative predictive factor for the response to gefitinib in lung cancer patients. 2008 , 7, 677-681	
1534	KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. 2008 , 453, 417-31	241
1533	The presence of carboxypeptidase-M in tumour cells signifies epidermal growth factor receptor expression in lung adenocarcinomas: the coexistence predicts a poor prognosis regardless of EGFR levels. 2008 , 134, 439-51	17
1532	Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer. 2008 , 134, 569-77	55
1531	A novel EGFR mutation D1012H and polymorphism at exon 25 in Japanese lung cancer. 2008 , 134, 1371-6	9
1530	Proliferation of Ewing sarcoma cell lines is suppressed by the receptor tyrosine kinase inhibitors gefitinib and vandetanib. 2008 , 8, 1	22
1529	Never-smoking nonsmall cell lung cancer as a separate entity: clinicopathologic features and survival. 2008 , 113, 1012-8	98
1528	Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors. 2008 , 113, 1453-61	78
1527	EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer. 2008 , 69, 359-372	34
1526	EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance. 2008 , 123, 2480-6	70
1525	SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients. 2008 , 47, 253-9	33
1524	Direct resequencing of the complete ERBB2 coding sequence reveals an absence of activating mutations in ERBB2 amplified breast cancer. 2008 , 47, 633-8	10
1523	The development of HKI-272 and related compounds for the treatment of cancer. 2008 , 341, 465-77	123
1522	The biochemistry of drug metabolism--an introduction: part 6. Inter-individual factors affecting drug metabolism. 2008 , 5, 2465-578	42

1521	Design, synthesis and in vitro antitumor activity of 4-aminoquinoline and 4-aminoquinazoline derivatives targeting EGFR tyrosine kinase. 2008 , 16, 7543-51	79
1520	Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy. 2008 , 48, 113-35	20
1519	Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. 2008 , 22, 686-707	304
1518	Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. 2008 , 21 Suppl 2, S16-22	268
1517	Translating insights from the cancer genome into clinical practice. 2008 , 452, 553-63	235
1516	Somatic mutations affect key pathways in lung adenocarcinoma. 2008 , 455, 1069-75	2280
1515	Translational research: the full cycle. 2008 , 453, 843-5	43
1514	The ERBB3 receptor in cancer and cancer gene therapy. 2008 , 15, 413-48	174
1513	EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: implications in targeting therapy. 2008 , 27, 957-65	32
1512	Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations. 2008 , 27, 3201-10	33
1511	Targeted therapy in the treatment of solid tumors: practice contradicts theory. 2008 , 73, 605-18	30
1510	Molecular diagnosis in oncology. 2008 , 42, 687-698	2
1509	BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. 2008 , 27, 4702-11	1099
1508	Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status. 2008 , 98, 749-55	87
1507	Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). 2008 , 98, 907-14	175
1506	Emerging ethnic differences in lung cancer therapy. 2008 , 99, 1757-62	101
1505	Absence of epidermal growth factor receptor mutations in cervical cancer. 2008 , 18, 749-54	30
1504	Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma. 2008 , 99, 303-8	34

1503	Occurrence of mutations in the epidermal growth factor receptor gene in X-ray-induced rat lung tumors. 2008 , 99, 241-5	15
1502	Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. 2008 , 99, 929-35	198
1501	Soy consumption reduces the risk of non-small-cell lung cancers with epidermal growth factor receptor mutations among Japanese. 2008 , 99, 1202-8	26
1500	Induction of lung adenocarcinoma in transgenic mice expressing activated EGFR driven by the SP-C promoter. 2008 , 99, 1747-53	19
1499	Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. 2008 , 99, 2280-5	152
1498	Association of epidermal growth factor receptor (EGFR) gene mutations with EGFR amplification in advanced non-small cell lung cancer. 2008 , 99, 2455-60	29
1497	Ligand-independent phosphorylation of Y869 (Y845) links mutant EGFR signaling to stat-mediated gene expression. 2008 , 314, 413-9	19
1496	A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. 2008 , 110, 140-5	72
1495	High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. 2008 , 8, 142	161
1494	A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment. 2008 , 8, 169	60
1493	Advances in genomic and proteomic studies of non-small-cell lung cancer: clinical and translational research perspective. 2008 , 9, 78-84	16
1492	Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin. 2008 , 9, 232-4	32
1491	Dynamic equilibrium between multiple active and inactive conformations explains regulation and oncogenic mutations in ErbB receptors. 2008 , 1785, 12-31	33
1490	Sensitive detection of EGFR mutations using a competitive probe to suppress background in the SMart Amplification Process. 2008 , 36, 234-8	10
1489	Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. 2008 , 13, 311-20	301
1488	The impact of next-generation sequencing technology on genetics. 2008 , 24, 133-141	1600
1487	Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer. 2008 , 59, 203-10	113
1486	ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. 2008 , 60, 401-7	72

1485	EGFR FISH versus mutation: different tests, different end-points. 2008 , 60, 160-5	39
1484	siRNA targeting against EGFR, a promising candidate for a novel therapeutic application to lung adenocarcinoma. 2008 , 75, 2-8	18
1483	Cancer drug resistance. 2008 , 405-423	2
1482	Biochemical assay-based selectivity profiling of clinically relevant kinase inhibitors on mutant forms of EGF receptor. 2008 , 28, 295-306	5
1481	Detection of mutations in EGFR in circulating lung-cancer cells. 2008 , 359, 366-77	1399
1480	Molecular profiling of non-small cell lung cancer: of what value in clinical practice?. 2008 , 17, 451-62	1
1479	Methods of Cancer Diagnosis, Therapy and Prognosis. 2008 ,	13
1478	EGFR Signaling Networks in Cancer Therapy. 2008 ,	7
1477	Carcinome bronchioalvéolaire (CBA) et adhocarcinome pulmonaire avec composante bronchioalvéolaire (ADC-CBA): un continuum anatomoclinique. 2008 , 25, 3S196-3S202	
1476	Le traitement de la rechute d'un cancer bronchique non ^ petites cellules de stade IV. 2008 , 25, 3S113-3S118	
1475	Phosphorylation status of epidermal growth factor receptor is closely associated with responsiveness to gefitinib in pulmonary adenocarcinoma. 2008 , 39, 316-23	19
1474	ErbB3 mRNA expression correlated with specific clinicopathologic features of Japanese lung cancers. 2008 , 146, 43-8	11
1473	EGFR polymorphism of the kinase domain in Japanese lung cancer. 2008 , 148, 260-3	16
1472	Epidermal growth factor receptor signaling in adenocarcinomas with bronchioalveolar components. 2008 , 85, 216-23	10
1471	EGFR mutations and EGFR tyrosine kinase inhibition in non-small cell lung cancer. 2008 , 24, 27-33	9
1470	Lung cancer. 2008 , 359, 1367-80	1920
1469	Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement. 2008 , 265, 55-66	22
1468	Better survival with EGFR exon 19 than exon 21 mutations ^ in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals. 2008 , 265, 307-17	94

1467	Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents. 2008 , 11, 99-109	27
1466	Prognostic versus predictive value of biomarkers in oncology. 2008 , 44, 946-53	228
1465	The characteristics and failure pattern of gefitinib responders with postoperative recurrence of pulmonary adenocarcinoma. 2008 , 34, 89-93	6
1464	Acquired resistance to tyrosine kinase inhibitors during cancer therapy. 2008 , 18, 73-9	247
1463	Pharmacogenetics: improving drug and dose selection. 2008 , 8, 639-46	18
1462	Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours. 2008 , 60 Suppl 2, S3-9	61
1461	Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors. 2008 , 60 Suppl 2, S10-8	16
1460	The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations. 2008 , 60 Suppl 2, S19-22	17
1459	KRAS mutational testing in the selection of patients for EGFR-targeted therapies. 2008 , 25, 288-94	13
1458	Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer. 2008 , 62, 105-12	37
1457	Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. 2008 , 26, 4268-75	600
1456	First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. 2008 , 26, 2442-9	725
1455	Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung. 2008 , 59, 111-8	87
1454	Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. 2008 , 26, 1472-8	257
1453	Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. 2008 , 8, 129-38	92
1452	Cutaneous reactions related to systemic immunomodulators and targeted therapeutics. 2008 , 26, 121-59, ix	23
1451	[What's new in the 2004 WHO classification of the lung tumors?]. 2008 , 64, 187-94	4
1450	Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors. 2008 , 10, 489-500	33

1449	Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. 2008 , 14, 2895-9		576
1448	Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. 2008 , 83, 584-94		1313
1447	Genetic influences in common respiratory disorders. 2008 , 20, 171-89, vi		5
1446	EGFR tyrosine kinase inhibitors in lung cancer: an evolving story. 2008 , 59, 429-42		120
1445	Structure and clinical relevance of the epidermal growth factor receptor in human cancer. 2008 , 26, 1742-51	209	
1444	Implications of EGFR PharmDx kit for cetuximab eligibility. 2008 , 8, 141-8		15
1443	A mouse model for EML4-ALK-positive lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 19893-7	11.5	413
1442	EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. 2008 , 10, 242-8		149
1441	Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry. 2008 , 10, 160-8		45
1440	Genetic predictors of MEK dependence in non-small cell lung cancer. 2008 , 68, 9375-83		216
1439	Signaling networks assembled by oncogenic EGFR and c-Met. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 692-7	11.5	433
1438	Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. 2008 , 19, 1624-8		42
1437	Aberrations of chromosome 19 in asbestos-associated lung cancer and in asbestos-induced micronuclei of bronchial epithelial cells in vitro. 2008 , 29, 913-7		28
1436	Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response. 2008 , 14, 162-8		118
1435	Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. 2008 , 68, 4853-61		429
1434	Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. 2008 , 14, 7519-25		227
1433	Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC. 2008 , 13, 1166-76		39
1432	Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance?. 2008 , 13, 933-44		35

1431	Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis. 2008 , 61, 487-93	68
1430	Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments. 2008 , 14, 957-60	110
1429	Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment. 2008 , 14, 6867-76	40
1428	Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. 2008 , 14, 5731-4	429
1427	Intratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cells. 2008 , 1, 201-7	46
1426	Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern. 2008 , 13, 1276-84	64
1425	Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study. 2008 , 3, 258-64	48
1424	EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. 2008 , 3, 13-7	387
1423	An alternative method for screening EGFR mutation using RFLP in non-small cell lung cancer patients. 2008 , 3, 1096-103	38
1422	Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. 2008 , 3, S146-9	56
1421	Targeting growth factors in lung cancer. 2008 , 133, 1209-16	28
1420	Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib. 2008 , 68, 571-9	51
1419	The role of gefitinib in the management of Asian patients with non-small cell lung cancer. 2008 , 17, 401-11	10
1418	Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 14112-7	11.5 103
1417	Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. 2008 , 14, 6963-73	106
1416	Tumor cell killing mechanisms of epidermal growth factor receptor (EGFR) antibodies are not affected by lung cancer-associated EGFR kinase mutations. 2008 , 180, 4338-45	20
1415	Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer?. 2008 , 14, 3860-6	47
1414	Does gefitinib shorten lung cancer survival? Chaos redux. 2008 , 26, 2428-30	6

1413	Small molecule tyrosine kinase inhibitors: potential role in pediatric malignant solid tumors. 2008 , 8, 76-85	16
1412	Epidermal growth factor receptor-targeted therapy. 2008 , 81 Spec No 1, S36-44	21
1411	Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGFR) phosphorylation events associated with mutated EGFR compared with wild type. 2008 , 7, 1902-24	93
1410	The potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancer. 2008 , 9, 252-62	16
1409	HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. 2008 , 7, 3499-508	111
1408	Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. 2008 , 26, 983-94	253
1407	Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. 2008 , 26, 2745-53	222
1406	Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. 2008 , 14, 4877-82	242
1405	The Translational Research Working Group developmental pathway for anticancer agents (drugs or biologics). 2008 , 14, 5685-91	8
1404	Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents. 2008 , 14, 4326-35	26
1403	Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. 2008 , 7, 1880-9	182
1402	Drug-sensitive FGFR2 mutations in endometrial carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 8713-7	11.5 292
1401	Modeling oncogene addiction using RNA interference. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 12480-4	11.5 40
1400	Modeling genomic diversity and tumor dependency in malignant melanoma. 2008 , 68, 664-73	248
1399	Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. 2008 , 68, 589-96	155
1398	Overview of gefitinib in non-small cell lung cancer: an Asian perspective. 2009 , 39, 137-50	50
1397	A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. 2008 , 14, 3867-74	70
1396	Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. 2008 , 14, 7060-7	135

1395	Exhaled breath condensate is not suitable to detect EGFR somatic mutations. 2008 , 32, 1126-7		11
1394	A subset of lung adenocarcinomas and atypical adenomatous hyperplasia-associated foci are genotypically related: an EGFR, HER2, and K-ras mutational analysis. 2008 , 129, 202-10		41
1393	[18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung. 2008 , 14, 7423-9		136
1392	Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway. 2008 , 7, 2866-75		58
1391	A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. 2008 , 14, 7878-83		95
1390	The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. 2008 , 7, 874-9		175
1389	The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 2070-5	11.5	1431
1388	In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation. 2008 , 7, 1337-46		10
1387	Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting analysis in small samples obtained from patients with non-small cell lung cancer. 2008 , 14, 4751-7		66
1386	Somatic microindels in human cancer: the insertions are highly error-prone and derive from nearby but not adjacent sense and antisense templates. 2008 , 17, 2910-8		10
1385	Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms. 2008 , 14, 4079-84		57
1384	Exploring kinase inhibitors as therapies for human arenavirus infections. 2008 , 3, 243-251		10
1383	Somatic pharmacogenomics in cancer. 2008 , 8, 305-14		21
1382	c-Met inhibitors with different binding modes: two is better than one. 2008 , 7, 1157-60		20
1381	Case records of the Massachusetts General Hospital. Case 23-2008. A 26-year-old man with back pain and a mass in the lung. 2008 , 359, 405-14		2
1380	Medikamentöse Therapie des kleinzelligen Bronchialkarzinoms (SCLC) - neue molekulare Therapieansätze. 2008 , 29, 81-90		
1379	Proliferation of breast cancer cells: regulation, mediators, targets for therapy. 2008 , 8, 872-85		19
1378	Gefitinib first or gefitinib second: is timing everything in the treatment of EGFR mutant non-small cell lung cancer?. 2008 , 178, 783-5		

1377	The Role of the NF-kappaB Transcriptome and Proteome as Biomarkers in Human Head and Neck Squamous Cell Carcinomas. 2008 , 2, 409-426	21
1376	High-throughput lung cancer cell line screening for genotype-correlated sensitivity to an EGFR kinase inhibitor. 2008 , 438, 331-41	23
1375	EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach. 2008 , 9, 55-69	11
1374	Allelic imbalances of the egfr gene as key events in breast cancer progression--the concept of committed progenitor cells. 2008 , 8, 431-45	17
1373	Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase. 2008 , 7, 599-606	59
1372	The potential role of mTOR inhibitors in non-small cell lung cancer. 2008 , 13, 139-47	98
1371	Second-line treatment of advanced non-small cell lung cancer. 2008 , 3, 430-40	52
1370	Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. 2008 , 3, 111-6	224
1369	Mutations of epidermal growth factor receptor in colon cancer indicate susceptibility or resistance to gefitinib. 2008 ,	1
1368	First-generation epidermal growth factor receptor tyrosine kinase inhibitors in EGFR mutation: positive non-small cell lung cancer patients. 2008 , 3, S143-5	19
1367	A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells. 2008 , 3, 1224-35	93
1366	Heat shock protein 90 inhibition in lung cancer. 2008 , 3, S152-9	58
1365	A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. 2008 , 3, 386-93	78
1364	High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. 2008 , 111, 4788-96	77
1363	Biological agents in non-small cell lung cancer: a review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor. 2008 , 3, 664-73	31
1362	Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database. 2008 , 3, 832-9	115
1361	EGFR mutant lung adenocarcinomas in patients with germline BRCA mutations. 2008 , 3, 805	16
1360	Clinical experience with gefitinib in Indian patients. 2008 , 3, 380-5	18

1359	Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study. 2008 , 3, 1439-45	67
1358	Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer. 2008 , 3, 1104-11	29
1357	Combining chemo-, hormonal and targeted therapies to treat breast cancer (Review). 2008 ,	2
1356	Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer: a time for excitement and equipoise. 2008 , 3, 84-93	24
1355	Sequential molecular changes during multistage pathogenesis of small peripheral adenocarcinomas of the lung. 2008 , 3, 340-7	70
1354	Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship. 2008 , 83, 584-594	1919
1353	Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities. 2008 , 14, 2983-98	68
1352	Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer. 2008 , 3, 400-4	53
1351	Unlocking the biological clues of lung cancer. 2008 , 3, 809-10	7
1350	New directions in the management of advanced pancreatic cancer: a review. 2008 , 19, 435-46	32
1349	Impact of preexisting pulmonary fibrosis detected on chest radiograph and CT on the development of gefitinib-related interstitial lung disease. 2008 , 31, 340-4	20
1348	Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. 2008 , 18, 29-35	66
1347	Mutational analyses of multiple oncogenic pathways in intraductal papillary mucinous neoplasms of the pancreas. 2008 , 36, 168-72	31
1346	EGFR assays in lung cancer. 2008 , 15, 241-7	42
1345	New insights in drug development for the non-small cell lung cancer therapy. 2008 , 13, 5108-19	4
1344	P68 RNA helicase (DDX5) alters activity of cis- and trans-acting factors of the alternative splicing of H-Ras. 2008 , 3, e2926	44
1343	Functional copy-number alterations in cancer. 2008 , 3, e3179	129
1342	Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET). 2008 , 3, e3908	70

1341	Non-BAC component but not epidermal growth factor receptor gene mutation is associated with poor outcomes in small adenocarcinoma of the lung. 2008 , 3, 704-10	37
1340	Targeted therapies in non-small cell lung cancer. 2008 , 8, 199-205	4
1339	EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab. 2009 , 215	
1338	What changes are needed to the current direction and interpretation of clinical cancer research to meet the needs of the 21st century?. 2009 , 190, 74-7	10
1337	. 2009 ,	19
1336	DNA/RNA Markers for Colorectal Cancer Risk in Preserved Stool Specimens: A Pilot Study. 2009 , 95, 753-761	8
1335	Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. 2009 , 119, 3000-10	268
1334	Epidermal growth factor receptor mutations and the clinical outcome in male smokers with squamous cell carcinoma of lung. 2009 , 24, 448-52	50
1333	[KRAS status versus EGFR status in lung cancer therapy]. 2009 , 96 Suppl, S75-83	1
1332	[Radiotherapy and targeted therapies in non-small-cell lung cancer]. 2009 , 96, 311-9	0
1331	[Metastatic colorectal cancers and targeted therapy against EGFR]. 2009 , 25 Spec No 1, 13-21	1
1330	Pharmacogenomics of Dasatinib (Sprycel®) 365-402	
1329	Gefitinib in combination with gemcitabine and carboplatin in never smokers with non-small cell lung carcinoma: a retrospective analysis. 2009 , 4, 988-93	3
1328	Mutation detection by real-time PCR: a simple, robust and highly selective method. 2009 , 4, e4584	73
1327	Sequence and structure signatures of cancer mutation hotspots in protein kinases. 2009 , 4, e7485	57
1326	EGFR genomic alterations in cancer: prognostic and predictive values. 2009 , E3, 879	3
1325	Amrubicin for the treatment of advanced lung cancer. 2009 , 5, 171-80	3
1324	KRAS mutations in non-small cell lung cancer. 2009 , 6, 201-5	399

1323	The future of targeted therapy approaches in melanoma. 2009 , 4, 445-56	1
1322	Micropapillary histology: a frequent morphology of mutation-associated lung adenocarcinoma?. 2009 , 131, 615-7	6
1321	Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. 2009 , 15, 5267-73	328
1320	Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer. 2009 , 27, 5620-6	76
1319	COLD-PCR finds hot application in mutation analysis. 2009 , 55, 2077-8	18
1318	High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications. 2009 , 34, 489-506	31
1317	Integration of molecular profiling into the lung cancer clinic. 2009 , 15, 5317-22	73
1316	(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 4519-24	11.5 444
1315	A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment. 2009 , 101, 1453-63	88
1314	Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer. 2009 , 18, 1735-51	52
1313	A reevaluation of the clinical significance of histological subtyping of non--small-cell lung carcinoma: diagnostic algorithms in the era of personalized treatments. 2009 , 17, 206-18	78
1312	Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. 2009 , 8, 2526-36	61
1311	Proteasome inhibition blocks ligand-induced dynamic processing and internalization of epidermal growth factor receptor via altered receptor ubiquitination and phosphorylation. 2009 , 69, 976-83	30
1310	Technological challenges of theranostics in oncology. 2009 , 3, 381-93	11
1309	Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy. 2009 , 15, 460-7	127
1308	Mutations and response to epidermal growth factor receptor inhibitors. 2009 , 15, 1133-9	107
1307	The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinoma. 2009 , 20, 1257-63	14
1306	Distinct biological roles for the notch ligands Jagged-1 and Jagged-2. 2009 , 284, 17766-74	42

1305	Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib and clinical outcome. 2009 , 39, 267-70	53
1304	Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy. 2009 , 8, 2084-96	78
1303	Mechanisms of tumor resistance to EGFR-targeted therapies. 2009 , 13, 339-62	66
1302	Current treatments for advanced stage non-small cell lung cancer. 2009 , 6, 233-41	113
1301	Renal Cell Carcinoma. 2009 ,	3
1300	Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response. 2009 ,	2
1299	Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo. 2009 , 69, 5091-8	52
1298	Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification. 2009 , 15, 907-13	44
1297	EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. 2009 , 15, 4554-60	223
1296	Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer. 2009 , 15, 5040-8	22
1295	Biological prognostic and predictive factors in lung cancer. 2009 , 77 Suppl 1, 90-6	24
1294	Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study. 2009 , 22, 683-91	20
1293	High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886). 2009 , 8, 2073-80	47
1292	Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists. 2009 , 8, 18-22	67
1291	Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodies. 2009 , 1, 590-9	5
1290	Gefitinib in lung cancer therapy: clinical results, predictive markers of response and future perspectives. 2009 , 8, 206-12	9
1289	EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. 2009 , 4, 1466-72	59
1288	Systematically linking drug susceptibility to cancer genome aberrations. 2009 , 8, 3652-6	3

1287	Lung cancer profiling: Genetic and molecular predictors of MEK-dependence. 2009 , 8, 2081-3	
1286	The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms. 2009 , 9, 703-15	34
1285	Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer. 2009 , 8, 3296-306	50
1284	Theme: oncology--molecular mechanisms determining the efficacy of EGF receptor-specific tyrosine kinase inhibitors help to identify biomarker candidates. 2009 , 3, 139-51	4
1283	Modular protein engineering in emerging cancer therapies. 2009 , 15, 893-916	31
1282	Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. 2009 , 30, 1097-105	68
1281	Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. 2009 , 4, e4576	154
1280	A systems perspective of ras signaling in cancer. 2009 , 15, 1510-3	35
1279	Hierarchical modeling of activation mechanisms in the ABL and EGFR kinase domains: thermodynamic and mechanistic catalysts of kinase activation by cancer mutations. 2009 , 5, e1000487	63
1278	EML4-ALK: honing in on a new target in non-small-cell lung cancer. 2009 , 27, 4232-5	258
1277	Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. 2009 , 69, 7644-52	123
1276	Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. 2009 , 15, 7502-7509	115
1275	Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. 2009 , 15, 3484-94	244
1274	Elevated epithelial insulin-like growth factor expression is a risk factor for lung cancer development. 2009 , 69, 7439-48	46
1273	Mesenchymal stem cells derived from bone marrow of diabetic patients portrait unique markers influenced by the diabetic microenvironment. 2009 , 6, 260-70	43
1272	Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer. 2009 , 15, 2361-72	50
1271	Lung cancer in never smokers: molecular profiles and therapeutic implications. 2009 , 15, 5646-61	122
1270	Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology. 2009 , 27, 5650-9	103

1269	EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors. 2009 , 131, 478-89	64
1268	Comparison of FISH, PCR, and immunohistochemistry in assessing EGFR status in lung adenocarcinoma and correlation with clinicopathologic features. 2009 , 18, 133-7	9
1267	Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer. 2009 , 20, 213-26	31
1266	Identification and preliminary characterization of novel small molecules that inhibit growth of human lung adenocarcinoma cells. 2009 , 14, 1176-84	22
1265	Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. 2009 , 15, 3023-8	198
1264	Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. 2009 , 20, 696-702	161
1263	Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. 2009 , 15, 4493-8	159
1262	Pathogenesis of lung cancer signalling pathways: roadmap for therapies. 2009 , 33, 1485-97	114
1261	Toward noninvasive genomic screening of lung cancer patients. 2009 , 27, 2589-91	15
1260	Structure-based design of molecular cancer therapeutics. 2009 , 27, 315-28	57
1259	S-1: a new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer. 2009 , 10, 290-4	24
1258	ErbBs in lung cancer. 2009 , 315, 557-71	57
1257	The ErbB kinase domain: structural perspectives into kinase activation and inhibition. 2009 , 315, 649-58	60
1256	ERBBs in the gastrointestinal tract: recent progress and new perspectives. 2009 , 315, 583-601	37
1255	Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma. 2009 , 113, 370-3	69
1254	ErbB receptors and signaling pathways in cancer. 2009 , 21, 177-84	701
1253	Tyrosine phosphorylation: thirty years and counting. 2009 , 21, 140-6	472
1252	Linking somatic genetic alterations in cancer to therapeutics. 2009 , 21, 304-10	54

1251	Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. 2009 , 625, 6-22	18
1250	EGFR protein overexpression and mutation in areca quid-associated oral cavity squamous cell carcinoma in Taiwan. 2009 , 31, 1068-77	22
1249	MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. 2009 , 124, 1778-84	120
1248	Family history of cancer and nonmalignant lung diseases as risk factors for lung cancer. 2009 , 125, 146-52	39
1247	EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy. 2009 , 125, 2479-82	83
1246	Induction of aneuploidy by single-walled carbon nanotubes. 2009 , 50, 708-17	136
1245	Modified PEG-anilinoquinazoline derivatives as potential EGFR PET agents. 2009 , 52, 41-52	13
1244	EGFR R497K polymorphism is a favorable prognostic factor for advanced lung cancer. 2009 , 135, 313-8	30
1243	Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis. 2009 , 135, 1483-93	22
1242	Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma. 2009 , 135, 1647-54	56
1241	Sex-specific aspects of tumor therapy. 2009 , 48, 115-24	9
1240	Clinical-molecular factors predicting response and survival for tyrosine-kinase inhibitors. 2009 , 11, 428-36	4
1239	Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer. 2009 , 4, 37-44	11
1238	Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors. 2009 , 4, 267-73	19
1237	Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors. 2009 , 63, 1065-71	14
1236	Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro. 2009 , 69, 1529-37	23
1235	Pulmonary preneoplasia--sequential molecular carcinogenetic events. 2009 , 54, 43-54	67
1234	Predictive biomarkers in the development of oncology drugs: a therapeutic industry perspective. 2009 , 85, 535-8	16

1233	EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. 2009 , 22, 508-15	380
1232	Outpacing cancer. 2009 , 15, 718-22	1
1231	Attacking cancer at its foundation. 2009 , 15, 1153-7	19
1230	Targeting PI3K signalling in cancer: opportunities, challenges and limitations. 2009 , 9, 550-62	1915
1229	Awakening guardian angels: drugging the p53 pathway. 2009 , 9, 862-73	713
1228	Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. 2009 , 6, 352-66	178
1227	Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. 2009 , 8, 709-23	259
1226	Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. 2009 , 28 Suppl 1, S14-23	163
1225	Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. 2009 , 28 Suppl 1, S24-31	636
1224	Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. 2009 , 28 Suppl 1, S32-7	202
1223	Detection of K-Ras mutations in tumour samples of patients with non-small cell lung cancer using PNA-mediated PCR clamping. 2009 , 100, 985-92	48
1222	Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. 2009 , 100, 1257-66	79
1221	Mitogen-activated protein kinase phosphatase-1 modulated JNK activation is critical for apoptosis induced by inhibitor of epidermal growth factor receptor-tyrosine kinase. 2009 , 276, 1255-65	21
1220	EGFR mutation testing in NSCLC: Patterns of care and outcomes in Western Australia. 2009 , 5, 66-71	3
1219	Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner. 2009 , 103, 1729-37	20
1218	Women and lung cancer: clinical and molecular profiling as a determinate for treatment decisions: a literature review. 2009 , 69, 223-36	7
1217	Targeted therapy for advanced non-small cell lung cancers: historical perspective, current practices, and future development. 2009 , 33, 73-111	17
1216	Evaluating the utility of the HTRF Transcreeper ADP assay technology: a comparison with the standard HTRF assay technology. 2009 , 391, 31-8	27

1215	Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. 2009 , 2, ra31	291
1214	Kinase domain mutations in cancer: implications for small molecule drug design strategies. 2009 , 52, 1493-509	139
1213	Protein kinase inhibitors: contributions from structure to clinical compounds. 2009 , 42, 1-40	196
1212	Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. 2009 , 15, 2076-84	330
1211	Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. 2009 , 27, 2523-9	189
1210	Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. 2009 , 27, 264-70	49
1209	Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy. 2009 , 12, 65-73	37
1208	EGFR protein overexpression and gene copy number increases in oral tongue squamous cell carcinoma. 2009 , 45, 1700-8	44
1207	Cancer driver mutations in protein kinase genes. 2009 , 281, 117-27	65
1206	Simple polymerase chain reaction for the detection of mutations and deletions in the epidermal growth factor receptor gene: applications of this method for the diagnosis of non-small-cell lung cancer. 2009 , 401, 68-72	12
1205	Integrative genomic approaches to understanding cancer. 2009 , 1790, 478-84	6
1204	EGFR mutation in kidney carcinoma confers sensitivity to gefitinib treatment: a case report. 2009 , 27, 548-50	12
1203	Efficacy of signal pathway inhibitors alone and in combination with Cisplatin varies between human non-small cell lung cancer lines. 2009 , 154, 9-12	9
1202	The predictive value of epidermal growth factor receptor tests in patients with pulmonary adenocarcinoma: review of current "best evidence" with meta-analysis. 2009 , 40, 356-65	34
1201	[Prognostic value study of lung cancer molecular markers]. 2009 , 132, 529-36	0
1200	Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. 2009 , 27, 2653-9	237
1199	Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability. 2009 , 96, 858-74	39
1198	Immunohistochemical analysis of phosphorylated epidermal growth factor receptor might provide a surrogate marker of EGFR mutation. 2009 , 63, 241-6	16

1197	Impact of EGFR mutation analysis in non-small cell lung cancer. 2009 , 63, 315-21	84
1196	NAT2 fast acetylator genotypes are associated with an increased risk for lung cancer with wildtype epidermal growth factor receptors in Taiwan. 2009 , 64, 9-12	11
1195	Prognostic factors in previously treated non-small cell lung cancer patients with and without a positive response to the subsequent treatment with gefitinib. 2009 , 64, 341-5	7
1194	Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations. 2009 , 64, 314-8	75
1193	Epidermal growth factor receptor gene amplification in surgical resected Japanese lung cancer. 2009 , 64, 295-300	22
1192	Differential ErbB receptor expression and intracellular signaling activity in lung adenocarcinomas and squamous cell carcinomas. 2009 , 65, 25-33	36
1191	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. 2009 , 65, 80-4	105
1190	Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas. 2009 , 65, 355-62	64
1189	Effect of gefitinib on N-nitrosamine-4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced lung tumorigenesis in A/J mice. 2009 , 65, 284-9	9
1188	Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. 2009 , 361, 947-57	6253
1187	Mechanisms of Resistance to Targeted Tyrosine Kinase Inhibitors. 2009 , 73-93	
1186	Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. 2009 , 10, 281-9	330
1185	Evaluation of 7q31 region improves the accuracy of EGFR FISH assay in non small cell lung cancer. 2009 , 4, 36	14
1184	Recent advances of novel targeted therapy in non-small cell lung cancer. 2009 , 2, 2	52
1183	Gefitinib for the treatment of non-small-cell lung cancer. 2009 , 9, 17-35	35
1182	Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity. 2009 , 9, 1199-206	71
1181	Targeting the EGF receptor ectodomain in the context of cancer. 2009 , 13, 1347-61	1
1180	Screening for epidermal growth factor receptor mutations in lung cancer. 2009 , 361, 958-67	1809

1179	Traitements histoguidés : vers un regain d'intérêt pour le diagnostic histologique des tumeurs pulmonaires. 2009 , 1, S13-S16	
1178	Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. 2009 , 11, 1084-92	76
1177	Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers. 2009 , 69, 8341-8	100
1176	Quantitative prediction of fold resistance for inhibitors of EGFR. 2009 , 48, 8435-48	61
1175	Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. 2009 , 69, 5467-74	125
1174	Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas. 2009 , 16, 565-72	35
1173	Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer. 2009 , 27, 6229-36	77
1172	Significant association between EGFR-mutated lung adenocarcinoma and past illness from gastric cancer or uterine myoma: its implication in carcinogenesis. 2009 , 66, 287-91	9
1171	Should we be surprised at the paucity of response to EGFR inhibitors?. 2009 , 10, 522-7	42
1170	Molecular predictive and prognostic markers in non-small-cell lung cancer. 2009 , 10, 1001-10	167
1169	Estrogen and its signaling pathway in non-small cell lung cancer(NSCLC). 2009 , 23, 217-223	2
1168	Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach. 2009 , 52, 4981-5004	95
1167	Applications of genomics in melanoma oncogene discovery. 2009 , 23, 397-414, vii	21
1166	Carcinome bronchiolo-alvéolaire (CBA) : particularités et prise en charge thérapeutique. 2009 , 1, 428-435	
1165	Enediylne lidamycin enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, in epidermoid carcinoma A431 cells and lung carcinoma H460 cells. 2009 , 20, 41-9	6
1164	Minimally invasive adenocarcinomas of the lung. 2009 , 16, 166-71	13
1163	Treatment of Advanced Lung Cancer. 2009 , 16, 157-171	2
1162	Combined treatment with TNF-alpha/gefitinib alleviates the resistance to gefitinib in PC-9 cells. 2009 , 20, 832-7	14

1161	New targeted therapies for non-small-cell lung cancer. 2009 , 6, 335-350	4
1160	Non-Small Cell Lung Carcinoma. 2009 , 14, 199-205	2
1159	Laser capture microdissection: a tool for the molecular characterization of histologic subtypes of lung adenocarcinoma. 2009 , 24, 473-9	2
1158	Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. 2009 , 4, 809-15	127
1157	Cetuximab inhibits growth, peritoneal dissemination, and lymph node and lung metastasis of endometrial cancer, and prolongs host survival. 2009 , 35, 725-9	10
1156	Molecular analysis of carcinogen-induced rodent lung tumors: Involvement of microRNA expression and KrB or Egfr mutations. 2010 , 3, 141-7	19
1155	Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. 2009 , 4, 22-9	185
1154	EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort. 2009 , 4, 318-25	45
1153	Expression of ABC transporters, p53, Bax, Bcl-2 in an archival sample of non-small cell lung cancer bearing a deletion in the EGFR gene. 2009 , 23, 609-14	3
1152	Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases. 2009 , 33, 1752-64	179
1151	Recent developments of targeted therapies in the treatment of non-small cell lung cancer. 2009 , 6, 91-102	24
1150	Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. 2009 , 20, 851-5	133
1149	Adjuvant cisplatin-based chemotherapy for resected NSCLC: one size fits all?. 2010 , 21, 799-804	9
1148	Lung Cancer: Are we up to the Challenge?. 2010 , 11, 513-8	82
1147	Molecular targeted therapy in prevalent tumors: learning from the past and future perspectives. 2010 , 5, 166-77	7
1146	Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer. 2010 , 11, 85-94	8
1145	Tyrosine kinases as molecular targets to inhibit cancer progression and metastasis. 2010 , 16, 1396-409	9
1144	Discovering tumor suppressor genes through genome-wide copy number analysis. 2010 , 11, 297-310	15

1143	Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. 2010 , 5, 1706-13	237
1142	Inducible EGFR T790M-mediated gefitinib resistance in non-small cell lung cancer cells does not modulate sensitivity to PI103 provoked autophagy. 2010 , 5, 765-77	15
1141	The genomics of lung adenocarcinoma: opportunities for targeted therapies. 2010 , 1, 1200-10	64
1140	Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer. 2010 , 11, 851-64	40
1139	Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. 2010 , 5, 1048-53	68
1138	Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer. 2010 , 22, 112-20	36
1137	Molecular Diagnostics Testing for Lung Adenocarcinoma. 2010 , 15, 103-110	1
1136	Research Highlights. 2010 , 11, 743-746	2
1135	Are there imaging characteristics associated with epidermal growth factor receptor and KRAS mutations in patients with adenocarcinoma of the lung with bronchioloalveolar features?. 2010 , 5, 344-8	63
1134	Pineal parenchymal tumor of intermediate differentiation: clinicopathological report and analysis of epidermal growth factor receptor variant III expression. 2010 , 66, 963-8; discussion 968	10
1133	Ovarian cancer in 2010. 2010 , 7, 205-208	
1132	Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status. 2010 , 5, 591-6	65
1131	Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer. 2010 , 5, 1623-9	79
1130	Human papillomavirus is frequently detected in gefitinib-responsive lung adenocarcinomas. 2010 , 23, 1085-92	35
1129	Octogenarians with advanced non-small cell lung cancer: treatment modalities, survival, and prognostic factors. 2010 , 5, 82-9	17
1128	Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503. 2010 , 5, 169-78	60
1127	Overexpression of EGFR pathway-related genes in the circulation is highly correlated with EGFR mutations and overexpression in paired cancer tissue from patients with non-small cell lung cancer. 2010 , 23,	6
1126	Spectrum of LKB1, EGFR, and KRAS mutations in chinese lung adenocarcinomas. 2010 , 5, 1130-5	79

1125	Ligands of epidermal growth factor receptor and the insulin-like growth factor family as serum biomarkers for response to epidermal growth factor receptor inhibitors in patients with advanced non-small cell lung cancer. 2010 , 5, 1939-48	24
1124	Correlation between HLA alleles and EGFR mutation in Japanese patients with adenocarcinoma of the lung. 2010 , 5, 1136-42	12
1123	Personalizing therapy for ovarian cancer. 2010 , 7, 229-239	1
1122	Biomarkers with predictive and prognostic function in non-small cell lung cancer: ready for prime time?. 2010 , 8, 822-32	31
1121	Prognostic implications of epidermal growth factor receptor and KRAS gene mutations and epidermal growth factor receptor gene copy numbers in patients with surgically resectable non-small cell lung cancer in Taiwan. 2010 , 5, 1175-84	42
1120	Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. 2010 , 17, 889-97	266
1119	Personalized medicine: marking a new epoch in cancer patient management. 2010 , 8, 1175-87	125
1118	Molekulardiagnostik des Lungenkarzinoms zur Therapiestratifizierung. 2010 , 3, 87-93	
1117	Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. 2010 , 62, 346-61	320
1116	Targeted inhibition of kinases in cancer therapy. 2010 , 77, 573-86	29
1115	Lung adenocarcinoma: lessons in translation from bench to bedside. 2010 , 77, 597-605	30
1114	Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors. 2010 , 66, 381-8	47
1113	[Molecular diagnostics in lung carcinoma for therapy stratification]. 2010 , 31, 22-8	3
1112	Quantifying the sensitivities of EGF receptor (EGFR) tyrosine kinase inhibitors in drug resistant non-small cell lung cancer (NSCLC) cells using hydrogel-based peptide array. 2010 , 26, 424-31	17
1111	Evolution of resistance to anti-cancer therapy during general dosing schedules. 2010 , 263, 179-88	62
1110	Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations. 2010 , 136, 527-35	11
1109	Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer. 2010 , 136, 1341-7	60
1108	Dose effect of cigarette smoking on frequency and spectrum of epidermal growth factor receptor gene mutations in Korean patients with non-small cell lung cancer. 2010 , 136, 1937-44	25

1107	Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?. 2010 , 13, 1-14	330
1106	Impact of biomarkers on non-small cell lung cancer treatment. 2010 , 5, 5-17	14
1105	Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents. 2010 , 5, 65-72	43
1104	EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992. 2010 , 5, 245-55	50
1103	Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma. 2010 , 27, 9-15	49
1102	Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer. 2010 , 27, 91-7	15
1101	Evaluation of PTEN and Mcl-1 expressions in NSCLC expressing wild-type or mutated EGFR. 2010 , 27, 853-60	19
1100	Non-small-cell lung cancer harbouring mutations in the EGFR kinase domain. 2010 , 12, 75-80	33
1099	Biomarkers in bronchopulmonary cancer. 2010 , 12, 92-9	3
1098	Circulating endothelial and endothelial progenitor cells in non-small-cell lung cancer. 2010 , 12, 521-5	9
1097	Low correspondence of EGFR mutations in tumor tissue and paired serum of non-small-cell lung cancer patients. 2010 , 22, 27-31	5
1096	Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy. 2010 , 29, 37-48	75
1095	Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. 2010 , 29, 49-60	164
1094	High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. 2010 , 99, 283-6	181
1093	KRAS gene mutations in lung cancer: particulars established and issues unresolved. 2010 , 60, 651-60	35
1092	The emerging role of biomarkers in advanced non-small-cell lung cancer. 2010 , 11, 149-59	18
1091	Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas. 2010 , 10, 189	58
1090	Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas. 2010 , 10, 376	48

1089	Validating cancer drug targets through chemical genetics. 2010 , 1806, 251-7	2
1088	Introduction to the Biochemical Pharmacology special issue on targeted cancer therapy. 2010 , 80, 549	
1087	Targeting epidermal growth factor receptor: central signaling kinase in lung cancer. 2010 , 80, 613-23	69
1086	Somatic mutations of signaling genes in non-small-cell lung cancer. 2010 , 203, 7-15	36
1085	Mechanisms of resistance to HER family targeting antibodies. 2010 , 316, 1083-100	123
1084	Molecular alterations in uterine serous carcinoma. 2010 , 116, 286-9	26
1083	Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis. 2010 , 14, 51-69	110
1082	Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. 2010 , 2, 146-58	333
1081	Implications of key trials in advanced nonsmall cell lung cancer. 2010 , 116, 1155-64	13
1080	KRAS mutation status in primary nonsmall cell lung cancer and matched metastases. 2010 , 116, 2682-7	59
1079	Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors. 2010 , 116, 4309-17	17
1078	CanProVar: a human cancer proteome variation database. 2010 , 31, 219-28	55
1077	Unnatural polyketide analogues selectively target the HER signaling pathway in human breast cancer cells. 2010 , 11, 573-80	8
1076	KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach. 2010 , 49, 353-62	92
1075	Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer. 2010 , 1804, 559-66	124
1074	Rapid detection of epidermal growth factor receptor mutations with multiplex PCR and primer extension in lung cancer. 2010 , 17, 37	8
1073	Gene amplification of the transcription factor DP1 and CTNND1 in human lung cancer. 2010 , 222, 89-98	32
1072	Epidermal growth factor receptor (EGFR) expression in periocular and extraocular sebaceous carcinoma. 2010 , 37, 231-6	18

1071	Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. 2010 , 277, 301-8	355
1070	Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy. 2010 , 277, 309-15	57
1069	EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors. 2010 , 277, 316-26	76
1068	Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification. 2010 , 101, 167-72	56
1067	Mechanistic insights into acquired drug resistance in epidermal growth factor receptor mutation-targeted lung cancer therapy. 2010 , 101, 1933-8	6
1066	Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells. 2010 , 29, 2616-27	66
1065	Lung cancer stem cells: tools and targets to fight lung cancer. 2010 , 29, 4625-35	112
1064	Oncogenic mutations as predictive factors in colorectal cancer. 2010 , 29, 3033-43	87
1063	Dissecting variability in responses to cancer chemotherapy through systems pharmacology. 2010 , 88, 34-8	46
1062	A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. 2010 , 6, 291-9	221
1061	Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. 2010 , 10, 760-74	802
1060	Integrating molecular diagnostics into anticancer drug discovery. 2010 , 9, 523-35	45
1059	Advances in understanding cancer genomes through second-generation sequencing. 2010 , 11, 685-96	890
1058	Predictive biomarkers in the management of EGFR mutant lung cancer. 2010 , 1210, 45-52	8
1057	Chromosomal imbalances in lung adenocarcinomas with or without mutations in the epidermal growth factor receptor gene. 2010 , 15, 700-5	7
1056	The current status of targeted therapy for non-small cell lung cancer. 2010 , 40, 611-8	17
1055	Gene Expression Analysis for Tumor Profiling. 2010 , 225-241	
1054	[Correlation between microsatellite instability and morphology in colorectal cancer]. 2010 , 54, 169-78	1

1053	Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC). 2010 , 4, 81-98	34
1052	Predictive molecular markers for EGFR-TKI in non-small cell lung cancer patients: new insights and critical aspects. 2010 , 1, 10	1
1051	Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study. 2010 , 2010, 709678	16
1050	Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. 2010 , 2010, 568938	89
1049	Characterizing tyrosine phosphorylation signaling in lung cancer using SH2 profiling. 2010 , 5, e13470	29
1048	Anti-tumor effect in human lung cancer by a combination treatment of novel histone deacetylase inhibitors: SL142 or SL325 and retinoic acids. 2010 , 5, e13834	19
1047	Genomic aberrations in lung adenocarcinoma in never smokers. 2010 , 5, e15145	54
1046	The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer. 2010 , 4, 173-85	29
1045	The emerging role of nimotuzumab in the treatment of non-small cell lung cancer. 2010 , 4, 289-98	25
1044	Molecular Diagnostics in the Evaluation of Cancer. 2010 , 215-223	
1043	EGFR gene alterations as a prognostic biomarker in advanced esophageal squamous cell carcinoma. 2010 , 15, 65-72	26
1042	Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer. 2010 , 2, 143-56	19
1041	EGFR-mutated lung cancer: a paradigm of molecular oncology. 2010 , 1, 497-514	143
1040	EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance. 2010 , 3, 37-52	94
1039	. 2010 ,	6
1038	Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer. 2010 , 16, 3349-55	91
1037	Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. 2010 , 31, 577-86	129
1036	Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy. 2010 , 16, 2852-60	52

1035	The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations. 2010 , 2, 301-7	26
1034	Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations. 2010 , 70, 3843-50	45
1033	Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis. 2010 , 16, 3163-70	98
1032	TP53 and EGFR mutations in combination with lifestyle risk factors in tumours of the upper aerodigestive tract from South America. 2010 , 31, 1054-9	21
1031	Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. 2010 , 28, 3076-83	343
1030	Clinical implications of the cancer genome. 2010 , 28, 5219-28	156
1029	Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much?. 2010 , 16, 5972-80	98
1028	The molecular and cellular biology of lung cancer: identifying novel therapeutic strategies. 2010 , 95, 47-61	27
1027	Tyrosine kinase expression in pulmonary metastases and paired primary tumors. 2010 , 10, 228-31	3
1026	Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor. 2010 , 9, 1647-56	58
1025	Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. 2010 , 28, 1387-94	155
1024	Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. 2010 , 16, 5489-98	175
1023	TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation. 2010 , 9, 2785-92	64
1022	The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer. 2010 , 19, 186-96	28
1021	Update on nonsmall cell lung cancer. 2010 , 19, 173-85	14
1020	Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. 2010 , 28, 357-60	615
1019	EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry. 2010 , 133, 922-34	92
1018	Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system. 2010 , 285, 7035-44	54

1017	Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. 2010 , 2, 62ra93	646
1016	NonSmall Cell Carcinomas of the Lung. 2010 , 51-110	
1015	If histology matters. 2010 , 28, 1810-2	10
1014	Power to detect selective allelic amplification in genome-wide scans of tumor data. 2010 , 26, 518-28	7
1013	Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas. 2010 , 23, 159-68	98
1012	A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. 2010 , 16, 4647-53	89
1011	Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. 2010 , 363, 1693-703	3577
1010	Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma. 2010 , 19, 709-22	68
1009	Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer. 2010 , 11, 1683-93	7
1008	Novel biomarkers of metastatic cancer. 2010 , 10, 581-90	12
1007	A major step towards individualized therapy of lung cancer with gefitinib: the IPASS trial and beyond. 2010 , 10, 955-65	11
1006	Understanding resistance to EGFR inhibitors-impact on future treatment strategies. 2010 , 7, 493-507	503
1005	Selection criteria for c-Met-targeted therapies: emerging evidence for biomarkers. 2010 , 4, 149-70	6
1004	Promiscuous Anticancer Drugs from Pathogenic Bacteria: Rational Versus Intelligent Drug Design. 2010 , 179-198	4
1003	Molecular testing in lung carcinoma: Quo vadis?. 2010 , 134, 7-9	3
1002	Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation. 2010 , 70, 868-74	165
1001	Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. 2010 , 28, 911-7	368
1000	Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma. 2010 , 3, 111-9	63

999	TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 15535-40	11.5	299
998	miRNA expression profiling of lung adenocarcinomas: correlation with mutational status. 2010 , 23, 1577-82		119
997	Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report. 2010 , 16, 755-63		69
996	Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations. 2010 , 70, 8715-25		128
995	Taking care of smoker cancer patients: a review and some recommendations. 2010 , 21, 1404-1409		17
994	EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. 2010 , 12, 1193-9		201
993	Computational method for estimating DNA copy numbers in normal samples, cancer cell lines, and solid tumors using array comparative genomic hybridization. 2010 , 2010,		2
992	HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation. 2010 , 70, 1989-99		58
991	Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. 2010 , 19, 358-65		48
990	A growing family: adding mutated Erbb4 as a novel cancer target. 2010 , 9, 1487-503		30
989	Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer. 2010 , 5, 1933-8		46
988	Differential contribution to neuroendocrine tumorigenesis of parallel egfr signaling in cancer cells and pericytes. 2010 , 1, 125-41		20
987	Ubiquitination-dependent regulation of signaling receptors in cancer. 2010 , 1, 725-34		31
986	Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib. 2010 , 9, 572-82		45
985	Individualisierte Therapie für Patienten mit fortgeschrittenen Lungenkarzinomen. 2010 , 31, 79-87		
984	EGFR Mutation Testing in Non-Small Cell Lung Cancer. 2010 , 6, 310-321		2
983	Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis. 2010 , 194, 266-9		96
982	Developing better treatments in hepatocellular carcinoma. 2010 , 4, 551-60		20

981	Strategies for overcoming inherent and acquired resistance to EGFR inhibitors by targeting downstream effectors in the RAS/PI3K pathway. 2010 , 10, 824-33	22
980	New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. 2010 , 195, W221-8	153
979	Molecular bases of liver cancer refractoriness to pharmacological treatment. 2010 , 17, 709-40	50
978	From Systems Biology to Systems Pathology: A New Subspecialty in Diagnostic and Personalized Medicine. 2010 , 8, 108-116	
977	Predictive molecular markers of response to epidermal growth factor receptor(EGFR) family-targeted therapies. 2010 , 10, 799-812	23
976	Favorable response to gefitinib treatment of lung adenocarcinoma with coexisting germline and somatic epidermal growth factor receptor mutations. 2010 , 28, e701-3	8
975	Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo. 2010 , 10, 903-17	67
974	Drug efficacy testing in mice. 2012 , 355, 19-38	10
973	Emerging MEK inhibitors. 2010 , 15, 203-23	50
972	Carcinome bronchiolo-alvéolaire (CBA) : particularités et prise en charge thérapeutique. 2010 , 2, 298-305	0
971	[Pretreatment molecular biology analysis on small size biopsies]. 2010 , 30, 67-72	2
970	Targeted Therapies in Lung Cancer. 2010 , 3, 71-82	25
969	A Gprc5a tumor suppressor loss of expression signature is conserved, prevalent, and associated with survival in human lung adenocarcinomas. 2010 , 12, 499-505	28
968	Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor. 2010 , 53, 2892-901	48
967	Tumor size matters differently in pulmonary adenocarcinoma and squamous cell carcinoma. 2010 , 67, 296-300	4
966	Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers. 2010 , 67, 355-60	59
965	Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. 2010 , 68, 198-203	83
964	Assessment of mean EGFR gene copy number is a highly reproducible method for evaluating FISH in histological and cytological cancer specimens. 2010 , 68, 192-7	8

963	Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: Comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization study. 2010 , 68, 375-82	56
962	Rationale of a relaunch of gefitinib in Caucasian non-small cell lung cancer patients. 2010 , 69, 265-71	10
961	Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and Erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis. 2010 , 70, 174-9	33
960	Lessons learnt from gefitinib and erlotinib: Key insights into small-molecule EGFR-targeted kinase inhibitors in non-small cell lung cancer. 2010 , 69, 259-64	16
959	Comparable rate of EGFR kinase domain mutation in lung adenocarcinomas from Chinese male and female never-smokers. 2010 , 31, 647-8	11
958	A colliding maxillary sinus cancer of adenosquamous carcinoma and small cell neuroendocrine carcinoma--a case report with EGFR copy number analysis. 2010 , 8, 92	19
957	Human papillomavirus-16 presence and physical status in lung carcinomas from Asia. 2010 , 5, 20	21
956	Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung. 2010 , 11, E1-4	47
955	Management of Rare Adult Tumours. 2010 ,	2
954	Pharmacogenetics: Making cancer treatment safer and more effective. 2010 ,	1
953	Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance. 2010 , 16, 2266-74	107
952	Characterization of surfaces presenting covalently immobilized oligopeptides using near-edge X-ray absorption fine structure spectroscopy. 2010 , 26, 6464-70	10
951	Potential pulmonary effects of engineered carbon nanotubes: in vitro genotoxic effects. 2010 , 4, 396-408	74
950	A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases. 2010 , 41, 94-102	71
949	The close correlation between 8-hydroxy-2'-deoxyguanosine and epidermal growth factor receptor activating mutation in non-small cell lung cancer. 2010 , 41, 951-9	9
948	EGFR fluorescence in situ hybridization-positive lung adenocarcinoma: incidence of coexisting KRAS and BRAF mutations. 2010 , 41, 1053-60	24
947	TP53, EGFR, and KRAS mutations in relation to VHL inactivation and lifestyle risk factors in renal-cell carcinoma from central and eastern Europe. 2010 , 293, 92-8	19
946	3,3'-Diindolylmethane (DIM) inhibits the growth and invasion of drug-resistant human cancer cells expressing EGFR mutants. 2010 , 295, 59-68	32

945	Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells. 2010 , 296, 150-9	44
944	Novel monoclonal antibodies recognizing the active conformation of epidermal growth factor receptor. 2010 , 394, 685-90	8
943	Cytohesins are cytoplasmic ErbB receptor activators. 2010 , 143, 201-11	70
942	Biomarkers in lung oncology. 2010 , 23, 508-14	10
941	Targeting erbB receptors. 2010 , 21, 961-6	25
940	EGFR expression and gene copy number in triple-negative breast carcinoma. 2010 , 203, 222-9	55
939	Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. 2010 , 36 Suppl 3, S21-9	97
938	Clinical Applications of Kinase Inhibitors in Solid Tumors. 2010 , 615-631	1
937	Impact of age, sex, and comorbidity on cancer therapy and disease progression. 2010 , 28, 4086-93	164
936	Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer. 2010 , 68, 99-104	46
935	Molecularly Targeted Therapy for Childhood Cancer. 2010 ,	1
934	The Gender-Specific Aspects of Lung Cancer. 2010 , 260-269	
933	Tyrosine Kinase Inhibitors. 435-525	
932	Receptor Tyrosine Kinases. 119-213	
931	Intérêt des thérapies ciblées dans les cancers bronchiques non ^petites cellules localement avancés, en association avec la radiothérapie. 2010 , 2, 193-199	
930	Biochemical mechanisms of resistance to small-molecule protein kinase inhibitors. 2010 , 5, 121-38	48
929	Principles of Clinical Cancer Genetics. 2010 ,	2
928	Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations. 2010 , 28, e111-2	14

927	Erlotinib: as maintenance monotherapy in non-small-cell lung cancer. 2011 , 25, 139-46	2
926	Correlation of activated STAT3 expression with clinicopathologic features in lung adenocarcinoma and squamous cell carcinoma. 2011 , 15, 347-52	55
925	Detection of epidermal growth factor receptor mutations in a few cancer cells from transbronchial cytologic specimens by reverse transcriptase-polymerase chain reaction. 2011 , 15, 353-9	8
924	Rapid and efficient detection of EGFR mutations in problematic cytologic specimens by high-resolution melting analysis. 2011 , 15, 21-9	15
923	Mechanistic insights into the activation of oncogenic forms of EGF receptor. 2011 , 18, 1388-93	69
922	Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. 2011 , 29, 3307-15	343
921	A randomized phase II study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non-small cell lung cancer. 2011 , 17, 1553-60	89
920	Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. 2011 , 29, 2046-51	509
919	A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. 2011 , 13, 74-84	155
918	Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivity. 2011 , 10, 305-19	52
917	Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy. 2011 , 10, 1993-9	110
916	Circulating tumor cells: approaches to isolation and characterization. 2011 , 192, 373-82	837
915	Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer. 2011 , 8, 2069-79	40
914	[A simple view on lung cancer biology: The EGFR pathway]. 2011 , 28, 565-77	9
913	Evaluation and treatment of patients with non-small cell lung cancer. 2011 , 95, 1041-54	20
912	Targeted therapies for thymic malignancies. 2011 , 21, 115-23, viii	8
911	A decade of advances in treatment for advanced non-small cell lung cancer. 2011 , 32, 839-51	50
910	Molecular biology of lung cancer: clinical implications. 2011 , 32, 703-40	156

909	Implications of personalized medicine--perspective from a cancer center. 2011 , 8, 177-83	44
908	Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. 2011 , 37, 624-31	256
907	Recomendaciones para la determinaci3n de las mutaciones del gen EGFR en el carcinoma de pulm3n no microc3nico. 2011 , 44, 17-31	2
906	Bronchoscopic microsampling is a useful complementary diagnostic tool for detecting lung cancer. 2011 , 72, 32-8	17
905	Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor. 2011 , 72, 199-204	43
904	Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. 2011 , 73, 195-202	78
903	Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs. 2011 , 73, 176-82	127
902	Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. 2011 , 71, 249-57	92
901	Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues. 2011 , 72, 3-8	35
900	Duration of prior gefitinib treatment predicts survival potential in patients with lung adenocarcinoma receiving subsequent erlotinib. 2011 , 73, 211-6	12
899	Screening for EGFR mutations in lung cancer, a report from India. 2011 , 73, 316-9	70
898	Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials. 2011 , 74, 469-73	53
897	EGFR inhibitors with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer. 2011 , 73, 249-55	14
896	Predictive markers in the adjuvant therapy of non-small cell lung cancer. 2011 , 74, 355-63	21
895	Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. 2011 , 5, 471-85	129
894	Chapter 5:Kinase Mutations and Resistance in Cancer. 2011 , 126-160	0
893	Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines. 2011 , 50, 371-403	80
892	Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations. 2011 , 71, 79-88	6

891	Role of genotyping in non-small cell lung cancer treatment: current status. 2011 , 71, 2231-46	17
890	Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice. 2011 , 30, 30	63
889	Immunohistology of Lung and Pleural Neoplasms. 2011 , 369-463	2
888	Analysis of Somatic Mutations in Cancer: Molecular Mechanisms of Activation in the ErbB Family of Receptor Tyrosine Kinases. 2011 , 3, 1195-231	16
887	Principles of Anticancer Drug Development. 2011 ,	
886	Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. 2011 , 1, 608-25	108
885	Lung cancer: epidemiology, etiology, and prevention. 2011 , 32, 605-44	825
884	Survival and death signals can predict tumor response to therapy after oncogene inactivation. 2011 , 3, 103ra99	34
883	Targeted Therapies. 2011 ,	3
882	Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. 2011 , 3, 90ra59	383
881	The landscape of EGFR pathways and personalized management of non-small-cell lung cancer. 2011 , 7, 519-41	35
880	Molecular Determinants of Radiation Response. 2011 ,	1
879	Cancer Systems Biology, Bioinformatics and Medicine. 2011 ,	3
878	Simple and sensitive method for detecting point mutations of epidermal growth factor receptor using cationic conjugated polymers. 2011 , 3, 4539-45	21
877	CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool. 2011 , 18, 54-62	69
876	Importance of molecular features of non-small cell lung cancer for choice of treatment. 2011 , 178, 1940-8	36
875	Standardization of epidermal growth factor receptor (EGFR) measurement by quantitative immunofluorescence and impact on antibody-based mutation detection in non-small cell lung cancer. 2011 , 179, 580-9	20
874	Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors. 2011 , 37, 456-64	55

873	Mutant onco-proteins as drug targets: successes, failures, and future prospects. 2011 , 21, 29-33	9
872	P21 (waf1/cip1) is required for non-small cell lung cancer sensitive to Gefitinib treatment. 2011 , 65, 151-6	20
871	CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism. 2011 , 47, 1962-70	27
870	Next-generation sequencing applied to molecular diagnostics. 2011 , 11, 425-44	32
869	Integrating predictive biomarkers and classifiers into oncology clinical development programmes. 2011 , 10, 735-48	76
868	Excision repair cross complementation group 1 polymorphisms predict overall survival after platinum-based chemotherapy for completely resected non-small-cell lung cancer. 2011 , 168, 206-12	24
867	[Bronchiolar-alveolar carcinoma: From concept to innovative therapeutic strategies]. 2011 , 40, 389-97	1
866	Emerging treatments for choroidal metastases. 2011 , 56, 511-21	41
865	2010 Consensus on Lung Cancer, new clinical recommendations and current status of biomarker assessment--first-line therapy. 2011 , 47 Suppl 3, S248-57	5
864	Basic science of lung cancer. 2011 , 47 Suppl 3, S319-21	2
863	Evolution of platinum resistance in high-grade serous ovarian cancer. 2011 , 12, 1169-74	141
862	Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. 2011 , 12, 795-805	175
861	Imaging of lung cancer in the era of molecular medicine. 2011 , 18, 424-36	33
860	Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy. 2011 , 13, R35	86
859	The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer. 2011 , 11, 673-82	34
858	Epidermal growth factor receptor mutation-guided treatment for lung cancers: Where are we now?. 2011 , 2, 1-6	4
857	Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry. 2011 , 74, 35-40	60
856	Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. 2011 , 377, 1846-54	317

855	Kinase-driven pathways of EGFR in lung carcinomas: perspectives on targeting therapy. 2011 , 16, 1714-32	5
854	Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy. 2011 , 52, 7248-55	40
853	Lung Cancer Metastasis. 369-381	2
852	Drugs, Genomic Response Signatures, and Customized Cancer Therapy. 301-319	
851	Optimizing response to gefitinib in the treatment of non-small-cell lung cancer. 2011 , 4, 1-9	2
850	Personalized Therapy in Lung Cancer: Focused on Molecular Targeted Therapy. 2011 , 10, 1	2
849	Effectiveness of maintenance treatments for nonsmall cell lung cancer. 2011 , 2, 29-39	
848	Comparative Analysis of Peptide Nucleic Acid (PNA)-Mediated Real-Time PCR Clamping and DNA Direct Sequencing for EGFR Mutation Detection. 2011 , 70, 21	9
847	Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer. 2011 , 2, 59-67	10
846	Radish (<i>Raphanus sativus</i> L. leaf) ethanol extract inhibits protein and mRNA expression of ErbB(2) and ErbB(3) in MDA-MB-231 human breast cancer cells. 2011 , 5, 288-93	23
845	Combined inhibition of insulin-like growth factor-1 receptor enhances the effects of gefitinib in a human non-small cell lung cancer resistant cell line. 2011 , 2, 1091-1095	12
844	EGFR genomic alterations in cancer: prognostic and predictive values. 2011 , 3, 879-87	23
843	Signatures of drug sensitivity in nonsmall cell lung cancer. 2011 , 2011, 215496	18
842	Receptor-tyrosine-kinase-targeted therapies for head and neck cancer. 2011 , 2011, 982879	17
841	The Gap between Tobacco Treatment Guidelines, Health Service Organization, and Clinical Practice in Comprehensive Cancer Centres. 2011 , 2011, 145617	8
840	EGFR Signaling in Colorectal Carcinoma. 2011 , 2011, 932932	81
839	Benchmarking of mutation diagnostics in clinical lung cancer specimens. 2011 , 6, e19601	95
838	Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells. 2011 , 6, e21428	67

837	Systems biology modeling reveals a possible mechanism of the tumor cell death upon oncogene inactivation in EGFR addicted cancers. 2011 , 6, e28930	9
836	Molecular Biology and Genetics of Lung Cancer. 2011 , 3-15	2
835	Comprehensive histologic analysis of ALK-rearranged lung carcinomas. 2011 , 35, 1226-34	239
834	Molecular tumor profiling for prediction of response to anticancer therapies. 2011 , 17, 71-9	19
833	Increasing the Odds of: Is This Treatment Going to Work? 2011 , 20, 1-2	
832	Detection of epithelial growth factor receptor mutations in cerebrospinal fluid from patients with lung adenocarcinoma suspected of neoplastic meningitis. 2011 , 6, 1215-20	38
831	PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells. 2011 , 11, 358-67	6
830	Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. 2011 , 6, 707-15	140
829	What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements. 2011 , 43, 103-15	46
828	Genotyping non-small cell lung cancer (NSCLC) in Latin America. 2011 , 6, 1955-9	83
827	Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. 2011 , 6, 1152-61	211
826	Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations. 2011 , 6, 569-75	102
825	Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer. 2011 , 6, 627-30	57
824	EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy. 2012 , 27, 880-90	10
823	The C-terminus of Hsp70-interacting protein promotes Met receptor degradation. 2011 , 6, 679-87	31
822	Personalized medicine in non-small-cell lung cancer: has it come of age?. 2011 , 1, 1601-1603	
821	Cell signaling molecules as drug targets in lung cancer: an overview. 2011 , 17, 286-91	2
820	Functional and clinical characterization of the putative tumor suppressor WWOX in non-small cell lung cancer. 2011 , 6, 1976-83	14

819	Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans. 2011 , 6, 28-31	107
818	EGFR gene alterations in a Norwegian cohort of lung cancer patients selected for surgery. 2011 , 6, 947-50	37
817	NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. 2011 , 9 Suppl 5, S1-32; quiz S33	195
816	Targeted therapy: an evolving world of lung cancer. 2011 , 16, 13-21	14
815	Identification of EGFR and KRAS mutations in Chinese patients with esophageal squamous cell carcinoma. 2011 , 24, 374-80	23
814	Unique p53 and epidermal growth factor receptor gene mutation status in 46 pulmonary lymphoepithelioma-like carcinomas. 2011 , 102, 282-7	53
813	Detection of low-level EGFR T790M mutation in lung cancer tissues. 2011 , 119, 403-11	22
812	An Integrated Next-Generation Sequencing System for Analyzing DNA Mutations, Gene Fusions, and RNA Expression in Lung Cancer. 2019 , 12, 836-845	11
811	Clinical development of targeted and immune based anti-cancer therapies. 2019 , 38, 156	93
810	Integrated Somatic and Germline Whole-Exome Sequencing Analysis in Women with Lung Cancer after a Previous Breast Cancer. 2019 , 11,	1
809	Signal Transduction in Disease. 2019 , 73-111	
808	Discovery Stories of RET Fusions in Lung Cancer: A Mini-Review. 2019 , 10, 216	19
807	Tyrosine Kinase Inhibitor Imatinib Mesylate Alters DMBA-Induced Early Onco/Suppressor Gene Expression with Tissue-Specificity in Mice. 2019 , 2019, 8670398	3
806	Glycerol kinase 5 confers gefitinib resistance through SREBP1/SCD1 signaling pathway. 2019 , 38, 96	16
805	On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation. 2019 , 25, 3341-3351	51
804	EGFR Gene Polymorphism Predicts Improved Outcome in Patients With EGFR Mutation-positive Non-small cell Lung Cancer Treated With Erlotinib. 2019 , 20, 161-166.e1	8
803	GSK-3 β regulates the endothelial-to-mesenchymal transition via reciprocal crosstalk between NSCLC cells and HUVECs in multicellular tumor spheroid models. 2019 , 38, 46	20
802	Non-Smoking-Associated Lung Cancer: A distinct Entity in Terms of Tumor Biology, Patient Characteristics and Impact of Hereditary Cancer Predisposition. 2019 , 11,	28

801	Gefitinib Plus Bevacizumab . Gefitinib Alone for Mutant Non-squamous Non-small Cell Lung Cancer. 2019 , 33, 477-482	12
800	Mutational profile of Brazilian lung adenocarcinoma unveils association of EGFR mutations with high Asian ancestry and independent prognostic role of KRAS mutations. 2019 , 9, 3209	18
799	An Overview, Current Challenges of Drug Resistance, and Targeting Metastasis Associated With Lung Cancer. 2019 , 21-38	
798	Update on emerging biomarkers in lung cancer. 2019 , 11, S81-S88	20
797	Lessons learned from exceptional responders. 2019 , 4, 73-80	
796	Computational Analysis of Structural Dynamics of EGFR and its Mutants. 2019 ,	2
795	Current Approaches in NSCLC Targeting K-RAS and EGFR. 2019 , 20,	23
794	Osimertinib-Induced Cardiotoxicity: A Retrospective Review of the FDA Adverse Events Reporting System (FAERS). 2019 , 1, 172-178	20
793	. 2019 ,	1
792	The Evolving Landscape of Cancer Therapeutics. 2019 , 260, 43-79	5
791	From the Broad Phase II Trial to Precision Oncology: A Perspective on the Origins of Basket and Umbrella Clinical Trial Designs in Cancer Drug Development. 2019 , 25, 245-253	3
790	Epidermal growth factor receptor first generation tyrosine-kinase inhibitors. 2019 , 8, S235-S246	6
789	The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. 2019 , 4, 61	223
788	microRNAs Tune Oxidative Stress in Cancer Therapeutic Tolerance and Resistance. 2019 , 20,	12
787	Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. 2019 , 8, S247-S264	27
786	Comparison of next-generation sequencing and immunohistochemistry analysis for targeted therapy-related genomic status in lung cancer patients. 2019 , 11, 4992-5003	9
785	Digital PCR After MALDI-Mass Spectrometry Imaging to Combine Proteomic Mapping and Identification of Activating Mutations in Pulmonary Adenocarcinoma. 2019 , 13, e1800034	11
784	Covalent vs. Non-Covalent Inhibition: Tackling Drug Resistance in EGFR - A Thorough Dynamic Perspective. 2019 , 16, e1800518	6

783	Noteworthy effect of slight variation in aliphatic chain length of trisubstituted imidazole inhibitors against epidermal growth factor receptor L858R/T790M/C797S mutant in cancer therapy. 2019 , 93, 798-810	6
782	Cancer biomarker discovery and translation: proteomics and beyond. 2019 , 16, 93-103	54
781	Multicenter experience with large panel next-generation sequencing in patients with advanced solid cancers in Japan. 2019 , 49, 174-182	3
780	Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy. 2019 , 53,	36
779	Structural insight into the binding mechanism of ATP to EGFR and L858R, and T790M and L858R/T790 mutants. 2019 , 37, 4671-4684	13
778	Prevalence of ROS1 fusion in Chinese patients with non-small cell lung cancer. 2019 , 10, 47-53	17
777	Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. 2019 , 139, 395-411	194
776	Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors. 2019 , 20, 82-87	11
775	Lung squamous cell carcinoma: A postoperative recurrence analysis of keratinizing and nonkeratinizing subtypes. 2019 , 45, 838-844	4
774	EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer. 2019 , 1871, 29-39	71
773	The Impact of Next-Generation Sequencing on Cancer Genomics: From Discovery to Clinic. 2019 , 9,	16
772	Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR. 2019 , 162, 507-524	8
771	The lonely driver or the orchestra of mutations? How next generation sequencing datasets contradict the concept of single driver checkpoint mutations in solid tumours - NSCLC as a scholarly example. 2019 , 58, 22-28	6
770	Screening system for epidermal growth factor receptor mutation detection in cytology cell-free DNA of cerebrospinal fluid based on assured sample quality. 2019 , 30, 144-149	9
769	Synthesis and structure-activity-relationship of 3,4-Diaryl-1H-pyrrolo[2,3-b]pyridines as irreversible Inhibitors of mutant EGFR-L858R/T790M. 2019 , 128, 91-96	3
768	Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations. 2019 , 127, 146-152	29
767	Chest radiography surveillance for lung cancer: Results from a National Health Insurance database in South Korea. 2019 , 128, 120-126	3
766	ZWINT is the next potential target for lung cancer therapy. 2019 , 145, 661-673	16

765	Cancer therapeutic targeting using mutant-p53-specific siRNAs. 2019 , 38, 3415-3427	11
764	MicroRNA-122 negatively associates with peroxiredoxin-II expression in human gefitinib-resistant lung cancer stem cells. 2019 , 26, 292-304	13
763	Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations. 2019 , 20, e186-e194	27
762	The KIF5B-RET Fusion Gene Mutation as a Novel Mechanism of Acquired EGFR Tyrosine Kinase Inhibitor Resistance in Lung Adenocarcinoma. 2019 , 20, e73-e76	9
761	Single-Molecule Fluorescence Detection of the Epidermal Growth Factor Receptor in Membrane Discs. 2019 , 58, 286-294	3
760	Smoking Status and Survival Among a National Cohort of Lung and Colorectal Cancer Patients. 2019 , 21, 497-504	15
759	Intracellular Signaling. 2020 , 24-46.e12	
758	Classification and Imaging Findings of Lung Neoplasms. 2020 , 55, 41-50	1
757	Structure Defines Function: Clinically Relevant Mutations in ErbB Kinases. 2020 , 63, 40-51	4
756	Advances in nanotechnology-based delivery systems for EGFR tyrosine kinases inhibitors in cancer therapy. 2020 , 15, 26-41	18
755	Cancer of the Lung: NonSmall Cell Lung Cancer and Small Cell Lung Cancer. 2020 , 1108-1158.e16	5
754	PAQR3 suppresses the growth of non-small cell lung cancer cells via modulation of EGFR-mediated autophagy. 2020 , 16, 1236-1247	27
753	Designing clinical studies for biomarker discovery: The Design criteria. 2020 , 441-466	
752	Practical Cytopathology. 2020 ,	
751	Detection of rare and novel EGFR mutations in NSCLC patients: Implications for treatment-decision. 2020 , 139, 35-40	16
750	The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. 2020 , 112, 1021-1029	61
749	Genomics and the History of Precision Oncology. 2020 , 29, 35-49	8
748	Imaging of Novel Oncologic Treatments in Lung Cancer Part 1: Systemic Therapies. 2020 , 35, 26-36	3

747	Imaging Features and Metastatic Patterns of Advanced -Rearranged Non-Small Cell Lung Cancer. 2020 , 214, 766-774	11
746	Twenty-five years of Respiriology: Advances in lung cancer. 2020 , 25, 26-31	2
745	Targeting the IL-17/EHD1/TUBB3 axis overcomes resistance to EGFR-TKI in NSCLC. 2020 , 39, 1739-1755	16
744	Collaboration Between RSK-EphA2 and Gas6-Axl RTK Signaling in Arginine Starvation Response That Confers Resistance to EGFR Inhibitors. 2020 , 13, 355-364	7
743	Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase-rearranged Advanced Non-Small Cell Lung Cancer Patients Treated With Crizotinib. 2020 , 35, 101-107	5
742	Detection of T790M Mutation by Droplet Digital Polymerase Chain Reaction in Lung Carcinoma Cytology Samples. 2020 ,	1
741	Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer. 2020 , 21, e191-e204	14
740	Compound 15c, a Novel Dual Inhibitor of EGFR and FGFR1, Efficiently Overcomes Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance of Non-Small-Cell Lung Cancers. 2019 , 10, 1533	3
739	Integrated analysis of long non-coding RNAs and mRNA profiles reveals potential sex-dependent biomarkers of bevacizumab/erlotinib response in advanced lung cancer. 2020 , 15, e0240633	
738	Targeting EGFR tyrosine kinase: Synthesis, in vitro antitumor evaluation, and molecular modeling studies of benzothiazole-based derivatives. 2020 , 104, 104259	7
737	Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer. 2020 , 149, 33-40	2
736	Integrative analysis of genomic alteration, immune cells infiltration and prognosis of lung squamous cell carcinoma (LUSC) to identify smoking-related biomarkers. 2020 , 89, 107053	6
735	A rare EGFR mutation L747P conferred therapeutic efficacy to both gefitinib and osimertinib: A case report. 2020 , 150, 9-11	3
734	Traitement des cancers bronchiques non ^ petites cellules de stades avancs muts EGFR : quels inhibiteurs ? Quelles squences thrapeutiques ?. 2020 , 12, 2S195-2S211	1
733	Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers. 2020 , 148, 113-121	11
732	Discrete Coiled Coil Rotamers Form within the EGFRvIII Jxtamembrane Domain. 2020 , 59, 3965-3972	1
731	Typical presentation of pulmonary lepidic adenocarcinoma: a rare case report. 2020 , 36, 11	
730	Structural Basis of AZD9291 Selectivity for EGFR T790M. 2020 , 63, 8502-8511	27

729	Clinicopathological characteristics of lung adenocarcinoma with compound EGFR mutations. 2020 , 103, 42-51	4
728	How should molecular findings be integrated in the classification for lung cancer?. 2020 , 9, 2245-2254	3
727	Patient-derived cell line, xenograft and organoid models in lung cancer therapy. 2020 , 9, 2214-2232	17
726	Impact of Lineage Plasticity to and from a Neuroendocrine Phenotype on Progression and Response in Prostate and Lung Cancers. 2020 , 80, 562-577	12
725	High frequency of exon 20 S768I EGFR mutation detected in malignant pleural effusions: A poor prognosticator of NSCLC. 2020 , 3, e1262	2
724	Emerging Therapies in Thoracic Malignancies-Immunotherapy, Targeted Therapy, and T-Cell Therapy in Non-Small Cell Lung Cancer. 2020 , 29, 555-569	3
723	Ion Channels in Lung Cancer. 2020 , 1	4
722	Medical management of brain metastases. 2020 , 2, vdaa015	6
721	New horizons in benzothiazole scaffold for cancer therapy: Advances in bioactivity, functionality, and chemistry. 2020 , 20, 100783	10
720	Is Structure-Based Drug Design Ready for Selectivity Optimization?. 2020 , 60, 6211-6227	10
719	Efficacy of afatinib for pulmonary adenocarcinoma with leptomeningeal metastases harboring an epidermal growth factor receptor complex mutation (exon 19del+K754E): A case report. 2020 , 99, e22851	0
718	Impact of Somatic Mutations in Non-Small-Cell Lung Cancer: A Retrospective Study of a Chinese Cohort. 2020 , 12, 7427-7437	1
717	Management of brain metastases according to molecular subtypes. 2020 , 16, 557-574	44
716	Somatic mutation detection efficiency in EGFR: a comparison between high resolution melting analysis and Sanger sequencing. 2020 , 20, 902	4
715	Concomitant genetic alterations are associated with response to targeted therapy in patients with lung adenocarcinoma. 2020 , 9, 1225-1234	5
714	Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor. 2020 , 12,	9
713	Transcriptome Profiling of Acquired Gefitinib Resistant Lung Cancer Cells Reveals Dramatically Changed Transcription Programs and New Treatment Targets. 2020 , 10, 1424	5
712	EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy. 2020 , 10, 10589-10605	8

711	Making NSCLC Crystal Clear: How Kinase Structures Revolutionized Lung Cancer Treatment. 2020 , 10, 725	1
710	EGFR testing and erlotinib use in non-small cell lung cancer patients in Kentucky. 2020 , 15, e0237790	3
709	What Is the Standard First-Line Treatment for Advanced Non-Small Cell Lung Cancer?. 2020 , 26, 485-495	3
708	RAS-targeted therapies: is the undruggable drugged?. 2020 , 19, 533-552	212
707	Transcriptional activation of cyclin D1 via HER2/HER3 contributes to EGFR-TKI resistance in lung cancer. 2020 , 178, 114095	7
706	Targeted Therapy for Non-Small Cell Lung Cancer. 2020 , 41, 409-434	6
705	Tumor volume dynamics and tumor growth rate in -rearranged advanced non-small-cell lung cancer treated with crizotinib. 2020 , 7, 100210	2
704	Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies. 2020 , 9,	9
703	Pharmacokinetic Profiles Determine Optimal Combination Treatment Schedules in Computational Models of Drug Resistance. 2020 , 80, 3372-3382	4
702	Pulmonary Administration: Strengthening the Value of Therapeutic Proximity. 2020 , 7, 50	5
701	Clinicopathological parameters for circulating tumor DNA shedding in surgically resected non-small cell lung cancer with EGFR or KRAS mutation. 2020 , 15, e0230622	21
700	Polymorphism and Survival of NSCLC Patients Treated with TKIs: A Systematic Review and Meta-Analysis. 2020 , 2020, 1973241	17
699	Determining the appropriate treatment for different EGFR mutations in non-small cell lung cancer patients. 2020 , 14, 565-576	5
698	Epidermal growth factor receptor (EGFR) involvement in epithelial-derived cancers and its current antibody-based immunotherapies. 2020 , 44, 1267-1282	15
697	Adefovir dipivoxil induces DNA replication stress and augments ATR inhibitor-related cytotoxicity. 2020 , 147, 1474-1484	2
696	Immunohistochemistry Profile Predicts Mutation Status in Lung Adenocarcinoma. 2020 , 28, 502-506	
695	Clinical Utility of Reflex Ordered Testing for Molecular Biomarkers in Lung Adenocarcinoma. 2020 , 21, 437-442	12
694	Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer. 2020 , 12, 2896-2909	2

693	Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer. 2020 , 86, 211-219	6
692	Successful Desensitization Treatment with Osimertinib after the Development of Osimertinib-induced Urticaria in a Patient Undergoing Treatment for Non-small Cell Lung Cancer Harboring the EGFR T790M Mutation. 2020 , 59, 2161-2164	2
691	Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment. 2020 , 147, 1-57	17
690	Gallbladder cancer with EGFR mutation and its response to GemOx with erlotinib: a case report and review of literature. 2020 , 18, 153	4
689	Inhibition of lncRNA PART1 Chemosensitizes Wild Type but Not KRAS Mutant NSCLC Cells. 2020 , 12, 4453-4460	3
688	Tumour content ratio matters for detecting epidermal growth factor receptor mutation by cobas test in small biopsies; a retrospective study. 2020 , 20, 104	
687	Plasma Next Generation Sequencing and Droplet Digital-qPCR-Based Quantification of Circulating Cell-Free RNA for Noninvasive Early Detection of Cancer. 2020 , 12,	15
686	Molecular Analysis of Liquid-Based Cytological Specimen Using Virtually Positive Sputum with Adenocarcinoma Cells. 2020 , 10,	5
685	New Preclinical Development of a c-Met Inhibitor and Its Combined Anti-Tumor Effect in c-Met-Amplified NSCLC. 2020 , 12,	4
684	Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples. 2020 , 18, 99	4
683	Multiple Growth Factor Targeting by Engineered Insulin-like Growth Factor Binding Protein-3 Augments EGF Receptor Tyrosine Kinase Inhibitor Efficacy. 2020 , 10, 2735	4
682	Current approaches to the management of brain metastases. 2020 , 17, 279-299	110
681	Diagnostic Molecular Pathology. 2020 , 2145-2159	
680	Interactions Between Tumor Biology and Targeted Nanoplatfoms for Imaging Applications. 2020 , 30, 1910402	15
679	Conjoint Analysis of DNA Methylation for Tumor Differentiation Using Cationic Conjugated Polymers.. 2020 , 3, 2867-2872	1
678	Identification of Novel CD74-NRG2 Fusion From Comprehensive Profiling of Lung Adenocarcinoma in Japanese Never or Light Smokers. 2020 , 15, 948-961	15
677	Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population. 2020 , 141, 82-88	13
676	[Molecular diagnostics of cytological specimens]. 2020 , 41, 39-45	3

675	Precision Management of Advanced Non-Small Cell Lung Cancer. 2020 , 71, 117-136	52
674	Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function. 2020 , 235, 8085-8097	5
673	Molekularpathologische Diagnostik an zytologischen Präparaten. 2020 , 23, 62-68	
672	Synthesis and Biological Activities of Novel Aryldiazo Substituted Heterocycles. 2020 , 52, 147-165	2
671	Fucoidan increased the sensitivity to gefitinib in lung cancer cells correlates with reduction of TGFβ-mediated Slug expression. 2020 , 153, 796-805	15
670	Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells. 2020 , 12,	2
669	Commentary: Where there is no smoke, but fire. 2021 , 161, 1920-1921	
668	Turning liabilities into opportunities: Off-target based drug repurposing in cancer. 2021 , 68, 209-229	11
667	search of triple mutant T790M/C797S allosteric inhibitors to conquer acquired resistance problem in non-small cell lung cancer (NSCLC): a combined approach of structure-based virtual screening and molecular dynamics simulation. 2021 , 39, 1491-1505	13
666	ECMarker: interpretable machine learning model identifies gene expression biomarkers predicting clinical outcomes and reveals molecular mechanisms of human disease in early stages. 2021 , 37, 1115-1124	6
665	Non-small cell lung cancer in never- and ever-smokers: Is it the same disease?. 2021 , 161, 1903-1917.e9	6
664	Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC. 2021 , 16, 205-215	36
663	An Unusual Presentation of Aggressive Primary Invasive Adenocarcinoma of Lung. 2021 , 361, 118-125	
662	Acquired MET amplification in non-small cell lung cancer is highly associated with the exposure of EGFR inhibitors and may not affect patients' outcome. 2021 , 118, 104572	1
661	Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations. 2021 , 152, 39-48	12
660	Three bufadienolides induce cell death in the human lung cancer cell line CL1-5 mainly through autophagy. 2021 , 31, 127715	1
659	2020 Innovation-Based Optimism for Lung Cancer Outcomes. 2021 , 26, e454-e472	4
658	Comprehensive genomic profiling of Brazilian non-small cell lung cancer patients (GBOT 0118/LACOG0418). 2021 , 12, 580-587	7

657	Clathrin-mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild-type EGFR non-small cell lung cancer. 2021 , 10, 372-385	4
656	Drug delivery to optimize angiogenesis imbalance in keloid: A review. 2021 , 329, 1066-1076	4
655	Visualization of Protein-Drug Interactions for the Analysis of Drug Resistance in Lung Cancer. 2021 , 25, 1839-1848	0
654	Simple Synthesis of a Heterocyclophane Exhibiting Anti-c-Met Activity by Acting as a Hatch Blocking Access to the Active Site*. 2021 , 27, 1648-1654	1
653	Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy. 2021 , 13, 1758835920949418	1
652	Geometrical Features of Epidermal Growth Factor Receptor-Related Dimers Reveal the Mechanisms of Drug Resistance in Lung Cancer Patients. 2021 , 9, 5704-5715	0
651	A novel synthetic acanthoic acid analogues and their cytotoxic activity in cholangiocarcinoma cells. 2021 , 29, 115886	3
650	Expression of HYOU1 via Reciprocal Crosstalk between NSCLC Cells and HUVECs Control Cancer Progression and Chemoresistance in Tumor Spheroids. 2021 , 44, 50-62	5
649	Osimertinib in EGFR-Mutant Non-Small Cell Lung Carcinoma: Clinical Activity and Mechanisms of Resistance. 2021 , 65-73	
648	Cell-Free Circulating Tumor DNA Improves Standard Genotyping of Non-Small-Cell Lung Cancer and Increases Detection of Targetable Alterations in a Selected Hispanic Cohort. 2021 , 99, 539-546	0
647	Lung Cancer. 2021 , 147-169	
646	Allosteric Inhibition of the Epidermal Growth Factor Receptor. 2021 , 60, 500-512	1
645	Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment: A cohort study. 2021 , 100, e23712	1
644	Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations. 2021 , 13,	23
643	One-step determination of deletion mutation based on loop-mediated isothermal amplification. 2021 , 616, 114087	3
642	Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor. 2021 , 112, 1963-1974	7
641	Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models. 2021 , 13, e13144	3
640	Prognostic role of epidermal growth factor receptor mutation status in patients with de novo lung adenocarcinoma.. 2021 , 10, 1549-1558	

639	Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response. 2021 , 11, 1736-1753	14
638	Clinical cancer genomic profiling. 2021 , 22, 483-501	15
637	Dacomitinib as first-line treatment for EGFR mutation-positive non-small cell lung cancer. 2021 , 6, 161-171	0
636	Ethacrynic Acid Enhances the Antitumor Effects of Afatinib in EGFR/T790M-Mutated NSCLC by Inhibiting WNT/Beta-Catenin Pathway Activation. 2021 , 2021, 5530673	1
635	Analysis of EGFR Mutation Status in Algerian Patients with Non-Small Cell Lung Cancer. 2021 , 22, 1063-1068	0
634	Impact of Radiotherapy Pattern on the Prognosis of Stage IV Lung Adenocarcinomas Harboring EGFR Mutations. 2021 , 13, 3293-3301	2
633	Genome-Wide Chromatin Analysis of FFPE Tissues Using a Dual-Arm Robot with Clinical Potential. 2021 , 13,	1
632	Utilizing Publicly Available Cancer Clinicogenomic Data on CBioPortal to Compare Epidermal Growth Factor Receptor Mutant and Wildtype Non-Small Cell Lung Cancer. 2021 , 13, e14683	
631	Presentation of mutations in 162 family probands with multiple primary lung cancer. 2021 , 10, 1734-1746	0
630	A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R. 2021 , 51, 956-965	2
629	Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. 2021 , 16, 583-600	18
628	A pan-cancer analysis of the HER family gene and their association with prognosis, tumor microenvironment, and therapeutic targets. 2021 , 273, 119307	1
627	A structural perspective on targeting the RTK/Ras/MAP kinase pathway in cancer. 2021 , 30, 1535-1553	6
626	Integrated analysis of the genomic and transcriptional profile of high-grade gliomas in different age groups. 2021 , 226, 108719	
625	Imaging of synchronous multiple primary lung adenocarcinoma with concomitant and mutations: a case report and review of the literature.. 2021 , 10, 2509-2515	0
624	Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review. 2021 , 10,	4
623	Clinical and Molecular Features of Skin Malignancies in Muir-Torre Syndrome. 2021 , 12,	1
622	Co-occurring MET Amplification Predicts Inferior Clinical Response to First-Line Erlotinib in Advanced Stage EGFR-Mutated NSCLC Patients. 2021 , 22, e870-e877	1

621	Analysis of Multigene Mutations in Lung Adenocarcinoma in Zunyi. 2021 , 2021, 9939065	0
620	KRAS and EGFR Mutations Differentially Alter ABC Drug Transporter Expression in Cisplatin-Resistant Non-Small Cell Lung Cancer. 2021 , 22,	4
619	Kinase drug discovery 20 years after imatinib: progress and future directions. 2021 , 20, 551-569	109
618	The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancer. 2021 , 16, 1091-1103	1
617	Current clinical trials and patent update on lung cancer: a retrospective review. 2021 , 10, LMT45	
616	EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance. 2021 , 13,	23
615	Distinct Characteristics and Clinical Outcomes to Predict the Emergence of Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. 2021 , 13,	3
614	A novel small molecule that induces cytotoxicity in lung cancer cells inhibits disulfide reductases GSR and TXNRD1.	
613	Effective degradation of EGFR mutant proteins by CRBN-based PROTACs through both proteasome and autophagy/lysosome degradation systems. 2021 , 218, 113328	17
612	Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies. 2021 , 13,	9
611	A Novel KIF5B-EGFR Fusion Variant in Non-Small-Cell Lung Cancer and Response to Afatinib: A Case Report. 2021 , 14, 3739-3744	1
610	Epidermal Growth Factor Receptor Gene Mutation Detection in Histology and Cytology Specimens of Primary Lung Adenocarcinoma: Immunohistochemistry Versus the Molecular Method. 2021 , 22, 1935-1942	
609	Targeting HSF1 as a Therapeutic Strategy for Multiple Mechanisms of EGFR Inhibitor Resistance in EGFR Mutant Non-Small-Cell Lung Cancer. 2021 , 13,	2
608	Evolution and functional divergence of the ERBB receptor family. 2021 , 22, 473-484	
607	Implementation of clinical sequencing for molecular profiling in patients with advanced cancer. 2021 , 31, 119-126	
606	Metabolic Phenotypes, Dependencies, and Adaptation in Lung Cancer. 2021 , 11,	
605	[Pulmonary adenocarcinoma with double mutation EGFR: L858R and G719X]. 2021 , 54, 211-214	
604	Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. 2021 , 39, 3391-3402	62

603	Lung cancer. 2021 , 398, 535-554	115
602	Programmed cell death ligand-1 expression and survival in a cohort of patients with non-small cell lung cancer receiving first-line through third-line therapy in Denmark. 2021 , 73, 101976	1
601	Pure drug nano-assemblies: A facile carrier-free nanoplatform for efficient cancer therapy.. 2022 , 12, 92-106	6
600	Machine Learning-Based Radiomics Signatures for EGFR and KRAS Mutations Prediction in Non-Small-Cell Lung Cancer. 2021 , 22,	13
599	Survival of gefitinib treated advanced non-small cell lung cancer patients harbouring EGFR mutations. 2021 , 9, 171-174	
598	Molecular Alterations in Lung Adenocarcinoma With Ground-Glass Nodules: A Systematic Review and Meta-Analysis. 2021 , 11, 724692	
597	Molecular Pathology of Lung Cancer. 2021 , 14, 369-377	0
596	Precision Dosing of Targeted Therapies Is Ready for Prime Time. 2021 ,	1
595	Synthesis and Anti-Proliferation Activity Evaluation of Novel 2-Chloroquinazoline as Potential EGFR-TK Inhibitors. 2021 , 18, e2100478	0
594	Preclinical Models for the Study of Lung Cancer Pathogenesis and Therapy Development. 2021 , 11,	1
593	Metal-free domino amination-Knoevenagel condensation approach to access new coumarins as potent nanomolar inhibitors of VEGFR-2 and EGFR. 2021 , 14, 576-597	1
592	Novel benzothiazole hybrids targeting EGFR: Design, synthesis, biological evaluation and molecular docking studies. 2021 , 1240, 130595	9
591	Hype or hope - Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?. 2021 , 166, 103454	5
590	The synthesis and bioactivity of pyrrolo[2,3-d]pyrimidine derivatives as tyrosine kinase inhibitors for NSCLC cells with EGFR mutations. 2021 , 224, 113711	0
589	Short- and long-term survival outcomes among never smokers who developed lung cancer. 2021 , 75, 102042	2
588	Management of Brain Metastasis in Non-Small Cell Lung Cancer (NSCLC). 2022 , 825-843	
587	Molecular Targetable Pathways in EGFR. 2022 , 844-852	
586	The prognostic landscape of genes and infiltrating immune cells in cytokine induced killer cell treated-lung squamous cell carcinoma and adenocarcinoma. 2021 ,	1

585	Antitumour immunity regulated by aberrant ERBB family signalling. 2021 , 21, 181-197	32
584	Format (2D vs 3D) and media effect target expression and response of patient-derived and standard NSCLC lines to EGFR inhibitors. 2021 , 29, 100463	
583	My personal mutanome: a computational genomic medicine platform for searching network perturbing alleles linking genotype to phenotype. 2021 , 22, 53	7
582	Cell-Surface Receptors: Structure, Activation, and Signaling. 1	1
581	Clinical Application of EGFR Inhibitors in Head and Neck Squamous Cell Cancer. 2008 , 132-149	1
580	Clinical development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors: what lessons have we learned?. 2008 , 610, 128-43	4
579	Somatic Genetic Alterations and Implications for Targeted Therapies in Cancer (GIST, CML, Lung Cancer). 2010 , 205-220	1
578	Signal Transduction Pathways as Therapeutic Targets in Cancer Therapy. 2010 , 37-83	2
577	Antibodies as Cancer Immunotherapy. 2013 , 335-376	2
576	Oncogenes and Tumor Suppressor Genes in Therapeutic Resistance. 2006 , 67-103	1
575	Molecular Basis of Lung Carcinogenesis. 2017 , 447-496	1
574	Concordance Between Tumor and Germline DNA. 2008 , 91-101	2
573	Onco-omics Approaches and Applications in Clinical Trials for Cancer Patients. 2019 , 1168, 79-90	2
572	Tyrosine kinase inhibitors and cancer therapy. 2007 , 172, 25-44	4
571	Targeting ERBB receptors in cancer. 2007 , 172, 45-57	7
570	Erlotinib. 2010 , 184, 21-31	3
569	Molecular Targeting of Growth Factor Receptor Signaling in Radiation Oncology. 2016 , 198, 45-87	2
568	Cancer of the Lung: Non-Small Cell Lung Cancer and Small Cell Lung Cancer. 2008 , 1307-1366	4

567	DEFINITIVE MANAGEMENT OF INOPERABLE NONSMALL CELL LUNG CANCER. 2008 , 804-821	1
566	NonSmall Cell Lung Cancer. 2012 , 805-838	3
565	Cancer of the Lung. 2014 , 1143-1192.e13	3
564	Antiproliferative and apoptotic effects of indole derivative, N-(2-hydroxy-5-nitrophenyl (4'-methylphenyl) methyl) indoline in breast cancer cells. 2020 , 881, 173195	1
563	Effect of epidermal growth factor receptor mutation on early-stage non-small cell lung cancer according to the 8th TNM classification. 2020 , 145, 111-118	2
562	Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinoma. 2006 , 16, 73-4	41
561	Combined Analysis of Molecular and Clinical Predictors of Gefitinib Activity in Advanced Non-Small Cell Lung Cancer: Epidermal Growth Factor Receptor Mutations Do Not Tell the Whole Story. 2006 , 1, 52-60	11
560	Mutation and Polymorphism in the EGFR-TK Domain Associated with Lung Cancer. 2006 , 1, 635-647	26
559	Clinico-Pathological and Biological Significance of Tyrosine Kinase Domain Gene Mutations and Overexpression of Epidermal Growth Factor Receptor for Lung Adenocarcinoma. 2006 , 1, 787-795	34
558	The Role of Gefitinib Treatment for Korean Never-Smokers with Advanced or Metastatic Adenocarcinoma of the Lung: A Prospective Study. 2006 , 1, 965-971	33
557	Bronchioloalveolar Carcinoma and Lung Adenocarcinoma: The Clinical Importance and Research Relevance of the 2004 World Health Organization Pathologic Criteria. 2006 , 1, S13-S19	100
556	Genetic Heterogeneity in Patients with Multiple Neoplastic Lung Lesions: A Report of Three Cases. 2007 , 2, 12-21	25
555	Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer. 2007 , 2, 22-28	129
554	A pilot study of preoperative gefitinib for early-stage lung cancer to assess intratumor drug concentration and pathways mediating primary resistance. 2010 , 5, 1806-14	43
553	Genetic determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo.	1
552	Is structure based drug design ready for selectivity optimization?.	2
551	ECMarker: Interpretable machine learning model identifies gene expression biomarkers predicting clinical outcomes and reveals molecular mechanisms of human disease in early stages.	0
550	Mouse models of human non-small-cell lung cancer: raising the bar. 2005 , 70, 241-50	50

549	Oncogenes come of age. 2005 , 70, 1-9	21
548	Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors. 2005 , 70, 483-8	7
547	Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer. 2019 , 79, 689-698	92
546	Altered Mitochondria Functionality Defines a Metastatic Cell State in Lung Cancer and Creates an Exploitable Vulnerability. 2021 , 81, 567-579	10
545	Squamous Cell Carcinoma - Similarities and Differences among Anatomical Sites. 2011 , 1, 275-300	65
544	Requirement for MUC5AC in KRAS-dependent lung carcinogenesis. 2018 , 3,	16
543	Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma. 2019 , 4,	25
542	Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. 2006 , 116, 2695-706	372
541	Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. 2007 , 117, 3846-56	512
540	Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. 2008 , 118, 2609-19	389
539	Mechanisms of resistance to ErbB-targeted cancer therapeutics. 2008 , 118, 2389-92	18
538	Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. 2009 , 119, 1727-40	205
537	Wnt/ β -catenin signaling accelerates mouse lung tumorigenesis by imposing an embryonic distal progenitor phenotype on lung epithelium. 2011 , 121, 1935-45	116
536	Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. 2011 , 121, 4311-21	159
535	CRIP1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance. 2014 , 124, 3003-15	70
534	TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer. 2018 , 128, 2500-2518	48
533	Cancer Genomics. 2015 , 4,	2
532	Tobacco Smoking and Lung Cancer: Perception-changing facts. 2013 , 13, 345-58	54

531	Absence of Epidermal Growth Factor Receptor Gene Mutations in Lung and Liver Tumors in Rats. 2007 , 20, 65-69	1
530	Cell signaling heterogeneity is modulated by both cell-intrinsic and -extrinsic mechanisms: An integrated approach to understanding targeted therapy. 2018 , 16, e2002930	28
529	Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors. 2016 , 12, e1005077	12
528	Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. 2009 , 4, e5133	116
527	High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). 2009 , 4, e7273	109
526	Profiling critical cancer gene mutations in clinical tumor samples. 2009 , 4, e7887	295
525	Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling. 2010 , 5, e8919	19
524	Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. 2011 , 6, e20351	298
523	Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy. 2011 , 6, e23756	78
522	Non-antioxidant properties of β -tocopherol reduce the anticancer activity of several protein kinase inhibitors in vitro. 2012 , 7, e36811	22
521	Complex mutations & subpopulations of deletions at exon 19 of EGFR in NSCLC revealed by next generation sequencing: potential clinical implications. 2012 , 7, e42164	44
520	Multiple analyses of G-protein coupled receptor (GPCR) expression in the development of gefitinib-resistance in transforming non-small-cell lung cancer. 2012 , 7, e44368	35
519	An anilinoquinazoline derivative inhibits tumor growth through interaction with hCAP-G2, a subunit of condensin II. 2012 , 7, e44889	11
518	Prognostic impact of $[^{18}\text{F}]$ fluorothymidine and $[^{18}\text{F}]$ fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib. 2013 , 8, e53081	30
517	Detection and clinical significance of intratumoral EGFR mutational heterogeneity in Chinese patients with advanced non-small cell lung cancer. 2013 , 8, e54170	76
516	EGFR mutations in Indian lung cancer patients: clinical correlation and outcome to EGFR targeted therapy. 2013 , 8, e61561	43
515	EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFR T790M mutation. 2013 , 8, e78389	17
514	Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification. 2013 , 8, e78656	31

513	DOK2 inhibits EGFR-mutated lung adenocarcinoma. 2013 , 8, e79526	8
512	Drug resistance missense mutations in cancer are subject to evolutionary constraints. 2013 , 8, e82059	20
511	Ras effector mutant expression suggest a negative regulator inhibits lung tumor formation. 2014 , 9, e84745	17
510	Clinical validation of a PCR assay for the detection of EGFR mutations in non-small-cell lung cancer: retrospective testing of specimens from the EURTAC trial. 2014 , 9, e89518	27
509	Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib. 2015 , 10, e0125232	16
508	The Use of Chemical-Chemical Interaction and Chemical Structure to Identify New Candidate Chemicals Related to Lung Cancer. 2015 , 10, e0128696	6
507	Classification of Epidermal Growth Factor Receptor Gene Mutation Status Using Serum Proteomic Profiling Predicts Tumor Response in Patients with Stage IIIB or IV Non-Small-Cell Lung Cancer. 2015 , 10, e0128970	7
506	The Use of Non-Variant Sites to Improve the Clinical Assessment of Whole-Genome Sequence Data. 2015 , 10, e0132180	10
505	Baseline and Trend of Lymphocyte-to-Monocyte Ratio as Prognostic Factors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Patients Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. 2015 , 10, e0136252	42
504	Bioinformatics Analyses of the Role of Vascular Endothelial Growth Factor in Patients with Non-Small Cell Lung Cancer. 2015 , 10, e0139285	10
503	Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy. 2015 , 10, e0140794	19
502	MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells. 2015 , 10, e0143333	19
501	Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study. 2015 , 10, e0143515	94
500	Antacid Use and De Novo Brain Metastases in Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Were Treated Using First-Line First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. 2016 , 11, e0149722	16
499	Real-World Patterns of EGFR Testing and Treatment with Erlotinib for Non-Small Cell Lung Cancer in the United States. 2016 , 11, e0156728	52
498	A Survival Scoring System for Non-Small Cell Lung Cancer Patients with De Novo Bone Metastases. 2016 , 11, e0167923	6
497	Discordance of Epidermal Growth Factor Receptor Mutation between Brain Metastasis and Primary Non-Small Cell Lung Cancer. 2019 , 7, 137-140	3
496	Inhibition of Ubiquitin-specific Peptidase 8 Suppresses Growth of Gefitinib-resistant Non-small Cell Lung Cancer Cells by Inducing Apoptosis. 2015 , 20, 57-63	16

495	Narrowing the focus: a toolkit to systematically connect oncogenic signaling pathways with cancer phenotypes. 2016 , 7, 218-228	5
494	Interplay Between HGF/SF-Met-Ras Signaling, Tumor Metabolism and Blood Flow as a Potential Target for Breast Cancer Therapy. 2014 , 1, 30-38	17
493	Pathways driving the endocytosis of mutant and wild-type EGFR in cancer. 2014 , 1, 504-12	51
492	Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung. 2014 , 1, 522-528	22
491	Chronic exposure to cigarette smoke leads to activation of p21 (RAC1)-activated kinase 6 (PAK6) in non-small cell lung cancer cells. 2016 , 7, 61229-61245	23
490	Targeting SALL4 by entinostat in lung cancer. 2016 , 7, 75425-75440	16
489	MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status. 2017 , 8, 8484-8498	36
488	Total DNA input is a crucial determinant of the sensitivity of plasma cell-free DNA EGFR mutation detection using droplet digital PCR. 2017 , 8, 5861-5873	29
487	Impact of country of birth on genetic testing of metastatic lung adenocarcinomas in France: African women exhibit a mutational spectrum more similar to Asians than to Caucasians. 2017 , 8, 50792-50803	1
486	Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib. 2014 , 5, 8252-69	40
485	A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer. 2017 , 8, 41474-41486	12
484	EGFR endocytosis is a novel therapeutic target in lung cancer with wild-type EGFR. 2014 , 5, 1265-78	34
483	Prediction of EGFR and KRAS mutation in non-small cell lung cancer using quantitative F FDG-PET/CT metrics. 2017 , 8, 52792-52801	24
482	Intersecting transcriptomic profiling technologies and long non-coding RNA function in lung adenocarcinoma: discovery, mechanisms, and therapeutic applications. 2017 , 8, 81538-81557	20
481	Structural basis of mutant-selectivity and drug-resistance related to CO-1686. 2017 , 8, 53508-53517	17
480	FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor. 2014 , 5, 5908-19	83
479	The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells. 2017 , 8, 70736-70751	20
478	Dynamic circulating tumor DNA quantification for the individualization of non-small-cell lung cancer patients treatment. 2017 , 8, 60291-60298	14

477	Long non-coding RNAs associated with non-small cell lung cancer. 2017 , 8, 69174-69184	34
476	Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells. 2014 , 5, 4765-78	35
475	Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations. 2017 , 8, 105479-105491	27
474	Personalizing therapy with targeted agents in non-small cell lung cancer. 2011 , 2, 165-77	49
473	Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of or. 2018 , 9, 21132-21140	
472	Antibody-assisted target identification reveals afatinib, an EGFR covalent inhibitor, down-regulating ribonucleotide reductase. 2018 , 9, 21512-21529	7
471	EGFR overexpression is not common in patients with head and neck cancer. Cell lines are not representative for the clinical situation in this indication. 2018 , 9, 28965-28975	15
470	Expression of sulfotransferase SULT1A1 in cancer cells predicts susceptibility to the novel anticancer agent NSC-743380. 2015 , 6, 345-54	9
469	Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A. 2015 , 6, 2164-79	35
468	Activation of RAS family members confers resistance to ROS1 targeting drugs. 2015 , 6, 5182-94	62
467	Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants. 2015 , 6, 8839-50	11
466	JAK2 inhibitor TG101348 overcomes erlotinib-resistance in non-small cell lung carcinoma cells with mutated EGF receptor. 2015 , 6, 14329-43	20
465	NF- κ B drives acquired resistance to a novel mutant-selective EGFR inhibitor. 2015 , 6, 42717-32	27
464	FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro. 2015 , 6, 20215-30	20
463	ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma. 2015 , 6, 22348-60	8
462	NCI's provocative questions on cancer: some answers to ignite discussion. 2011 , 2, 1352-67	46
461	Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status. 2015 , 6, 26090-103	30
460	Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells. 2015 , 6, 30072-87	34

459	Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology. 2015 , 6, 32602-9	13
458	In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer. 2015 , 6, 38789-803	104
457	Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer. 2016 , 7, 3068-83	17
456	Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation. 2016 , 7, 13797-809	5
455	Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer. 2013 , 4, 118-27	31
454	Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer. 2016 , 7, 22005-15	39
453	Functional role of eukaryotic translation initiation factor 4 gamma 1 (EIF4G1) in NSCLC. 2016 , 7, 24242-51	20
452	Are TKIs favourable for the elderly with non-small-cell lung cancer?. 2016 , 7, 46871-46877	6
451	Efficacy of epidermal growth factor receptor inhibitors in combination with chemotherapy in advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials. 2016 , 7, 39823-39833	7
450	Expression of the receptor for hyaluronic acid mediated motility (RHAMM) is associated with poor prognosis and metastasis in non-small cell lung carcinoma. 2016 , 7, 39957-39969	39
449	Prioritizing molecular markers to test for in the initial workup of advanced non-small cell lung cancer: wants versus needs. 2017 , 5, 371	2
448	Molecular genetic profiling of small cell lung carcinoma in a Chinese cohort.. 2019 , 8, 255-261	3
447	HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer. 2020 , 9, 2178-2183	3
446	Novel compounds in the treatment of lung cancer: current and developing therapeutic agents. 2011 , 3, 21-34	2
445	Highly Sensitive Droplet Digital PCR Method for Detection of de novo EGFR T790M Mutation in Patients with Non-Small Cell Lung Cancer. 2020 , 13, 10621-10630	3
444	Correlation between in vitro and in vivo Data of Radiolabeled Peptide for Tumor Targeting. 2019 , 19, 950-960	1
443	The PIK3CA gene as a mutated target for cancer therapy. 2008 , 8, 733-40	29
442	Achievements in Cancer Research and its Therapeutics in Hundred Years. 2019 , 19, 1545-1562	0

441	From Biology to Therapy: Improvements of Therapeutic Options in Lung Cancer. 2018 , 18, 1235-1240	5
440	An introduction to molecular targeted therapy of cancer. 2008 , 53, 130-8	15
439	Current practices and guidelines for clinical next-generation sequencing oncology testing. 2016 , 13, 3-11	38
438	Identification of Genetic Mutations in Cancer: Challenge and Opportunity in the New Era of Targeted Therapy. 2019 , 9, 263	34
437	Comprehensive Perspective for Lung Cancer Characterisation Based on AI Solutions Using CT Images. 2020 , 10,	6
436	Consensus recommendations for optimizing biomarker testing to identify and treat advanced mutated non-small-cell lung cancer. 2020 , 27, 321-329	4
435	Target genes discovery through copy number alteration analysis in human hepatocellular carcinoma. 2013 , 19, 8873-9	19
434	Changing strategies for target therapy in gastric cancer. 2016 , 22, 1179-89	29
433	Axl is a novel target of celastrol that inhibits cell proliferation and migration, and increases the cytotoxicity of gefitinib in EGFR mutant non-small cell lung cancer cells. 2019 , 19, 3230-3236	7
432	Multiplexed molecular profiling of lung cancer with malignant pleural effusion using next generation sequencing in Chinese patients. 2020 , 19, 3495-3505	7
431	Emerging non-invasive detection methodologies for lung cancer. 2020 , 19, 3389-3399	2
430	Implications of lipid droplets in lung cancer: Associations with drug resistance. 2020 , 20, 2091-2104	10
429	Patients with advanced non-small cell lung cancer with EGFR mutations in addition to complex mutations treated with osimertinib have a poor clinical outcome: A real-world data analysis. 2020 , 20, 2266-2272	4
428	Treatment of advanced non small cell lung cancer. 2011 , 3, 122-33	69
427	Lung cancer, thyroid cancer or both: An unusual case presentation. 2011 , 3, 271-3	11
426	Dacomitinib, an emerging HER-targeted therapy for non-small cell lung cancer. 2012 , 4, 639-42	10
425	Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer. 2013 , 5 Suppl 5, S579-92	29
424	Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification. 2014 , 6, S502-25	9

423	Evaluation of phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma. 2013 , 4, 20-9	18
422	Irreversible EGFR-TKIs: dreaming perfection. 2013 , 2, 40-9	19
421	Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients. 2013 , 2, 226-37	28
420	Immunotherapy in lung cancer. 2014 , 3, 53-63	43
419	Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. 2015 , 4, 36-54	389
418	Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review. 2015 , 4, 67-81	186
417	The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer. 2015 , 4, 119-25	28
416	Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond. 2015 , 4, 126-41	48
415	Clinicopathologic characteristics of patients with ROS1 fusion gene in non-small cell lung cancer: a meta-analysis. 2015 , 4, 300-9	26
414	Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M. 2015 , 4, 809-15	39
413	Integration of tobacco cessation services into multidisciplinary lung cancer care: rationale, state of the art, and future directions. 2015 , 4, 339-52	24
412	Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trials. 2015 , 4, 465-74	16
411	[Mutation testing for non-small-cell lung cancer]. 2012 , 132, 952-5	5
410	From the bench to bedside: biological and methodology considerations for the future of companion diagnostics in nonsmall cell lung cancer. 2011 , 2011, 312346	8
409	Future Cancer Therapy with Molecularly Targeted Therapeutics: Challenges and Strategies. 2011 , 19, 371-389	6
408	Molecular targeted therapy in advanced renal cell carcinoma: A review of its recent past and a glimpse into the near future. 2009 , 25, 427-36	8
407	Gefitinib in the treatment of nonsmall cell lung cancer with activating epidermal growth factor receptor mutation. 2016 , 7, 119-23	16
406	Prevalence of the epidermal growth factor receptor mutations in lung adenocarcinoma patients from the Middle East region. 2019 , 14, 173-178	5

405	Molecularly targeted therapies in non-small cell lung cancer: The evolving role of tyrosine kinase inhibitors. 2019 , 56, S23-S30	5
404	How Molecular Understanding Affects to Prescribing Patterns and Clinical Outcome of Gefitinib in Non-small Cell Lung Cancer? 10 Year Experience of Single Institution. 2013 , 45, 178-85	11
403	Prevalence of Epidermal Growth Factor Receptor Mutations in Patients with Non-Small Cell Lung Cancer in Turkish Population. 2017 , 34, 567-571	6
402	Carcinomatous meningitis and EGFR mutation. 2015 , 23, 14-18	2
401	Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: A clinical perspective and review of published literature. 2014 , 5, 858-64	7
400	Mechanistic insights into differential requirement of receptor dimerization for oncogenic activation of mutant EGFR and its clinical perspective. 2020 , 53, 133-141	2
399	Relationship between epidermal growth factor receptor gene mutation and copy number in Chinese patients with non-small cell lung cancer. 2012 , 31, 491-9	11
398	New evidence-based adaptive clinical trial methods for optimally integrating predictive biomarkers into oncology clinical development programs. 2013 , 32, 233-41	2
397	New lung cancer panel for high-throughput targeted resequencing. 2014 , 12, 50-7	5
396	Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features?. 2010 , 134, 66-72	70
395	Molecular testing of solid tumors. 2011 , 135, 67-82	28
394	Molecular diagnostics of lung carcinomas. 2011 , 135, 622-9	21
393	Reflex testing for epidermal growth factor receptor mutation and anaplastic lymphoma kinase fluorescence in situ hybridization in non-small cell lung cancer. 2011 , 135, 655-64	27
392	Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients. 2012 , 67, 419-24	34
391	Differences in epidermal growth factor receptor gene mutations and relationship with clinicopathological features in NSCLC between Uyur and Han ethnic groups. 2013 , 14, 2879-83	6
390	Epidermal growth factor receptor gene polymorphisms and gastric cancer in Iran. 2013 , 14, 3187-90	5
389	Relationship between epidermal growth factor receptor gene mutations and clinicopathological features in patients with non-small cell lung cancer in western Turkey. 2013 , 14, 3705-9	18
388	Lack of mutations in protein tyrosine kinase domain coding exons 19 and 21 of the EGFR gene in oral squamous cell carcinomas. 2014 , 15, 4623-7	5

387	Relationships between EGFR mutation status of lung cancer and preoperative factors - are they predictive?. 2014 , 15, 657-62	34
386	Correlation between EGFR Gene Mutations and Lung Cancer: a Hospital-Based Study. 2015 , 16, 7071-6	5
385	Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks. 2013 , 10, 192-205	37
384	Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways. 2015 , 4,	30
383	Molecular basis for multimerization in the activation of the epidermal growth factor receptor. 2016 , 5,	91
382	Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells. 2018 , 7,	29
381	Single-molecule functional anatomy of endogenous HER2-HER3 heterodimers. 2020 , 9,	5
380	Advances in molecular mechanisms of interaction between and lung cancer: a narrative review. 2021 , 10, 4012-4026	2
379	Algorithme thérapeutique des cancers bronchiques non ^petites cellules tendus avec mutation de EGFR. 2021 , 13, 2S135-2S154	
378	Small Molecule Kinase Inhibitor Drugs (1995-2021): Medical Indication, Pharmacology, and Synthesis. 2021 ,	11
377	Central Nervous System Metastases. 2022 , 36, 161-188	2
376	A Sensitive PCR-Based Method for Somatic Mutations Enrichment and Screening. 2021 , 13, 8099-8107	
375	Recent Advances on Quinazoline Derivatives: A Potential Bioactive Scaffold in Medicinal Chemistry. 2021 , 5, 73	3
374	Three Cases of Primary Non-Small Cell Lung Carcinoma with Mutation of the Epidermal Growth Factor Receptor Gene that Responded to Gefitinib. 2005 , 55, 169-176	
373	EGF Receptor Gene Mutations Are Common in Lung Cancers From Never Smokers and Are Associated With Sensitivity of Tumors to Gefitinib and Erlotinib. 2006 , 2006, 223-225	
372	Gefitinib: impact on survival benefit. 2006 , 21, 58-63	
371	Gefitinib. 2007 , 1-5	
370	Molecular Classification of Lung Adenocarcinoma by Genetic Alteration Profiling. 2007 , 47, 905-908	

- 369 [Influence of chemiotherapeutic protocol and neuroendocrine differentiation on metastatic non-small cell lung cancer treatment results]. **2007**, 64, 591-6 1
- 368 High Density Tissue Microarray for Establishing Lung Cancer Expression Profiling Database and Its Clinical Application. **2007**, 47, 915-919
- 367 Assessment of protein profiles (proteomics) as biomarkers. **2007**, 167-171
- 366 Signal Transduction Inhibitors, HER Family, EGFR Inhibition and Clinical Achievements. **2007**, 19-44
- 365 Molecular Genetics of Lung and Pleural Neoplasms. **2008**, 47-157 1
- 364 Monoclonaux contre inhibiteurs de tyrosine kinase. **2008**, 81-97
- 363 Targeting Survival Cascades Induced by Activation of Ras/Raf/MEK/ERK and PI3K/Akt Pathways to Sensitize Cancer Cells to Therapy. **2008**, 81-114
- 362 Cellular sensitivity to EGF receptor inhibitors. **2008**, 340-355
- 361 Response to Conventional Therapy and Targeted Molecular Therapy. **2008**, 226-232
- 360 Molecular Pathology of Squamous Cell Carcinoma and Its Precursors. **2008**, 270-278
- 359 Epidermal Growth Factor Receptor Mutations and Sensitivity to Selective Kinase Inhibitors in Human Lung Cancer. **2008**, 103-126
- 358 EGFR Mutations, Other Molecular Alterations Related To Sensitivity to EGFR Inhibitors, and Molecular Testing for EGFR-Targeted Therapies in Non-Small Cell Lung Cancer. **2008**, 281-324
- 357 Pharmacogenetics in Cancer Chemotherapy. **2008**, 113-128 1
- 356 Molecular Signatures of Drug Resistance. **2009**, 271-294
- 355 LUNG CANCER. **2009**, 921-931
- 354 Pharmacogenomics and Personalized Medicine in the Treatment of Human Diseases. **2009**, 613-622
- 353 Selective Use of Gefitinib and Erlotinib on Non-small Cell Lung Cancer Patients. **2009**, 49, 950-956
- 352 Bronchioloalveolar carcinoma and adenocarcinoma with bronchioloalveolar carcinoma features: a clinico-pathological spectrum. **2009**, 445-452

- 351 Intron 1 Polymorphism, Mutation and the Protein Expression of Epidermal Growth Factor Receptor in Relation to the Gefitinib Sensitivity of Korean Lung Cancer Patients. **2009**, 43, 509
- 350 EGFR and HER2: Relevance in Renal Cell Carcinoma. **2009**, 287-303
- 349 Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib. **2009**, 133, 470-7 36
- 348 Ewing's Sarcoma Family of Tumors: Molecular Targets Need Arrows. **2010**, 373-400
- 347 Inhibitory Effect of Epidermal Growth Factor on the Proliferation of Lung Cancer Cell Lines. **2010**, 9, 64
- 346 Biology of Non-small Cell Lung Cancer. **2010**, 1080-1097 1
- 345 Molecular Pathology of Lung Cancer. **2010**, 1-25 1
- 344 Pharmacogenetics in Lung Cancer. **2010**, 87-99
- 343 Pharmacogenetics of Lung Cancer. **2010**, 87-106
- 342 Targeting EGFR in HPV-Associated Cancer. **2010**, 211-234
- 341 Overview of Efficacy and Limitation of Standard and Targeted Therapy for Malignant Disease Using Lung Cancer as a Case Study. **2010**, 3-21
- 340 Abstract PL2-1: The impact of genomic changes on the treatment of lung cancer. **2010**,
- 339 Targeted Therapeutics in Cancer Treatment. **2011**, 403-461
- 338 Lung Adenocarcinoma. **2011**, 177-183
- 337 Clinical Applications of Systems Biology Approaches. **2011**, 409-428
- 336 Resistance to Targeted Therapies As a Result of Mutation(s) in the Target. **2011**, 1-31
- 335 EGFR Signaling and Radiation. **2011**, 201-226
- 334 Glioblastoma Cancer Stem Cells: Response to Epidermal Growth Factor Receptor Kinase Inhibitors. **2011**, 213-226

- 333 Diagnostic and Prognostic Cancer Biomarkers: From Traditional to Systems Approaches. **2011**, 329-366
- 332 Accuracy of Cytology Specimen and Needle Core Biopsies for Detection of Mutation in Non-Small Cell Carcinoma: Comparison With Resection Specimen. **2011**, 2, 275-280 1
- 331 Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo. **2011**, 123, 13-18
- 330 Interrogating Resistance to Targeted Therapy Using Genetically Engineered Mouse Models of Cancer. **2011**, 135-153
- 329 Principes van de medicamenteuze antikankerbehandeling. **2011**, 175-195
- 328 Pharmacogenomics and Personalized Medicine. **2011**, 1359-1382
- 327 Mouse Models of Human Cancer: Role in Preclinical Testing and Personalized Medicine. **2012**, 569-589
- 326 The Development and Use of Genetically Tractable Preclinical Mouse Models. **2012**, 477-495 1
- 325 Oncogene Addiction: Mouse Models and Clinical Relevance for Molecularly Targeted Therapies. **2012**, 527-547
- 324 Lung Cancer. **2012**, 151-165
- 323 Somatic Alterations and Targeted Therapy. **2012**, 51-101
- 322 Erlotinib Responds to Brain Metastasis of Lung Adenocarcinoma where Gefitinib Failed : A Case Report. **2012**, 38, 332-336 2
- 321 Squamous Cell Carcinoma. **2012**, 163-167
- 320 Targeted Therapies for Non-small-Cell Lung Cancer. **2012**, 93-114
- 319 Efficacy and Safety of Gefitinib or Platinum plus Taxane in Egfr-Mutant Advanced Non-Small Cell Lung Cancers: A Meta-Analysis of First-Line Randomized Controlled Trials. **2012**, 03, 467-476
- 318 JNK-Mediated FOXO Expression Plays a Critical Role in EGFR Tyrosine Kinase Inhibitor-Induced BIM Expression and Apoptosis. **2012**, 03, 424-434
- 317 Molecular Targeted Therapy of Lung Cancer. **2012**, 99-107
- 316 A Case of EGFR-wild-type Adenocarcinoma of Recurrent Non-small Cell Lung Cancer Responding to Erlotinib. **2012**, 52, 315-319 0

315 Mutation Analysis in Cancer. **2012**, 261-279

314 HGFK1 is associated with a better prognosis and reverses inhibition by gefitinib in NSCLC cases. **2012**, 13, 1457-61

313 Predictive role of computer simulation in assessing signaling pathways of crizotinib-treated A549 lung cancer cells. **2012**, 13, 3119-21

2

312 Potential of Tocotrienols in Lung Cancer. **2012**, 151-162

311 Molecular Pathology of Lung Cancers. **2013**, 83-94

310 TYPES OF DNA DAMAGE. **2013**, 115-118

309 Epidemiology of Lung Cancer in Women. **2013**, 1191-1208

308 Systemic Therapy for Lung Cancer. **2013**, 125-135

307 Radiosensitizing biological modifiers enhancing efficacy in non-small-cell lung cancer treated with radiotherapy. **2013**, 2, 251-255

306 Epidermal Growth Factor Receptor Testing in Lung Adenocarcinoma. **2014**, 15-22

305 Molecular Pathology and Diagnostics of Non-small Cell Lung Carcinoma. **2014**, 75-118

304 Signal Transduction Inhibitors of the HER Family. **2013**, 17-50

303 Lungcarcinoom. **2014**, 117-124

302 An Introduction to Small Molecule Inhibitors and Chronic Myeloid Leukemia. **2014**, 11-17

301 Monitoring Responses to Therapy in Oncology. **2014**, 155-171

300 Molecular Testing in Pulmonary Tumors. **2014**, 211-228

299 The Human Epidermal Growth Factor Receptor (HER) Family: Structure and Function. **2014**, 7-17

298 Intracellular Signaling. **2014**, 22-39.e8

- 297 Frequency of Epidermal Growth Factor Mutation Status and Its Effect on Outcome of Patients with Adenocarcinoma of the Lung. **2014**, 05, 1012-1020 1
- 296 The 2013 Incentive Award of the Okayama Medical Association in Cancer Research (2013 Hayashibara Prize and Yamada Prize). **2014**, 126, 191-194
- 295 Reporting Clinical Genomic Assay Results and the Role of the Pathologist. **2015**, 277-293
- 294 Role of Immunohistochemistry in the Detection of Targetable Mutations. **2015**, 109-127 1
- 293 Portfolio Optimization of Therapies and Their Predictive Biomarkers. **2015**, 155-180 0
- 292 EGFR and HER2: Relevance in Renal Cell Carcinoma. **2015**, 285-302 1
- 291 Rate of EGFR mutation in patients with pulmonary adenocarcinoma. **2014**, 2, 020420
- 290 Synthetic Sickness with Molecularly Targeted Agents Against the EGFR Pathway. **2015**, 381-412
- 289 The EGFR/ERBB Receptor Family. **2015**, 107-164 0
- 288 From Bench to Bedside with Targeted Therapies. **2015**, 621-634.e2
- 287 CRE: a cost effective and rapid approach for PCR-mediated concatenation of KRAS and EGFR exons. **2015**, 4, 160 2
- 286 EGFR Analysis in Cytologic Samples of Lung Adenocarcinoma by Microdissection. **2015**, 47, 125-131
- 285 EGFR Mutations. **2016**, 4-18-4-19
- 284 CRE: a cost effective and rapid approach for PCR-mediated concatenation of KRAS and EGFR exons. **2015**, 4, 160 2
- 283 Epidermal growth factor receptor mutation in adenocarcinoma lung in a North Indian population: Prevalence and relation with different clinical variables. **2016**, 37, 189-95 3
- 282 Biomarkers/Molecular Targets, Immunotherapy, and Treatments for Non-Small Cell Lung Cancer. **2016**, 7, 514-524 1
- 281 Have adjuvant tyrosine kinase inhibitors lost their shine?. **2016**, 4, 285 0
- 280 The execution of molecular genetic tests using DNA of tumor cells obtained from cytologic preparations. **2017**, 6, 23 2

279 Methods in Molecular Diagnosis. **2017**, 63-77

278 Companion Diagnostics. **2017**, 117-136

277 Patient-Derived Xenografts From Lung Cancer and Their Potential Applications. **2017**, 273-289

276 EGFR Mutant. **2017**, 167-189

275 Cancer Genomics and Precision Medicine: A Way Toward Early Diagnosis and Effective Cancer Treatment. **2017**, 31-41

274 Principes van de medicamenteuze antikankerbehandeling. **2017**, 137-159

273 Identification and Validation of Driver Kinases from Next-Generation Sequencing Data. **2017**, 1636, 179-195

272 Early Diagnosis with 11-Gene Panel Screening for Non Small Cell Lung Cancer. **2017**, 8,

271 Targeted Therapies for Lung Cancer. **2018**, 239-255

270 Whole-exome sequencing of plasma cell-free DNA portrays the somatic mutation landscape of refractory metastatic colorectal cancer and enables the discovery of mutated KDR/VEGFR2 receptors as modulators of anti-angiogenic therapies.

269 Mutation Testing of Lung Cancer Biomarkers (Excluding IHC and NGS). **2018**, 93-108

268 Clinicopathological and genetic characteristics of pulmonary large cell carcinoma under 2015 WHO classification: a pilot study. **2017**, 8, 100754-100763

3

267 Hyperactivation of extracellular signal-regulated kinase (ERK) by RAS-mediated signaling or inhibition of dual specificity phosphatase 6 (DUSP6) is associated with toxicity in lung adenocarcinoma cells with mutations in KRAS or EGFR.

266 Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors.

265 Excellent response to gefitinib in a patient with erlotinib refractory, exon 21, L858r epidermal growth factor receptor-mutated lung adenocarcinoma. **2018**, 39, 421

264 Comparison of Thoracic Radiotherapy Efficacy Between Patients With and Without -mutated Lung Adenocarcinoma. **2018**, 32, 203-209

263 Detecting Mutations in Patients with Non-small Cell Lung Cancer. **2018**, 21, 13-17

1

262 K&Hcreli DAkciBr Kanseri Hastalarıda Onkogen MutasyonlarBB AraEtmasB

- 261 Reporting Clinical Genomic Assay Results and the Role of the Pathologist. **2019**, 253-266
- 260 Clinical Strategies for Developing Next-Generation Cancer Precision Medicines. **2019**, 105-117
- 259 Recent Advances in the adjuvant Treatment Strategies of Lung Cancers. **2019**, 701-729
- 258 Les avancès dans la prise en charge des cancers bronchopulmonaires : ce qui change pour le ranimateur. **2019**, 28, 290-299
- 257 Detection of EGFR deletion using unique RepSeq technology.
- 256 The Cancer Precision Medicine Diagnosis and Treatment (K-MASTER) Enterprise. **2019**, 94, 246-251
- 255 Correlative analysis of gene mutation and clinical features in patients with non-small cell lung cancer.. **2019**, 8, 736-751
- 254 Discovering novel long non-coding RNA predictors of anticancer drug sensitivity beyond protein-coding genes.
- 253 Lung Carcinoma. **2020**, 83-101
- 252 Case report: Management of Progressive Lung Cancer Patients after First-Line EGFR Tyrosine Kinase Inhibitor Therapy. **2019**, 55, 239
- 251 Traitement des cancers bronchiques non ^petites cellules de stades avancs muts EGFR: quelle(s) squence(s) ?. **2019**, 11, 364-379
- 250 Lung and Respiratory Tract Cytology. **2020**, 95-117
- 249 Brain Metastases from Lung Tumors. **2020**, 259-266
- 248 Characterization of Chromosomal Abnormalities in Cancer by Spectral Karyotyping. **2019**, 13, 1-10
- 247 Transcriptional activation of cyclin D1 via HER2/HER3 contributes to cell survival and EGFR tyrosine kinase inhibitor resistance in non-small cell lung carcinoma.
- 246 High frequency of Exon 20 S768I EGFR mutation detected in malignant pleural effusions: a poor prognosticator of NSCLC?.
- 245 Systemic Therapy of Brain Metastases: Lung Cancer. **2020**, 207-217
- 244 Therapy-induced transdifferentiation promotes glioma growth independent of EGFR signaling.

- 243 Developing Pathology Measures for the Quality Payment Program-Part I: A Quest for Meaningful Measures. **2020**, 144, 686-696 1
- 242 A tyrosine kinase protein interaction map reveals targetable EGFR network oncogenesis in lung cancer.
- 241 Biobanks in oncology: global experience and Russian reality. **2020**, 22, 82-88 0
- 240 Retrospective study on the clinicogenomic characteristics of EGFR mutant and wildtype NSCLC.
- 239 Harnessing the predictive power of preclinical models for oncology drug development. **2021**, 3
- 238 Mefatinib as first-line treatment of patients with advanced EGFR-mutant non-small-cell lung cancer: a phase Ib/II efficacy and biomarker study. **2021**, 6, 374 1
- 237 Testing for Driver Oncogenes is Essential for the Optimal Treatment of Advanced Non-small-cell Lung Cancer. **2020**, 66, 403-409
- 236 Chapter 17: Oncology: Somatic Disease and Pharmacogenomics. **2020**,
- 235 Therapy Response Imaging in Thoracic Malignancy. **2020**, 79-97
- 234 Experience with Large Panel Next-generation Sequencing in Patients with Advanced Solid Cancers at Juntendo University Hospital. **2020**, 66, 392-402
- 233 Triple Mutation Epidermal Growth Factor Receptor (EGFR) Exon 18 (G719S), 20 (T790M) and 21 (L858R) in a Male Patient with Lung Adenocarcinoma: A Case Report. **2020**, 6, 13
- 232 Effect of epidermal growth factor receptor gene mutation on the prognosis of pathological stage II-IIIa (8th edition TNM classification) primary lung cancer after curative surgery. **2021**, 162, 128-134 0
- 231 Lung Cancer in Women. **2021**, 0
- 230 Technologies in Molecular Biology: Diagnostic Applications. **2006**, 269-284
- 229 Aspects morphologiques et moléculaires des lésions pré-invasives broncho-pulmonaires : impact sur leur évolutivité. **2005**, 89-110
- 228 Les thérapies ciblées ou le traitement des mécanismes moléculaires de la progression tumorale. **2006**, 515-527
- 227 Integration of Biological Therapies in Locally Advanced Non-Small-Cell Lung Cancer. **2006**, 261-270
- 226 Chemoprevention of Lung Cancer. **2006**, 609-626

225	Molecular Biology of Lung Cancer. 2006 , 67-80	
224	Pathology of Lung Cancer. 2006 , 93-105	
223	Combinations of Cytotoxic Drugs, Ionizing Radiation and EGFR Inhibitors. 2006 , 115-125	
222	Phyllodes Tumor of the Breast: Prognostic Assessment Using Immunohistochemistry. 2008 , 263-273	
221	Non-Small Cell Lung Carcinoma: EGFR Gene Mutations and Response to Gefitinib. 2008 , 291-306	
220	Non-Small Cell Lung Cancer with Brain Metastasis: Role of Epidermal Growth Factor Receptor Gene Mutation. 2008 , 371-387	
219	Molecular pathology. 95-118	1
218	Achievements in targeted therapies. 215-233	
217	Untargeted Use of Targeted Therapy. 2008 , 227-240	
216	Targeted lung cancer therapy: what have we learned from gefitinib?. 2005 , 2, 1-2	
215	Clinical features and mutation status of EGFR, KRAS, BRAF, EML4-ALK and ROS1 between surgical resection samples and non surgical resection samples in lung cancer. 2015 , 7, 875-80	10
214	A time to test, a time to treat. 2012 , 4, 223-5	1
213	Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents. 2015 , 3, 81	9
212	Renal cell carcinoma and the use of sorafenib. 2006 , 2, 87-98	11
211	Simultaneous EGFR and VEGF alterations in non-small cell lung carcinoma based on tissue microarrays. 2007 , 3, 275-84	2
210	Review of erlotinib in the treatment of advanced non-small cell lung cancer. 2007 , 1, 335-46	22
209	Targeted therapy of advanced non-small cell lung cancer: the role of bevacizumab. 2007 , 1, 185-94	4
208	EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab. 2009 , 3, 215-24	24

207	Lung cancer cytology: potential pitfalls and mimics - a review. 2010 , 3, 367-85	47
206	A translational approach to lung cancer research: From EGFRs to Wnt and cancer stem cells. 2009 , 15, 213-20	8
205	Mutations in epidermal growth factor receptor gene in esophageal squamous cell carcinoma patients in kashmir- a high incidence area of India. 2008 , 2, 17-25	3
204	Emerging tactical strategies for fighting the war on cancer based on the genetic landscape. 2011 , 3, 251-8	1
203	Roles of EGFR and KRAS Mutations in the Treatment Of Patients With Non-Small-Cell Lung Cancer. 2011 , 36, 263-79	14
202	N-cadherin expression is a potential survival mechanism of gefitinib-resistant lung cancer cells. 2011 , 1, 823-33	19
201	Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. 2010 , 2, 48-51	184
200	Patient selection in non-small cell lung cancer: Histologic versus molecular subtypes?. 2010 , 2, 189-91	1
199	Targeted therapy: a new approach for the treatment of locally advanced oropharyngeal cancer. 2012 , 4, 82-5	
198	EGFR inhibition and more: a new generation growing up. 2012 , 4, 553-5	2
197	Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer. 2013 , 25, 90-4	12
196	The 5 stages of biotechnology management. 2005 , 2, 45-50	
195	Comprehensive molecular oncogenomic profiling and miRNA analysis of prostate cancer. 2013 , 5, 200-11	30
194	Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancer. 2013 , 5, 481-96	13
193	Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps. 2014 , 17, 101-14	35
192	Investigating Molecular Mechanisms of Activation and Mutation of the HER2 Receptor Tyrosine Kinase through Computational Modeling and Simulation. 2011 , 4, 1-35	5
191	Implementing the new IASLC/ATS/ERS classification of lung adenocarcinomas: results from international and Chinese cohorts. 2014 , 6, S568-80	8
190	ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. 2014 , 12, 429-39	167

189	Detection of EGFR mutation in supernatant, cell pellets of pleural effusion and tumor tissues from non-small cell lung cancer patients by high resolution melting analysis and sequencing. 2014 , 7, 8813-22	23
188	Advances on EGFR mutation for lung cancer. 2012 , 1, 5-13	38
187	Does the order of factors affect the product? Lessons learned from the TORCH trial. 2013 , 2, 50-4	
186	10(th) Congress on Lung Cancer-updates on clinical trials: goal. 2014 , 3, 66-9	1
185	Adjuvant molecularly targeted therapy-epidermal growth factor tyrosine kinase inhibition and beyond. 2013 , 2, 411-4	1
184	Interventional pulmonology approaches in the diagnosis and treatment of early stage non small cell lung cancer. 2013 , 2, 316-31	6
183	Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence. 2015 , 5, 2531-61	46
182	DNA/RNA markers for colorectal cancer risk in preserved stool specimens: a pilot study. 2009 , 95, 753-61	4
181	Role of epidermal growth factor receptor in lung cancer and targeted therapies. 2017 , 7, 187-202	39
180	The selective c-Met inhibitor tepotinib can overcome epidermal growth factor receptor inhibitor resistance mediated by aberrant c-Met activation in NSCLC models. 2017 , 7, 962-972	29
179	Prevalence of EGFR and ALK Mutations in Lung Adenocarcinomas in the Levant Area - a Prospective Analysis. 2017 , 18, 107-114	9
178	[Advances in the Transformation to Small Cell Lung Cancer from Non-small Cell Lung Cancer Following Acquired Drug-resistance to EGFR Tyrosine Kinase Inhibitors]. 2017 , 20, 720-726	1
177	[Prognostic Analysis of Patients with Advanced Non-small Cell Lung Cancer ?in Different Genotypes]. 2017 , 20, 741-750	1
176	[Classification and regression tree analysis of clinical patterns that predict survival in 127 Chinese patients with advanced non-small cell lung cancer treated by gefitinib who failed to previous chemotherapy]. 2011 , 14, 699-703	
175	[Research Advancement on EGFR Mutation Detection of Cell-free DNA and Tumor Cell in Peripheral Blood of Patients with Non-small Cell Lung Cancer]. 2016 , 19, 766-772	
174	[The detection methods of EGFR mutations in non-small cell lung cancer]. 2011 , 14, 297-302	0
173	[Sequence-dependent effect of docetaxel with gefitinib on the proliferation and apoptosis of lung adenocarcinoma cell H1975]. 2012 , 15, 127-38	0
172	[Discordance of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in non-small cell lung cancer]. 2011 , 14, 518-22	4

- 171 [Classification and regression tree analysis of clinical patterns to predict the survival of patients with advanced non-small cell lung cancer treated with erlotinib]. **2011**, 14, 785-9 0
- 170 [Immunohistochemical detections of EGFR status in NSCLC]. **2015**, 18, 212-8
- 169 [Clinical Research of EGFR and KRAS Mutation in Fine Needle Aspiration Cytology Specimens of Non-small Cell Lung Carcinoma]. **2015**, 18, 199-205
- 168 [Detection of epidermal growth factor receptor mutations in non-small cell lung cancer tumor specimens from various ways by denaturing high-performance liquid chromatography]. **2010**, 13, 850-5 1
- 167 [Effects of 17-DMAG on non-small cell lung cancer cell lines A549 and H1975? being resistant to EGFR-TKI]. **2014**, 17, 778-82
- 166 [Advances on driver oncogenes of lung adenocarcinoma]. **2013**, 16, 91-6 0
- 165 [The predictive value of EGFR status in non-small cell lung cancer patients treated with EGFR-TKIs]. **2010**, 13, 375-9
- 164 [Personalized targeted therapy for lung cancer]. **2013**, 16, C21-34
- 163 Incense burning smoke sensitizes lung cancer cells to EGFR TKI by inducing AREG expression. **2018**, 8, 2575-2589
- 162 [Clinical Predictive Factors associated with First Line EGFR-TKI Efficacy ?in Advanced NSCLC Patients with EGFR Mutations]. **2019**, 22, 99-104 1
- 161 [Characteristics of Epidermal Growth Factor Receptor with Rare Mutations in Non-small Cell Lung Cancer and the Effect of EGFR Tyrosine Kinase Inhibitors on Them]. **2019**, 22, 299-305
- 160 Transglutaminase 2 induces intrinsic EGFR-TKI resistance in NSCLC harboring EGFR sensitive mutations. **2019**, 9, 1708-1721 2
- 159 Impact of age on EGFR mutations in never-smoking female lung adenocarcinoma patients with malignant pleural effusion. **2018**, 11, 2811-2815
- 158 [Studies and Progress of EGFR exon 20 Insertion Mutation in Non-small Cell Lung Cancer]. **2020**, 23, 118-126
- 157 Click ferrocenyl-erlotinib conjugates active against erlotinib-resistant non-small cell lung cancer cells in vitro. **2021**, 119, 105514 1
- 156 The 2021 WHO Classification of Lung Tumors: Impact of advances since 2015. **2021**, 26
- 155 Pathology and Cancer Genomic Medicine. **2021**, 61, 887-892
- 154 Frequency of Epidermal Growth Factor Receptor and T790M Mutations Among Patients With Non-Small Cell Lung Carcinoma: A Hospital-Based Study in the King Khalid University Hospital (KKUH) Since 2009-2017.. **2021**, 13, e19816

- 153 Targeting MERTK and AXL in Mutant Non-Small Cell Lung Cancer. **2021**, 13, 2
- 152 Failure to EGFR-TKI-based therapy and tumoural progression are promoted by MEOX2/GLI1-mediated epigenetic regulation of EGFR in the human lung cancer. **2021**, 2
- 151 Nicht-kleinzelliges Lungenkarzinom: Wandel und Möglichkeiten der molekularen Diagnostik.
- 150 Accounting for EGFR mutations in epidemiological analyses of non-small cell lung cancers: Examples based on the International Lung Cancer Consortium data.. **2022**,
- 149 Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials.. **2022**, 27, e286-e293 0
- 148 Tumor-specific imaging probes in preclinical applications and clinical trials. **2022**, 49-138
- 147 Influence Factors of Gefitinib Concentration in Patients with Non-Small Cell Lung Cancer in Clinical Treatment. **2022**, 12, 196-205 0
- 146 Mutation patterns of epidermal growth factor receptor gene in non-small cell lung cancer among Egyptian patients. **2022**, 9, 77-90 0
- 145 Fluorescence Imaging of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer.. **2022**, 14, 0
- 144 Computational Methods for the Analysis and Prediction of EGFR-mutated Lung Cancer Drug Resistance: Recent Advances in Drug Design, Challenges and Future Prospects.. **2022**, PP, 0
- 143 Extracellular vesicles released by non-small cell lung cancer cells drive invasion and permeability in non-tumorigenic lung epithelial cells.. **2022**, 12, 972 0
- 142 Discovery of novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy.. **2022**, 120, 105605 1
- 141 Characterization of a small molecule inhibitor of disulfide reductases that induces oxidative stress and lethality in lung cancer cells.. **2022**, 38, 110343 1
- 140 Deciphering the Mechanism of Binding Selectivity of Chloroacetylamide-Based Covalent Inhibitors toward L858R/T790M Resistance Mutation.. **2022**, 1
- 139 Comprehensive analysis of PD-L1 expression, tumor-infiltrating lymphocytes, and tumor microenvironment in LUAD: differences between Asians and Caucasians.. **2021**, 13, 229 1
- 138 Multidisciplinary and real life data: practical management of () mutant non-small cell lung cancer (NSCLC).. **2022**, 14, 805-808
- 137 Biology and pathophysiology of central nervous system metastases. **2022**, 55-78
- 136 Industry Corner: Perspectives and Controversies: Paradigms for the development of transformative medicines - lessons from the EGFR story.. **2022**, 0

135	Concurrent lung adenocarcinoma and bladder diffuse large B-cell lymphoma: a case report and literature review.. 2022 , 50, 3000605221081672	1
134	Machine Learning-Assisted Dual-Marker Detection in Serum Small Extracellular Vesicles for the Diagnosis and Prognosis Prediction of Non-Small Cell Lung Cancer.. 2022 , 12,	0
133	Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers.. 2022 , 21, 61	0
132	The Frequency of Epidermal Growth Factor Receptor (EGFR) Mutation in Patients with Lung Adenocarcinoma Referred to a Lung Diseases Hospital; A Cross-Sectional Study from Iran.. 2022 , 17, 159-165	
131	Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer.. 2022 , 12, 869672	3
130	Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation. 2022 , 2022,	
129	Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer.	0
128	Structural insights into the non-inhibitory mechanism of the anti-EGFR EgB4 nanobody.. 2022 , 23, 12	0
127	Multiplex SuperSelective PCR Assays for the Detection and Quantitation of Rare Somatic Mutations in Liquid Biopsies.. 2021 ,	
126	Switch Pocket Kinase: An Emerging Therapeutic Target for the Design of Anticancer Agents.. 2022 ,	
125	Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice.. 2022 , 167, 87-97	0
124	The Development of Positron Emission Tomography Tracers for In Vivo Targeting the Kinase Domain of the Epidermal Growth Factor Receptor.. 2022 , 15,	0
123	Imaging Endocytosis Dynamics in Health and Disease.. 2022 , 12,	1
122	Survival prediction of lung cancer patients by integration of clinical and molecular features using machine learning. 2021 ,	0
121	The emergence of cancer genomics in diagnosis and precision medicine.. 2021 , 2, 1263-1264	1
120	Association of EGFR mutations in second primary lung cancer and HER2 expression in breast cancer survivors.. 2021 , 10, 5204-5211	
119	Basic Understandings of EGFR-mutated Lung Cancer and Its Clinical Applications. 2021 , 61, 911-918	
118	A Six-Gene Prognostic and Predictive Radiotherapy-Based Signature for Early and Locally Advanced Stages in Non-Small-Cell Lung Cancer.. 2022 , 14,	1

- 117 EGFR signaling pathway as therapeutic target in human cancers.. **2022**, 1
- 116 Analysis to determine the effect of mutations on binding to small chemical molecules.. **2022**, 2240003
- 115 Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives.. **2022**, 13, 875330 1
- 114 Discovery and structural optimization of potent epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M/C797S resistance mutation for lung cancer treatment.. **2022**, 237, 114381 0
- 113 Data_Sheet_1.PDF. **2019**,
- 112 Image_1.PDF. **2020**,
- 111 Table_1.XLSX. **2020**,
- 110 Table_2.XLSX. **2020**,
- 109 Data_Sheet_1.docx. **2018**,
- 108 Data_Sheet_1.zip. **2019**,
- 107 Data_Sheet_1.pdf. **2018**,
- 106 Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.. **2022**, 2
- 105 Efficacy of liquid biopsy for disease monitoring and early prediction of tumor progression in EGFR mutation-positive non-small cell lung cancer.. **2022**, 17, e0267362 0
- 104 Molecular Radiobiology in Non-Small Cell Lung Cancer: Prognostic and Predictive Response Factors.. **2022**, 14, 0
- 103 Management of Non-Small Cell Lung Cancer: Updates from the European Lung Cancer Congress 2022.. **2022**, 1-27
- 102 Pleural, Pericardial, and Peritoneal Fluids. **2014**, 127-153 2
- 101 NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease. **2022**, 23, 6748 1
- 100 Leptomeningeal Metastatic L858R EGFR-mutant Lung Cancer: Prompt Response to Osimertinib in the Absence of T790M-mutation and Effective Subsequent Pulsed Erlotinib. Volume 15, 659-667

99	Multicomponent Synthesis of Heterocycles. 2022 , 215-275	1
98	Aberrant Epidermal Growth Factor Receptor Signaling and Enhanced Sensitivity to EGFR Inhibitors in Lung Cancer. 2005 , 65, 226-235	93
97	EGFR, NF- κ B and noncoding RNAs in precision medicine. 2022 ,	
96	Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre. 2022 ,	0
95	Depatuxizumab-mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial.	2
94	Clinico-pathological Profile of Lung Cancer Patients in a Tertiary Care Hospital, India: A Prospective, Cross-sectional Study. 2022 , 64, 79-85	
93	Tumor response to radiotherapy and expression of epidermal growth factor receptor mutation and echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearrangement in patients with non-small cell lung cancer. 2022 , 34,	
92	A Functional Common Polymorphism in a Sp1 Recognition Site of the Epidermal Growth Factor Receptor Gene Promoter. 2005 , 65, 46-53	33
91	Two Distinct Primary EGFR-Mutated Lung Adenocarcinoma Within the Same Patient: A Case Report.	
90	Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022 , 119,	11.5 1
89	Epidermal Growth Factor Receptor Kinase Inhibitor Ameliorates β Amyloid Oligomer-Induced Alzheimer Disease in Swiss Albino Mice. 2022 , 27, 5182	
88	Real-world management patterns in EGFR-mutant advanced non-small-cell lung cancer before first-line adoption of osimertinib: the REFLECT study in Greece.	
87	EGFR-mutant NSCLC: monitoring the molecular evolution of tumors in 2022.	0
86	Clinical Validation of Companion Diagnostics for the Selection of Patients with Non-Small Cell Lung Cancer Tumors Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutations for Treatment with Amivantamab. 2022 ,	0
85	The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled Trials. 2022 , 2022, 1-11	
84	Discovery of novel thiazolyl-pyrazolines as dual EGFR and VEGFR-2 inhibitors endowed with in vitro antitumor activity towards non-small lung cancer. 2022 , 37, 2265-2282	2
83	Overcoming C797S mutation: The challenges and prospects of the fourth-generation EGFR-TKIs. 2022 , 128, 106057	0
82	EGFR Mutations and PD-L1 Expression in Early-Stage Non-Small Cell Lung Cancer: A Real-World Data From a Single Center in Brazil.	0

81	Control of cell metabolism by the epidermal growth factor receptor. 2022 , 1869, 119359	1
80	Therapeutic Schedule of EGFR Mutation in Non-Small Cell Lung Cancer and Review of Health Insurance Policy. 2022 , 12, 174-183	0
79	Targeted Therapies in Non-small Cell Lung Cancer. 2022 ,	1
78	Substanzen gegen molekulare Zielstrukturen. 2022 , 1-14	0
77	Chapter 21: Oncology: Rasburicase/G6PD Case. 2022 ,	0
76	Abbreviations. 2022 ,	0
75	Chapter 29: Pharmacogenomics in Ethical and Social Contexts. 2022 ,	0
74	Appendix 2: Glossary. 2022 ,	0
73	Chapter 27: Rheumatology/Musculoskeletal Pain: Codeine/CYP2D6 Case. 2022 ,	0
72	Chapter 8: Cardiology: Simvastatin/SLCO1B1 Case. 2022 ,	0
71	Chapter 28: Information Resources for Pharmacogenomics. 2022 ,	0
70	Chapter 18: Oncology: Somatic Disease and Pharmacogenomics. 2022 ,	0
69	Chapter 17: Neurology: Fosphenytoin/Phenytoin/CYP2C9, HLA-B Case. 2022 ,	0
68	Chapter 9: Cardiology: Warfarin/CYP2C9, VKORC1, CYP4F2 Case. 2022 ,	0
67	Chapter 25: Rheumatology/Musculoskeletal Pain: Allopurinol/HLA-B Case. 2022 ,	0
66	Chapter 12: Infectious Diseases: Abacavir/HLA-B Case. 2022 ,	0
65	Chapter 15: Infectious Diseases: Gentamicin/MT-RNR1 Case. 2022 ,	0
64	Pharmacogenomics: Foundations, Competencies, and the Pharmacists' Patient Care Process, 2nd Edition. 2022 ,	0

63	Chapter 13: Infectious Diseases: Atazanavir/UGT1A1 Case. 2022,	o
62	Chapter 30: Pharmacogenomics and Secondary/Incidental Findings. 2022,	o
61	Chapter 16: Neurology: Carbamazepine/HLA-A, HLA-B Case. 2022,	o
60	Dedication. 2022,	o
59	Chapter 3: Pharmacogenomics Testing. 2022,	o
58	Chapter 24: Metabolic/Respiratory: Ivacaftor/CFTR Case. 2022,	o
57	Chapter 23: Psychiatry: Paroxetine/CYP2D6 Case. 2022,	o
56	Copyright. 2022,	o
55	Chapter 2: Pharmacogenomics: Drug Exposure and Response. 2022,	o
54	Chapter 22: Psychiatry: Amitriptyline/CYP2C19, CYP2D6 Case. 2022,	o
53	Chapter 6: The Pharmacists' Patient Care Process (PPCP). 2022,	o
52	A novel EGFR exon 21 indel mutation in lung adenocarcinoma and response to dacomitinib: A case report. 2022, 101, e30269	o
51	Chapter 10: Endocrinology: Glipizide/G6PD Case. 2022,	o
50	Chapter 1: Foundations of Pharmacogenomics. 2022,	o
49	Chapter 20: Oncology: Capecitabine/DPYD Case. 2022,	o
48	Preface. 2022,	o
47	Chapter 14: Infectious Diseases: Voriconazole/CYP2C19 Case. 2022,	o
46	Chapter 19: Oncology: Mercaptopurine/TPMT, NUDT15 Case. 2022,	o

45	Chapter 7: Cardiology: Clopidogrel/CYP2C19 Case. 2022,	0
44	Chapter 4: Pharmacists' Competencies in Genomics. 2022,	0
43	Appendix 1: Competency Connections. 2022,	0
42	Chapter 5: Implementation of Pharmacogenomics across Practice Settings. 2022,	0
41	Chapter 26: Rheumatology/Musculoskeletal Pain: Azathioprine/TPMT, NUDT15; Celecoxib/CYP2C9 Case. 2022,	0
40	Chapter 11: Immunology: Tacrolimus/CYP3A5 Case. 2022,	0
39	Liquid Biopsy: A Multi-Parametric Analysis of Mutation Status, Circulating Tumor Cells and Inflammatory Markers in EGFR-Mutated NSCLC. 2022, 12, 2360	0
38	Osimertinib (Tagrisso), A Potent and Selective Third-Generation EGFR Inhibitor for the Treatment of Both Sensitizing and T790M-Resistance Mutations. 2022, 165-182	0
37	Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020. 12,	0
36	Discovery of a potent EGFR and ALK dual mutation inhibitor containing N-(3-((4-((2-(cyclopropylsulfinyl)phenyl)amino)pyrimidin-2-yl)amino) phenyl)acrylamide scaffold. 2022, 106188	1
35	New Strategies and Novel Combinations in EGFR TKI-Resistant Non-small Cell Lung Cancer. 2022, 23, 1626-1644	1
34	Algorithme thérapeutique des cancers bronchiques non ^petites cellules tendus avec mutation de EGFR. 2022, 14, 2S189-2S208	0
33	Molecular Biology, Genetics, and Translational Models of Human Cancer. 1-34	0
32	Novel EGFR-Mutant Mouse Models of Lung Adenocarcinoma Reveal Adaptive Immunity Requirement for Durable Osimertinib Response.	0
31	Association of smoking status with non-small cell lung cancer patients harboring uncommon epidermal growth factor receptor mutation. 13,	0
30	A Beclin 1-targeting stapled peptide synergizes with erlotinib to potently inhibit proliferation of non-small-cell lung cancer cells. 2022, 636, 125-131	1
29	Invasive Adenocarcinoma Versus Adenocarcinoma In Situ. 2022, 31-37	0
28	Antiproliferative, antiangiogenic and apoptotic effect of new hybrids of quinazoline-4(3H)-ones and sulfachloropyridazine. 2023, 245, 114912	0

- 27 Machine learning based personalized drug response prediction for lung cancer patients. **2022**, 12, ○
- 26 Analyses of P16INK4a gene promoter methylation relative to molecular, demographic and clinical parameters characteristics in non-small cell lung cancer patients: A pilot study. ○
- 25 In silico design of EGFR L858R/T790M/C797S inhibitors via 3D-QSAR, molecular docking, ADMET properties and molecular dynamics simulations. **2022**, 8, e11537 ○
- 24 Molecular Biomarkers at the Interface of Basic and Clinical Dengue Research. **2013**, 42, 608-610 1
- 23 A narrative review of cancer molecular diagnostics: past, present, and future. Publish Ahead of Print, ○
- 22 Somatic A-to-I RNA-edited RHOA isoform 2 specific-R176G mutation promotes tumor progression in lung adenocarcinoma. ○
- 21 Novel EGFR-mutant mouse models of lung adenocarcinoma reveal adaptive immunity requirement for durable osimertinib response. **2023**, 216062 ○
- 20 Historical development of EGFR-targeted therapy. **2023**, 1-11 ○
- 19 Comparing Gefitinib and Traditional Chemotherapy for Better Survival in Patients With Non-Small Cell Lung Cancer: A Systematic Review. **2023**, ○
- 18 Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. **2023**, 13-27 ○
- 17 Investigating regulated signaling pathways in therapeutic targeting of non-small cell lung carcinoma. **2023**, 161, 114452 ○
- 16 Molecular Testing for Diagnostics, Prognostication, and Treatment Stratification in Cancers. **2023**, 29, 3-8 ○
- 15 A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy. **2023**, 177, 44-50 ○
- 14 Development of Furanopyrimidine-Based Orally Active Third-Generation EGFR Inhibitors for the Treatment of Non-Small Cell Lung Cancer. **2023**, 66, 2566-2588 ○
- 13 The development and implementation of EGFR inhibitors in advanced NSCLC. **2023**, 13-36 ○
- 12 Liquid Biopsy for Oral Cancer Diagnosis: Recent Advances and Challenges. **2023**, 13, 303 ○
- 11 Comprehensive profiling of EGFR mutation subtypes reveals genomic-clinical associations in non-small-cell lung cancer patients on first-generation EGFR inhibitors. **2023**, 38, 100888 ○
- 10 An intrinsic purine metabolite AICAR blocks lung tumour growth by targeting oncoprotein mucin 1. ○

- 9 Cereblon-Recruiting PROTACs: Will New Drugs Have to Face Old Challenges?. **2023**, 15, 812 ○
- 8 Acquiring tissue for advanced lung cancer diagnosis and comprehensive biomarker testing: A National Lung Cancer Roundtable best-practice guide. ○
- 7 Evolution of cancer genomics and its clinical implications. **2019**, 9, 173-178 ○
- 6 Intelligent Genetic Decoding System Based on Nucleic Acid Isothermal Amplification for Non-Small Cell Lung Cancer Diagnosis. **2023**, 14, 647 ○
- 5 Triptolide reduces PD-L1 through the EGFR and IFN- γ /IRF1 dual signaling pathways. **2023**, 118, 109993 ○
- 4 Synthesis and evaluation of sulfonamide derivatives targeting EGFR790M/L858R mutations and ALK rearrangement as anticancer agents. **2023**, 85, 117241 ○
- 3 Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer. **2023**, 15, 175883592311614 ○
- 2 EBUS-TBNA of a Left Lower Paratracheal Node (Level 4L) in a Patient with a Left Upper Lobe Lung Mass and Suspected Lung Cancer. **2012**, 207-218 ○
- 1 Challenges of EGFR-TKIs in NSCLC and the potential role of herbs and active compounds: From mechanism to clinical practice. 14, ○